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Zusammenfassung 
Marine Aktinomyceten stellen eine beliebte Quelle neuer Naturstoffe dar, welche unter 
Umständen Anwendung als therapeutische Arzneimittel finden. Daher steht die Untersuchung 
neuer Aktinomyceten Stämme im Fokus der Naturstoffforschung. Die dargelegte Arbeit handelt 
von der Isolierung und strukturellen Charakterisierung neuer Naturstoffe, welche von 
Streptomyceten produziert wurden. Desweiteren, wird die Konstruktion eines neuen Biosensors 
dargestellt, welcher die Produktion von Sekundärmetaboliten detektieren soll.  
Es wurden zwei neue spiroindimicine E und F aus der Streptomyces sp. MP131-18 isoliert und 
die chemische Struktur mittels NMR bestätigt. Das Genom von MP131-18 wurde sequenziert 
und der Gencluster, welcher verantwortlich ist für die Synthese der Bisindole-Substanzen 
identifiziert und den Lynamicinen/Spiroindmicinen zugeordnet. Weiterhin, wurden vier neue 
Alpiniamide B-D aus dem Stamm Streptomyces sp. IB 2014/11-12 isoliert. Das sequenzierte 
Genom ermöglichte die Identifizierung des Genclusters, welcher für die Alpiniamide 
Produktion verantwortlich ist. Die vorgeschlagene Biosyntheseroute wurde bestätigt durch 
Fütterungsexperimente und Gendeletierungen in einem Hostorganismus.  
Abschließend wurde ein Beitrag zur Konstruktion eines Repressor-basierender Biosensors 
geleistet, welcher die Aktivierung von zuvor inaktiven Gencluster in Streptomyceten 
detektieren soll. Dieses Konzept wurde erfolgreich an dem aktivierten Coelimycin Gencluster 
angewendet. 
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Abstract 
Marine actinomycetes are known to be a promising source for new natural products with 
putative application as therapeutic agents. Thus, the exploitation of novel discovered 
actinomycetes strains remains in the focus of NP research. The presented thesis deals on the 
one hand with the isolation and structural characterization of new NPs produced by 
streptomycetes species. On the other hand, the construction of a novel biosensor concept for 
the detection of secondary metabolite production is discussed. 
New spiroindimicins E and F were isolated from the Streptomyces sp. MP131-18 and structures 
were confirmed by NMR. Additionally, two new lagunapyrones D and E were identified by 
characteristic MS/MS fragmentation. The genome of MP131-18 has been sequenced and the 
gene cluster, responsible for the synthesis of bisindole compounds has been identified and 
connected to lynamicins/spiroindimicin production. Furthermore, four new alpiniamides B-D 
have been isolated from the Streptomyces sp. IB 2014/11-12. The sequenced genome enabled 
the identification of the gene cluster responsible for alpiniamide production. The predicted 
biosynthetic pathway was confirmed by feeding experiments and gene deletions in a 
heterologous host.  
Finally, a contribution to the construction of a repressor-based biosensor, which detects the 
products of awakened silent gene clusters in streptomycetes, has been made. This concept was 
successfully applied to the activated coelimycin gene cluster. 
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1. Introduction 
1.1 Impact of Natural Products in Drug Development 
Pharmacologically active substances from natural sources play an important role in human life 
since the earliest times of traditional medicine and until the modern medical practice. The 
number of new chemical entities (NCEs) with a natural background between 1981 and 2014, 
recorded by the U.S. Food and Drug Administration (FDA), reflects the significance of natural 
products (NPs). As it has been summarized by Newman and Cragg, 39% of a total number of 
1562 new approved drugs during these 34 years, are unmodified NPs, semisynthetic modified 
NPs or synthesized substances with a NP pharmacophore.1 The indications of these drugs in 
human medicine are versatile. They can be used as antibacterial, anticancer, anti-inflammatory, 
antiviral or immunosuppressive agents, to name a few. However, many of them seem to be 
applicable in cancer therapy or in the treatment of infectious diseases which belong to the ten 
leading causes of death worldwide, according to the World Health Organization.2 NPs and/or 
their derivatives account for 52% and 59% of antibacterial and anticancer NCEs respectively. 
These numbers illustrate that NPs remain an important source to treat life-threatening diseases.1 
However, the usage of NPs for the antibiotic industry is declining. The difficulties and huge 
costs, which accompany the process from the initial NP discovery to the final drug caused a 
decreased NP based antibiotic research by many pharmaceutical companies.3 Screening of 
libraries of bacterial extracts using the “Waksman platform” resulted in re-discovery with 
increased regularity of already known compounds. Moreover, the chemical complexity of the 
existing NPs aggravates their synthesis or derivatization, which makes them less favorable for 
the development of suitable drugs. Altogether, the examination of microorganisms, screening 
of NP extracts libraries for activity and the eventual upscaling for the isolation and purification 
of compounds are time-consuming and expensive. Instead, the high-throughput screening 
(HTS) using “screen-friendly”, synthetic compounds libraries have been introduced.4 The 
benefits of such libraries are reliable supply of compounds and a better, chemical accessibility 
for the subsequent drug optimization. Although, this approach has been successful for the 
discovery of many therapeutics, it has only moderate success (hit rate HTS < 0.001%, 
“Waksman platform” 0.3%) in the finding of medicines against infectious diseases.3  
Moreover, the fast development of resistance among pathogenic strains against most of the 
newly introduced antibiotics exacerbates the situation.5 The decrease in discovery of new 
antibiotics together with the growing resistance evokes an immense disequilibrium between the 
number of available antibiotics in contrast to the number of resistant strains, which makes once 
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treatable diseases again lethal. The most dangerous, multiresistant nosocomial pathogens with 
currently missing treatment options are summarized as the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, 
Pseudomonas aeruginosa and Enterobacter species).6 The foundation of the “10 x ’20 
Initiative” in 2010 by the Infectious Disease Society of America (IDSA) was supposed to fill 
that gap. The initiative was meant to motivate scientists and the pharmaceutical industry in 
order to develop and approve 10 new, efficient and save drugs against bacterial infections, 
especially those caused by the ESKAPE-pathogens, until 2020.7 The success of this program is 
reflected by the approval of several new antibacterial drugs between 2010-2015, e.g. ceftaroline 
fosamil acetate (2010), dalbavancin (2014), tedizolid (2014), oritavancin (2014) and 
ceftolozane/tazobactam (2014), ceftazidime/avibactam (2015), meropenem/vaborbactam 
(2017) as combined agents against pathogens with extended spectrum ß-lactamases (ESBLs, 
Fig. 1).8,9 Similarly, the European Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) initiates and supports research and educational projects aiming for a better 
application of antibiotics, an improved treatment and prevention of infectious diseases.10 
Despite the introduction of new effective antibiotics, which can combat resistant strains, most 
of them are only improved versions of already existing compounds. The basic effective 
pharmacophore in most cases is the same as in many other medicines on the market with the 
same mode of action within the bacterial cell. Hence, to overcome the resistance issue, new 
compound classes with new core structures and new mode of action are needed. The 
introduction of drugs with entirely new molecular targets can prevent the fast adaption of 
bacterial strains to the antibiotic and thus enable a longtime and effective usage.  
The discovery of suitable antibiotics against the resistant Gram-negative bacteria 
(Acinetobacter baumanii, Pseudomonas aeruginosa, Enterobacteriaceae) represents even 
bigger challenge to overcome.11 The cell envelope of Gram-negative bacteria is more difficult 
to penetrate, which is why antibiotics for their treatment are much harder to discover. This is 
also the main reason for the failure of compounds resulting from HTS of chemical libraries. 
Even though they are toxicologically and pharmacologically more suitable than NPs they often 
lack the effective characteristics of typical NP antibiotics such as the ability to penetrate the 
cell envelope.12 The likelihood to discover active agents within NPs is also reflected by the fact 
that 73 % of all antibacterial agents introduced between 1981 and 2014 derive from NPs.1 As a 
consequence, it is necessary to maintain NP discovery programs and expand the research by 
novel approaches with 21st century techniques. Only then, the huge demand for new, effective 
antibacterial drugs can be fulfilled. 
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Figure 1. Newly approved antibiotics in clinical use with NP pharmacophore. 
1.2 Natural Products from Actinobacteria 
Actinomycetes (mainly of Streptomyces and related genera) are Gram-positive, mostly soil-
dwelling, filamentously growing bacteria and represent a major source of valuable NPs.13 They 
occupy different ecological niches but are predominately distributed in soil (population density 
106-109 cells per 1 g), whereas 95% of them belong to the genus Streptomyces.12 Unsurprisingly, 
representatives of this genus were one of the first producers of medically useful NPs and 
provide to date more than half of all clinical used antibiotics. The first actinobacterial antibiotic 
produced in industrial scale was the aminoglycoside streptomycin (Fig. 2), isolated from 
Streptomyces griseus in 1944, used for the tuberculosis treatment.14 Many other medically 
valuable antibiotics derived from streptomycetes were subsequently discovered, the latest one 
being the cyclic lipopeptide daptomycin (Fig. 2) from S. roseosporus in 2003 for the treatment 
of life-threatening infections caused by Gram-positive pathogens such as the methicillin 
resistant Staphylococcus aureus (MRSA).15 Actinobacterial NPs originate from a divers 
secondary (or auxiliary) metabolism. In most cases these compounds are not required for 
bacterial survival and their role is still under debates.16 Beside the compounds used in human 
medicine, actinobacteria produce many other NPs some of which have herbicidal and 
insecticidal properties.17,18  
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Thus, it is not surprising that actinomycetes from terrestrial sources have been the focus in drug 
discovery research for a long time. However, the likelihood to discover promising secondary 
metabolites with new core structures from terrestrial actinomycetes has meanwhile 
considerably decreased. The over-exploitation of soil actinomycetes leads more and more often 
to a rediscovery of same strains and hence to the isolation of already known metabolites. One 
of the reasons lies in the specific growth characteristics of different species. The faster growing, 
and phenotypically more visible streptomycetes are prone to be chosen more easily at the 
expense of slower growing, less distributed minor groups, which are thus often overlooked. 
Only recently, scientists put more efforts in the discovery of minor groups of actinobacteria 
resulting in diversification of NPs.19 Another reason for the abundant rediscovery of known 
compounds, is the widespread horizontal gene transfer (HGT) among soil actinomycetes.20 The 
conjugative transfer of biosynthetic gene clusters between bacterial cells leads to generation of 
distant species with a similar NP profile, even though the strains derive from different habitats. 
As a consequence, researchers started to move towards highly underexplored niches. Especially 
the marine and freshwater environments with its much higher biological diversity compared to 
the terrestrial surroundings are believed to provide an auspicious alternative for the discovery 
of novel drug leads.21-23 Marine actinobacteria are often exposed to extreme conditions such as 
low temperatures, high pressures, specific pH-values, depleted nutrient supply and alternating 
oxygen concentration as opposed to their terrestrial counterparts. In order to survive these living 
circumstances they have to adapt physiologically and metabolically. This fact encouraged 
scientists to explore the marine environment assuming that the metabolic adaption of 
actinomycetes will also lead to production of bioactive secondary metabolites with unique 
structures. Marine sources including fjords sediments, deep-sea floors, tidal-flats and coral reefs 
as well as fresh-water lakes are currently under investigation for new actinobacterial strains.24 
Beside the terrestrial counterparts of actinomycetes often found in marine samples, also 
indigenous, taxonomically distinct actinomycetes exist in the oceans. Besides the well-known 
genus Streptomyces, other members of actinobacteria can be found, e.g. Marinispora, 
Rhodococcus, Salinispora or Dietzia.25 Nocardiopsis sp. isolated in a sediment sample from the 
Trondheim Fjord in Norway produces the thiopeptide TP1161 (Fig. 2) which represents a good 
example for the rewarding exploitation of such sources.26 This thiopeptide possesses activity 
against a panel of Gram-positive strains. A further example is the discovery of Salinispora 
arenicola strain CNT-088 which was isolated from a marine sediment sample collected around 
the islands of Fiji.27 The strain was found to produce the cyclohexadepsipeptides arenamides 
A-C which possess anti-inflammatory properties (Fig. 2). Moreover, the investigation of marine 
Introduction 
 
13 
invertebrates symbiotic living bacteria such as corals, tunicates, sponges or cone snails resulted 
in identification of promising new compounds.28 Sponges, sessile multicellular organism, 
which are found in several marine and fresh-water ecosystems, are known to harbor 
microorganisms capable of production of bioactive secondary metabolites. An example for this 
is the strain Streptomyces axinellae which lives in symbiosis with the Mediterranean sponge 
Axinella polypoides, collected from Banyuls-sur-Mer, France.29 This strain was found to 
produce new tetromycin derivatives with antiparasitic and cytotoxic activities (Fig. 2).30 
Another example of strains living in symbiosis is the Streptomyces sp. CP32, which inhabits 
the cone snail Conus pulicarius. New neuroactive thiazoline compounds pulicatins A-E were 
isolated from this strain (Fig. 2).31 
However, the majority of microorganisms can’t be isolated by conventional methods, since 
99% of all bacteria, terrestrial as well as aquatic, are not cultivable under standard laboratory 
conditions.32 Also, the applied cultivation conditions do not reflect the stressful natural 
situations on which bacteria react individually by tuning their metabolic processes, including 
secondary metabolism. These differences make the majority of secondary metabolism pathways 
silent under laboratory conditions. Thus, a large part of secondary metabolites is yet waiting to 
be discovered and alternative approaches are required to unlock the full biosynthetic potential 
of yet “unculturable” strains. A prominent example of a NP discovered by a new technique is 
teixobactin. This cyclic depsipeptide was isolated via an iChip in 2015, from a yet-uncultured 
bacterial strain and shows antibacterial activity against some clinical relevant Gram-positive 
pathogens including multidrug-resistant strains.33 Through its specific mode of action during 
cell-wall synthesis, which is different from the common mechanism, it is believed that treated 
bacteria might not become resistant as fast as with other antibiotics.34 Another strategy is the 
metagenomic approach, a cultivation-independent technique which requires the isolation of 
DNA directly from the environment (eDNA) and the subsequent cloning into cultivable  host 
strains.35 An example are the recently discovered calcium-dependent macrocyclic lipopeptides 
malacidins.36 The isolation was achieved through a metagenomic-approach using eDNA from 
soil samples. Noteworthy, is the activity against Gram-positive pathogens including MRSA 
caused through binding of malacidin to Lipid II during cell wall synthesis.  
Despite the growing potential of new techniques, in most cases the method of choice for 
discovery of new actinobacterial NPs is still based on the classical way. Isolation of metabolites 
from the culture broth of cultivated strains seems to be preferred in many laboratories since the 
potential of even well characterized strains appeared to be far not exhausted. Often simple 
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alteration of cultivation conditions can induce production of new metabolites. In conclusion, 
the exploration of new ecological niches comprises great possibilities for the discovery of new 
strains and thus new NPs. 
 
Figure 2. NPs from soil streptomycetes in clinical use (streptomycin, daptomycin) compared 
to NPs isolated from actinomycetes derived from new ecological niches (pulicatin, thiopeptide 
TP-1161, arenamide, tetronomycin).   
1.3 Dereplication 
The abundant rediscovery of the same compounds remains a major concern in NP research. In 
order to avoid time-consuming work, the reliable discrimination of known and new compounds 
is necessary. This process, known as dereplication, refers to an effective, preceding discard of 
futile or ineffectual compounds (Fig. 3).37 For this purpose, high resolution analytical 
techniques are required in order to identify the targeted compound in a complex mixture such 
as the crude extracts of cultivated bacterial strains. A common technique is the analytical 
separation of the crude material by high performance liquid chromatography (HPLC) and the 
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subsequent detection of eluting compounds by the use of diode array detectors (DAD), mass 
spectrometry (MS) or nuclear magnetic resonance spectroscopy (NMR).38 These techniques 
yield useful properties e.g. retention time, UV/vis absorption, exact mass, semi-structures, 
elemental composition, fragmentation patterns, which can be than used for the comparison of 
data of known NPs. In order to enable efficient dereplication, many NP databases appeared over 
the last years, providing various types of searching possibilities.39 The most useful, 
commercially and publically available databases in terms of the number of included, known 
NPs are for instance CAS/SciFinder, PubChem and the Chapman & Hall/CRC Dictionary of 
Natural Products (DNP).40-42 CAS/Scifinder includes over 283,000 NPs and provides the 
possibility to search with complete or partial drawn structures or molecular formula. For each 
result, predicted properties and analytical spectra and also the respective reference to the 
literature are given. Pubchem, a public domain for searching and comparing substances, 
provides around 438,000 entries for NPs. Similar, as in other databases, a structure based or 
molecular formula based search can be performed resulting in hits with listed chemical 
properties, literature references and derivatives of the given structure, as well as biological 
properties of compounds including specific activity records. The DNP database contains around 
260,000 NPs and provides the broadest list of possibilities to search for instance by an accurate 
mass, UV maxima, a biological source or a molecular formula. Particularly useful is the 
information about the source of the described metabolite that greatly narrows down the search 
results.  
 
Figure 3. General workflow: metabolic profiling and genomic analysis of new bacterial strains. 
The process of dereplication helps to evaluate the novelty of metabolites in a crude extract and 
saves time if the metabolite can be identified as known compound. In order to increase the 
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confidence of prediction it is important to have an additional confirmation whether the NP 
proposed by dereplication is known or new. Nowadays, a genome mining approach creates a 
strong link between the compound and corresponding biosynthetic genes and can be used to 
validate the prediction made by analytical methods. 
1.4 Genomic Profiling of Actinomycetes 
1.4.1 Bacterial Genome Sequencing and Identification of Biosynthetic gene cluster (BGC) 
In the early years of antibiotic research, the isolation of the compounds from the culture broth 
was a precondition to determine the metabolic profile of a specific strain. Nowadays, the 
sequencing of bacterial genome provides the opportunity to analyze the biosynthetic potential 
of an organism in silico. Through the development of low-cost “Next-Generation Sequencing” 
techniques (NGS), genome sequencing became mundane, which lead to a sudden rise in the 
availability of genomic information.43 In order to deal with the increasing amount of newly 
obtained data, effective in silico methods for the identification of secondary metabolism gene 
clusters and connection of these clusters to the vast amount of already known metabolites 
(genome mining) were developed.44 This way, core biosynthetic genes of already known 
compounds can be identified, supporting or denying the dereplication results and moreover, 
pointing on unknown gene clusters within a genome and thus leading to the discovery of novel 
NPs (Fig.3). Several software for an automated cluster mining were developed to date, e.g.  
DECEIPHER® (2001), NP.searcher, CLUSEAN (2009), antiSMASH (2011) and PRISM 
(2015).45-49 For instance, antiSMASH, first launched in 2011, is a comprehensive platform for 
the analysis of genomic data. It combines several computing tools for a better comparison of 
genomic sequences, for the identification of BGCs and prediction of putative secondary 
metabolites. Approximately 44 different types of gene clusters (including type I-III polyketide 
synthase (PKS), non-ribosomal-peptidesynthethase (NRPS), lantipeptide, indole, bacteriocin, 
lassopeptide, phenazine, terpene, siderophore, melanin, ectoine etc.) can be identified by 
comparison of the genome sequence of a bacterium of interest against a library of common 
enzyme/protein domains from different biosynthetic pathways. The completed analysis is 
shown as an overview of all identified BGCs within the genome and additionally the degree of 
homology to known BGCs is given (Fig. 4 a)). Furthermore, for each cluster detailed 
information is provided, such as domain annotation (Fig. 4 b)), cluster boarder prediction, 
regulatory TTA codon annotation and ten closest gene clusters from other bacteria, which are 
homologous to the query sequence. Moreover, the antiSMASH algorithm provides the detailed 
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prevision of domain’s substrate specificity for NPRS and PKS assembly lines, as well as based 
on this prediction, the possible core structure of metabolite (Fig. 4 b)).  
a) 
 
b)  
 
Figure 4. Genome mining software antiSMASH: a) output genome analysis; list of identified 
secondary BGCs and most similar known cluster b) cluster annotation with identified domains 
(left) and predicted core structure based on predicted monomer choice (right).50 
Finally, the external reference to Minimum Information about a Biosynthetic Gene cluster 
(MIBiG) database for each of the analyzed genes in the predicted gene cluster is accessible, 
showing the closest experimentally characterized orthologues of the gene, thus giving clues to 
the function of the respective protein in the biosynthetic pathway.51 Similar software called 
PRISM was developed by Magarvey et al. in 2015, also as a tool for a facilitated BGC analysis. 
Compared to antiSMASH, PRISM provides for example structure prediction for type II 
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polyketide synthase products and is also suited for a better identification and annotation of 
cluster-associated genes involved in resistance mechanism. Moreover, structure prediction 
seems to be more detailed through the addition of foresight of mechanism of cyclization and 
sugar biosynthesis and attachment. However, PRISM has limitations regarding the type of data 
submitted, since it cannot process fragmented genomes (multiple contigs) and can work only 
with the fully assembled genomic data. Also, the wide usage of antiSMASH prompted the 
development of satellite software (MIBiG, ARTS, etc.) that provide additional possibilities in 
secondary metabolites gene cluster analysis, like prioritization of compounds of interest based 
on prediction of their mode of action. The latter is achieved by the identification of self-
resistance genes within the gene cluster, pointing on possible mode of action of the produced 
compound.52  
Tools, like antiSMASH and PRISM became indispensable for the NP researchers since they 
help to evaluate the importance of a specific cluster. Identification of biosynthetic genes for a 
particular compound of interest can thus often verify dereplication results by connecting the 
identified metabolite to the respective BGC. In general, genome mining has one major 
limitation. The prediction of chemical structures from the cluster organization is not reliable so 
far so that the revers approach connecting genes to their products remains difficult. The 
development of better tools for gene/protein based compound structure prediction is required 
and is a major focus of antiSMASH like software development.  
1.4.2 Enzyme Machinery for Secondary Metabolite Production 
Bacteria are able to synthesize a vast number of structurally diverse metabolites. In most cases, 
genes for the production of secondary metabolites are clustered within the bacterial genome. 
Despite the clear structural variety of secondary metabolites produced by bacteria, still two 
types of chemistry are dominating in their biosynthesis: Claisen condensation, similar to 
assembly of malonyl-CoA units during fatty acid biosynthesis and transpeptidation, a 
condensation of amino acids forming an amide bond as in the case of ribosomal protein 
synthesis. In both cases the resulting secondary metabolites, polyketides and non-ribosomal 
peptides, originate from a simple monomer supplied from the primary metabolism. Due to the 
obvious simplicity of the primary chemistry behind the polyketides and non-ribosomal peptide 
synthesis, they represent the major classes of NPs produced by bacteria including 
actinobacteria. The structural diversity is achieved either by utilization of unusual building 
blocks or post-assembly modification of the initial product. 
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Polyketide NPs are assembled by repetitive Claisen condensation events conducted by enzymes 
called polyketide synthase (PKS). Polyketide synthases are similar to fatty acid synthase (FAS) 
by both structural and functional features.53 Both enzymes initiate the biosynthesis with an 
acetyl-coenzyme A (CoA) as starter unit, which is then elongated with an extender unit (e.g. 
malonyl-CoA) through a decarboxylative condensation. For this basic reaction, three core 
activities are required: the β-ketoacylsynthase (KS) which is responsible for covalent junction 
of the starter/growing polymer and extender unit; the acyltransferase (AT) selecting and loading 
the extender unit; and the phosphopantetheinylated acyl-carrier protein (ACP), holding the 
growing chain during the synthesis. Alternatively, it is known that FAS uses also amino acid 
derived starter units and PKSs can employ beside acetyl-CoA as well malonyl-CoA, propionyl-
CoA and the more uncommon aminoacid derived isobutyryl-CoA, isovaleryl-CoA and 2-
methylbutyryl-CoA.54 The completed chain is released by a thioesterase enzyme, through 
cyclization or hydrolysis depending on the type of the final molecule. Despite the similarity in 
polymer formation mechanism, the major difference between FAS and PKS lies in the different 
degree of post-assembly modification. The β-keto group in fatty acids biosynthesis is fully 
reduced after each elongation cycle, through the combined actions of ketoreductase (KR), 
dehydratase (DH) and enoylreductase (ER) enzymes. The KR reduces first the ß-keto function 
to a hydroxyl group, which is further eliminated by DH, leading to a double bond at the 
respective position and finally the ER reduces this double bond resulting in a fully reduced alkyl 
chain intermediate. In a similar fashion the growing polyketide chain is modified by the same 
set of ketoreduction enzymes, but unlike the fatty acid biosynthesis, the ketoreduction steps are 
rather optional, leading to a high variety of functional groups in the resulting polymer. 
Additionally, the AT domain in PKSs can select from a broader pool of precursors beside the 
malonyl-CoA, e.g. methylmalonyl-CoA, ethylmalonyl-CoA, hydroxymalonyl-CoA, etc.55 
Further modifications such as oxidation, glycosylation, hydroxylation, amination, acylation 
also contribute to the diversity of polyketide NPs.  
Polyketide synthases have been classified into subgroups (type I, II and III) depending on their 
architecture and functional properties. Modular type I PKS consists of linearly arranged 
obligatory KS, ACP and AT domains, as well as optional KR, DH, ER, MT and TE domains 
grouped into modules, each performing one elongation and ketoreduction step (Fig.5). The 
primary structure of type I PKS generated polyketides is dictated by the composition and order 
of domains within the linearly arranged modules, leading to co-linearity between the 
architecture of the megaenzyme complex and its product.56 This feature of type I PKS makes it 
possible to predict the primary structure of the produced polyketide. Type I PKS are producing 
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three major classes of compounds (macrolides, polyenes and polyethers) that differ by type of 
cyclization and degree of ketoreduction.  
 
Figure 5. Mechanism of modular type I PKS and typical structures. 
Macrolides consist of a large 14 to 16-membered lactone ring with one or more sugars attached. 
Representatives of this group are for instance erythromycin, bafilomycin or anthracimycin.57-59 
Macrolide antibiotics act as bacteriostatic agent by inhibiting the bacterial protein synthesis.60 
Polyene antibiotics, a subgroup of macrolides, contain a lactone ring with 25-38 carbon atoms 
including a series of conjugated double bonds. Nystatin, amphotericin and candicidin, the most 
prominent examples, are used in the treatment of mycotic infections caused by different fungi. 
The fungicidal properties are attributable to the interaction of the antibiotic with the ergosterol 
rich region of the fungal plasma membrane.61-63 Polyethers have multiple tetrahydrofuran and 
tetrahydropyran rings which derive from internal cyclization events. The inophore properties 
of these NPs are the key contributors to their antibiotic activity.64 The major application of 
compounds such as monensin, narasin and salinomycin are in veterinary medicine due to their 
activity against bacteria causing coccidiosis.65 Several variations of type I PKS exist. The 
classical cis-AT modular type I PKS, described above, are commonly accepted as a structural 
and activity model for this type of enzymes. They are mostly found in bacteria, but can also be 
found in fungi and algae.66 Vice versa, iterative type I PKSs (iPKSs) were believed to be 
predominant in fungi, but were recently also discovered in bacteria.67  
The iPKS consists of only one module, which is used in a repetitive manner to conduct a series 
of acyl-CoA condensations resulting in different degree of reduction in the polyketide chain 
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(Fig. 6). Typical structures synthesized by this enzyme are 6-methylsalicylic acid (6-MSA) and 
lovastatine produced by fungi.68,69 Bacterial iPKS were found to be involved in the biosynthesis 
of polyketomycin, chlorothricin and avilamycin whereas the iPKS provides 6-methylsalicylic 
acid for the small aromatic structural component attached to the sugar chain.70-72 
 
Figure 6. a) Mechanism of iterative type I PKS and typical representatives lovastatine and 6-
MSA. b) the structure of chlorothricin, aromatic part in the box is assembled by iPKS. 
Another large group of bacterial modular type I polyketide synthases is comprised of enzymes 
lacking acyltransferase domain.73 Usually, each module employs its own AT-domain (cis-AT 
PKS) with the defined substrate specificity, introducing the alkyl sidechain diversity into the 
growing polyketide. However, in so called trans-AT PKS, the AT domain is provided by a free-
standing enzyme, that typically have a narrow preference to malonyl-CoA as a substrate. Trans-
AT PKS systems were thought to be rare in streptomycetes, only recently it has been discovered 
that almost half (38%) of all modular bacterial polyketide synthases belong to the trans-AT 
system.74 Although that trans-AT PKS are more likely to be found in rather unusual bacteria 
species like those living in symbiosis with higher organisms.73 Another large difference of 
trans-AT PKS is the lack of correlation between the module architecture and the chemical 
structure of the resulting polyketide. This absence of co-linearity makes it difficult to predict 
structures deriving from this type of a PKS enzyme. However, over the years, comparison of 
many trans-AT PKS sequences and the corresponding polyketide structures lead to some 
regularity in how the specific domains are used and which starter and extender units are 
preferred. Nonetheless, they are often unpredictable due to the many conjunction possibilities 
of the domains in contrast to the cis-AT-PKSs. Trans-AT PKS can harbor domains performing 
new unusual chemistry, domains acting in different orders, non-functional domains or even 
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domains which act across modules. The former, is another distinguishable feature of trans-AT 
PKS. These enzymes are described to conduct several biochemical reactions during primary 
polyketide assembly, that are not found in classical cis-AT type I PKS: in line C- and O-
methylation, β-branching, double bond migration, 5- and 6-membered ring formation etc.74 This 
unusual type of PKS megaenzymes revealed many extraordinary NPs, e.g. bacillaene, 
mupirocin, macrolactin or bryostatin.75-78 Interestingly, recently the iterative trans-AT-PKS 
system was discovered, conducting the biosynthesis of chejuenolides, 17-membered 
carbocyclic tetraenes isolated from the marine bacterium Hahella chejuensis MB-108.79 
The type I PKS ketoreduction cycle, when resulting in a hydroxy group, and in line 
methylations of the polyketide typically lead to formation of a stereocenter. Thus many NPs 
assembled by type I PKS represent stereoisomers which often define their activity. The 
stereochemical outcome of the processing enzymes KR, DH as well as C-methyltransferase (C-
MT) can be predicted according to their active site residues. KR domains are divided into 
groups depending on stereospecificity of performed reaction.80 A-type KRs generate L-β-
hydroxy group, whereas B-type KRs generate D-β-hydroxy groups. Starting from a D-α-
substituted substrate, L-β-hydroxy groups derive from A1-type KRs and D-β-hydroxy groups 
from B1-type KRs. The optional epimerization of the α-substituent results in L-α-substituted 
substrate which is than reduced by A2- or B2-type KRs respectively. C2-type KRs perform 
solely the epimerization step. The hydroxy group generated by reduction of the keto group can 
be further dehydrated by the action of the DH domain which generates either a cis or a trans 
double bond. The binding of the substrate in the active site cavity has to be specific so that the 
β-hydroxy group can be protonated by aspartatic acid and L-α-proton can be abstracted by 
histidine. Due to this specific binding, DHs generate a cis double bond from L-β-hydroxy group 
substrates (A-type KR product) and trans double bonds from D-β-hydroxy group substrates (B-
type KR product).80,81 Little is known about the stereospecifity of MT domains which transfer 
a methyl group to the α-carbon mediated by S-adenosylmethionine (SAM). However, the 
investigation of four different C-MTs from trans-AT-PKSs conducting biosynthesis of 
bongkrekic acid, bacillaene, difficidine and mupirocin, resulted always in D-configuration of 
the installed methyl group.82 The fact that KR differ by their sequence around the active site 
residues can be thus used to predict the configuration by specialized software. Although, at the 
current state such prediction is still far from being completely reliable, these bioinformatics 
tools are of great help during analysis of type I PKS megaenzymes and their products. 
Iterative type II polyketide synthases (often called aromatic PKS), solely found in prokaryotic 
organism (mostly actinobacteria with some rare exceptions), are composed of two distinct 
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ketosynthase enzymes KSα and KSβ (the latter is lacking active site Cys residue and often called 
as chain length factor (CLF)), an ACP and a malonyl-CoA:ACP transacylase (MAT), loading 
the malonyl extender unit on ACP (Fig.7 a)).83 The first three proteins are forming a complex, 
called “minimal polyketide synthase”, performing a repetitive cycle of malonyl-CoA 
condensation leading to the formation of a nascent unreduced β-polyketide chain. The growing 
polymer due to its high reactivity is hidden inside the “minimal PKS” enzymatic complex that 
also determines the number of condensation events, resulting in the chains of specific length. 
Unlike the type I PKS, which incorporates the ketoreduction cycle into each step of 
condensation, type II PKS system employs no or only one ß-ketoreduction event, that is also 
proposed to dictate the first cyclization position of the polyketide chain. At the same time, type 
II PKS typically involves multiple post-PKS modification enzymes, such as cyclases (Cyc) for 
ring system formation and an aromatase/dehydratase for dehydration of cyclic alcohols 
resulting in an aromatic structure. The resulting rings can be further modified by tailoring 
enzymes such as oxygenases, hydroxylases, reductases, aminotransferases and O- or C- 
glycosyltransferase. The attachment of deoxysugars is quite often determining the biological 
activities of aromatic polyketides. Typically, genes for biosynthesis of these sugars are clustered 
together with the PKS genes. The products of type II PKS are aromatic polycyclic compounds 
that are divided into several groups depending on the type of cyclization: anthraquinones 
(actionrhodin, galvaquinone),84,85 tetracyclines (chlortetracycline, chelocardin (anti-
bacterial)),86,87 anthracyclines (doxorubicin, daunorubicin, nogalamycin (anticancer)),88-90 
angucyclines (aquayamycin, landomycin, urdamycin, simocyclinone (anticancer/anti-
bacterial)).91-94 
Type III PKS have been predominantly found in plants, but throughout the last decades, 
numerous type III PKS have been also found in bacterial and fungal genomes. This type of NP 
biosynthesis enzymes are often referred as chalcone/stilbene synthase superfamily and can be 
divided into 5 groups according to post-PKS processing enzymes (RppA, PhID, DpgA, 
ArsB/SarsS, Gcs/ArsC/PKS18).95 As type II PKS, they operate iteratively but are composed of 
one ketosynthase enzymes forming a homodimer, elongating the growing chain with a specific 
number of malonyl units (Fig. 7 b)). The distinctive feature of type III PKS is the lack of ACP 
and direct utilization of coenzyme A to deliver the extender units and hold the growing 
polyketide chain during assembly process. Products of these enzymes contain small, 
hydroxylated aromatic structures with singular aromatic rings or lactones with attached alkyl 
side chains such as in pyrones or phlorogluycinols (Fig. 7 b)). 
Introduction 
 
24 
 
Figure 7. a) Structures and mechanism of a bacterial type II PKS b) Mechanism of the ACP 
independent type III PKS and possible products.   
Nonribosomal peptides represent the second largest group of NPs. These compounds are highly 
modified oligo- or polypeptides that are produced in ribosome independent way by the enzyme 
called nonribosomal peptidesynthetase (NRPS).96 NRPS, similar to type I PKS, have a modular 
organization, leading to collinearity of the megaenzyme organization and the primary structure 
of the resulted product. The NRPS module typically consists of three major domains: 
adenylation (A), condensation (C) and peptide-carrier-protein (PCP) (Fig.8). The A-domain is 
responsible for activation and loading of a specific amino acid onto the PCP-domain, whereas 
the C-domain catalyzes the amide-bond formation between two amino acids. The A-domain 
determines the amino acid to be included into the growing polypeptide chain at each step of an 
assembly. The specificity of the A-domain to particular amino acid is determined by its primary 
sequence and is often referred to as nonribosomal code.97 Some modules might contain 
additional modification domains, like N- or C- methyltransferase, epimerase, reductase, etc. 
The final peptide is then released by a TE-domain through aminolysis, hydrolysis or 
intramolecular cyclization resulting in formation of peptidyl amides, lactones or lactams. The 
great structural diversity of non-ribosomal peptides is achieved by the incorporation of 
proteinogenic as well as non-proteinogenic aminoacids and additionally through tailoring 
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enzymes performing methylation, epimerization, hydroxylation, heterocyclization or 
glycosylation.98,99 Similar to PKS, some NRPS enzymes can act iteratively, resulting in 
structures with repeated amino acids motifs. Prominent examples of nonribosomally 
synthesized NPs are vancomycin, bacitracin or teixobactin.33,100,101  
 
Figure 8. General biosynthetic scheme for nonribosomal peptide synthesis. 
The further diversity of bacterial NPs is achieved by combining type I PKS and NRPS enzyme 
machineries to produce a hybrid polyketide-peptide compounds. An interesting feature of 
hybrid PKS/NRPS systems is that at the interface between PKS and NRPS enzymes the growing 
chain has to be translocated between them. This means that the KS domain has to accept rather 
a peptidyl chain than a polyketide chain and vice versa the C domain has to accept a polyketide 
chain rather than a peptidyl substrate.102 The hybrid enzymes employ all the features of both 
components, leading to formation of highly complex metabolites. Examples for such complex 
hybrid compounds are bleomycin and epothilone.103,104  
Non-ribosomal peptides and polyketides are by far the largest groups of bacteria derived NPs. 
Biosynthetic gene clusters encoding terpene, lantipeptide, lassopeptide, RiPP (ribosomally 
synthesized and post-translationally modified peptide) or indole NPs occur less frequent within 
the bacterial genomes, however they contribute to great variety of bacterial NPs. Only indoles 
biosynthesis will be discussed in more details. The bisindole NPs consist of two tryptophan 
units fused together, often forming an additional ring-system such as in spiroindimicin or 
borregomycin and in the indolocarbazoles erdasporine and rebeccamycin. The biosynthesis of 
bisindoles requires four core enzymes involved in modification and processing of amino acid 
L-tryptophan precursor.105 At first, L-tryptophan is converted into indolpyruvate imine by an 
amino acid oxidase. Its active species, indolpyruvate enamine undergoes than a radical coupling 
catalyzed by chromopyrrolic acid synthase to give the intermediate chromopyrrolic acid (CPA). 
The combined action of cytochrome P450 and a flavin-dependent enzyme generates the final 
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indolocarbazole core structure (Fig.9). However, the last step is sometimes skipped, like in case 
of the violacein or lynamicin. The indolocarbazoles are often modified by halogenation and 
genes encoding corresponding enzymes are coupled with the core genes. The halogenation of 
the tryptophan occurs usually before synthesis of the core structure.106 The indolocarbazoles 
have different biological activities, however the most prominent of them are rebeccamycin and 
staurosproine which are used as drug leads in anticancer therapy due to their cytotoxic 
properties.107  
 
Figure 9. General biosynthetic scheme for indole biosynthesis. 
The understanding of the logic behind the biosynthetic machinery of NPs enables scientists to 
predict the secondary metabolism potential of an examined organism when genomic data is 
available. In combination with metabolic profiling (test cultivation, analytics and dereplication) 
the detailed examination of the predicted biosynthetic gene clusters (genome sequencing, 
identification of BGC and biosynthesis pathway prediction) are a basis for identification of 
known compounds and provide hints about putatively new metabolites produced by the strain 
of interest. Such a pre-analysis prevents the needless isolation of irrelevant compounds and 
helps to prioritize the NPs produced by the isolated actinobacteria using the analytical methods 
before proceeding to their purification and characterization.  
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1.5 Isolation and Characterization of Secondary Metabolites 
If the metabolic and genomic assessments result in an annotation of an identified NP as 
potentially new, the next steps involve isolation and structure elucidation. Furthermore, the 
isolation of a compound provides a possibility for characterization of its biological activity. For 
an efficient isolation and purification procedure the combination of different extraction-, pre-
purification- and final purification methods are applied. 
1.5.1 Extraction and Purification 
Crude extracts usually consist of a large number of chemically diverse substances which differ 
in size, molecular weight and lipophilicity/hydrophilicity. According to these physicochemical 
properties, the optimal purification procedure has to be chosen individually. The initial step 
after harvesting a large cultivation batch is the appropriate separation of the compounds from 
the cellular matrix by an extraction. A liquid-liquid extraction with low or high polarity solvents 
yields either more lipophilic or more hydrophilic compounds, which decreases simultaneously 
the amount of unwanted materials. Subsequent pre-purification steps such as solid phase 
extraction (SPE), size exclusions chromatography (SEC) or flash chromatography (medium 
pressure chromatography) can give manageable fractions containing compounds of interest. As 
a final purification step, often HPLC with normal phase or reversed phase columns and 
equipped with an automated fraction collection and detectors such as DAD (diode array 
detection), FD (fluorescence detection), RID (refractive index detection), NIR (near-infrared 
detection), CD (circular dichroism), MS (mass spectrometry) or MS-MS (tandem mass 
spectrometry) is used.108-110 Overall, there is no general procedure for efficient extraction, 
separation and purification. The procedure includes always multiple steps and has to be adjusted 
to the certain NP. Nowadays, the isolation is often activity-guided or target-guided (focus on 
specific compounds selected during dereplication) in order to facilitate and accelerate the 
process.111 
1.5.2 Structure Elucidation and Assignment of Stereochemistry 
1.5.2.1 Nuclear Magnetic Resonance Spectroscopy (NMR) 
In the early years of NP research, the elucidation of the chemical structure was a complicated 
and time-consuming task due to the lack of an appropriate instrumentation. The elucidation of 
a molecule’s structure required the partial degradation of the compound into smaller fragments 
and often only a total synthesis could give the final proof. The general improvement of 
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spectroscopic techniques during the last 50 years facilitated the NP structure elucidation. 
Particularly NMR spectroscopy became a powerful and reliable tool for this purpose. In the 
beginning, the low sensitivity of the first NMR spectrometers (60 MHz magnets) and the 
absence of multiple pulse sequences for the acquisition of two-dimensional NMR spectra 
limited utilization of this technology. However, NMR spectroscopy improved to such an extent 
that it became the method of choice in NP research. The high sensitivity nowadays, provided 
by spectrometers with up to 1 GHz magnets, allows the measurement of less than 1 mg samples 
in a reasonable timeframe. The principle of NMR spectroscopy is the fact that NMR active 
nuclei (e.g. 1H, 13C, 15N) when exposed to a strong magnetic field, possess a characteristic 
precession. If radiofrequency (Rf), which matches the precessional frequency (Larmor 
frequency v0) of the nucleus, is applied perpendicular to the external magnetic field, absorption 
occurs and the nucleus changes from a lower to a higher energy level. The relaxation process 
(return to the lower energy level) causes a change in the impedance of the oscillator coils which 
is detected as signal, known as free induction decay (FID). Fourier transformation of this time-
dependent signal gives the conventional NMR spectrum. Depending on the structural 
surroundings, a nucleus is shielded or deshielded and has thus a different precessional 
frequency. The chemical shift value indicates the extent of this shielding/deshielding effect and 
can be thus used to distinguish between chemical inequivalent groups. The scalar coupling (J 
in Hz) and the resulting splitting pattern and dipolar coupling are used for constitutional and 
configurational assignment of the molecule. 
1.5.2.2 Determination of Stereochemistry 
Many NPs carry in their structure stereocenters resulting from specific steps during 
biosynthesis. The assignment of the configuration of each stereocenter in a particular molecule 
is a relevant step during structure elucidation of NPs. The stereochemistry influences the 
chemical and physical properties of a given compound and hence the pharmacological 
properties including biological mode of action. This fact is evident for many enantiomeric pairs 
of compounds. For instance, (+)-nanaomycin A possesses antibacterial activity, however its 
enantiomeric counterpart (-)-nanaomycin A exhibits additionally antifungal and 
antimycoplasma activities.112 Due to the different 3-dimensional structures of enantiomers, the 
mode of action of the two chiral drugs could significantly differ due to specifically targeting 
different binding sites of the inhibited enzyme or even inactivating different processes within 
the cell. Thus unambiguous determination of the stereochemistry of NP is very important, since 
different enantiomers in a racemic mixture can be more or less active, inactive, provoke 
undesired side effects or be even toxic.  
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a) Relative Configuration 
The relative stereochemistry of a molecule describes the position of two chiral centers in 
relation to each other. The NOESY (nuclear Overhauser effect spectroscopy) experiment, 
which is based on the observation of interproton nuclear Overhauser effects (nOe), provides 
one possibility to reveal the relative configuration of two neighbored stereocenters. Cross-peaks 
appearing in the NOESY spectrum connect protons that are spatially close to each other. In 
general, a strong signal can be seen for a pair of protons with a distance of 1.8-2.5 Å, a medium 
or weak signal for distances of 2.5-6 Å and no signal for distances larger than 6 Å.113 However, 
in NOESY experiments, nOe signals can become very close to zero in the case of molecules 
with size of 1000-3000 Da.114 In such cases the ROESY experiment (rotating frame nuclear 
Overhauser effect spectroscopy) is used to circumvent the signal loss. Although the nOe based 
assignment is very reliable for cyclic compounds, it has its limits when it comes to non-cyclic, 
highly flexible molecules, which can coexist in multiple conformers. In some circumstances, 
the large contribution of minor conformers to the nOe signal can lead to inconsistent results. 
NOESY or ROESY experiments are mainly used for the determination of the cis/trans 
configuration of double bonds or cyclic structures (Fig. 10).  
 
Figure 10. NOESY/ROESY correlation for (1)  cis/trans geometry of a double bond and (2) a 
cyclic system.115 
The determination of the relative stereochemistry in acyclic systems is also possible via the J-
based (J = spin coupling constant) configurational analysis.116 The vicinal coupling constants 
of two protons (3JHH) or a proton and a carbon (
3JHC) are strongly dependent on the dihedral 
angle ϕ (Karplus equation) and can be thus used for the relative configurational assignment in 
a polysubstituted acyclic molecule.90 The geminal carbon-proton coupling (2JHC) can be taken 
into account as well, if the carbon (C3) bears an electronegative substituent. The size of the 
2JHC 
value then depends on the angle between the proton and the electronegative substituent Z (Fig. 
11). Considering the Newman projection of a 2,3-disubstituted butane system, the vicinal 
coupling constant ranges from 0-16 Hz for 3JH2H3 and from 0-9 Hz for 
3JH2C4. The geminal 
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coupling constant 2JH2C3 values ranges from -6 to 8 Hz.  In all cases the value additionally 
strongly depends on the substitution pattern. Based on these empirical values and all 2,3JHX 
measured values extracted from the respective NMR experiment, the relative conformation of 
two or more adjoining or alternating chiral centers in a linear molecule can be estimated.  
 
Figure 11. Estimation of vicinal and geminal coupling constants of a linear system dependent 
on the dihedral angle ϕ.117 
Although the J-based configurational assignment became a powerful and reliable tool for the 
determination of the relative stereochemistry in acyclic systems, some possible limitations 
should be mentioned. In principle, the method considers only staggered rotamers of the two 
possible configurations threo and erythro. Thus, if a given conformer differs more than 15° 
from the staggered arrangement, the analysis of the J-values may lead to false results.118 Also, 
the range of variability of 2,3JHX depends strongly on the electronegativity of the substituents 
attached to the stereogenic center. Thus, a correct prediction of J values in advance may be 
difficult.119 Lastly, the J-based configurational analysis considers only the most populated 
staggered rotamer while the remaining rotamers are neglected.116 Therefore, the unambiguous 
assignment of the relative stereochemistry can be impossible in some cases. Nevertheless, the 
J-based method became an indispensable tool and facilitated the assignment of the relative 
stereochemistry in many NPs. 
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b) Absolute configuration 
The relative stereochemistry describes solely the arrangement of two stereocenters in relation 
to each other. However, it is necessary to determine the absolute configuration of the compound 
of interest. A chiral center is assigned as R or S in accordance to the spatial arrangement of the 
substituents following the Cahn-Ingold-Prelog (CIP) convention. Before NMR became the 
method of choice for the assignment of the absolute configuration, it was more common to use 
for instance chiroptical methods like circular dichroism (CD) and optical rotatory dispersion 
(ORD), crystallographic X-ray diffraction (XRD) or rotation dependent methods like infrared 
vibrational CD or Raman-spectroscopy.120-123 Although, these methods yield reliable results 
they require large amounts of the compound and even crystallized samples in the case of XRD. 
These reasons were decisive for the development of suitable NMR techniques for the 
determination of the absolute configuration. The use of NMR requires comparatively small 
amount of sample which can be recovered, the method is applicable to both solid and liquid 
samples and NMR instruments are usually more often available and easier to use. In general, 
there are two approaches for the assignment of the absolute configuration using NMR.124 The 
first is based on the fact that the addition of a chiral solvating agent (CSA) to the non-chiral 
standard NMR solvent provokes a difference in the chemical shifts compared to the sample 
without CSA. The second approach includes the derivatization of the sample of interest with 
two enantiomers of a chiral derivatization agent (CDA), whereas the differences of the chemical 
shifts of the two resulting diastereomers can be used for the determination of the absolute 
configuration. Although many CDAs have been developed so far, the "Mosher's method" first 
described in 1973 which uses α-methoxy-α-trifluoro-methylphenylacetic acid (MTPA) as chiral 
derivatization agent, has been used most often.125  The “Mosher’s method” takes advantage of 
the fact that the phenyl group of the derivatization agent exerts an anisotropic effect on both 
residues R1 and R2 of the stereocenter. The preparation of the sample with both diastereomers 
of MTPA results in two (R)- and (S)-MTPA ester derivatives which differ in their chemical 
shift values when compared to each other (Fig. 12).126 This chemical shift difference is 
expressed in the value ∆δSR. If this value becomes positive for R2 (shielded by phenyl group) 
and negative for R1 (unaffected by phenylgroup), the residues have to be arranged as it is shown 
in Fig. 12 (left) and vice versa if the signals for R1 and R2 are opposite (Fig. 12 right). Mosher’s 
method is a powerful tool for the assignment of the absolute configuration and has been 
successfully applied in many cases. Nevertheless, it has its limitations. For a reliable 
assignment, the ∆δSR should lie above the experimental error and the sign distribution within 
R1 and R2 has to be uniform. These criteria are not always met by MTPA, which engendered 
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the development of CDAs adjusted to specialized cases resulting in much cleaner chemical 
shifts.124 
 
Figure 12. Mosher reaction of a secondary alcohol with R/S-MTPA yielding R/S-MTPA ester. 
Shielding effects are indicated by arrows in the respective Newman projection. Expected 
chemical shift differences ∆δSR and subsequent arrangement of R1 and R2.124,126  
In conclusion, there is no universal applicable procedure for the determination of a 3-
dimensional structure, since the success of the assignment is highly dependent on the structural 
properties of a compound. NPs have often highly complex chemical structures which 
complicates the determination of the absolute configuration. A combination of different 
methods is thus often needed for the unambiguous assignment of stereocenters. Nevertheless, 
NMR based methods are often the first choice due to the rather simple sample preparation 
procedure and the possibility to recover the sample in most cases.  
1.6 Outline of the work 
The aim of the presented work was the isolation and characterization of novel NPs aided by a 
metabolic and genomic evaluation of the actinobacteria strains isolated from unusual 
environmental samples. The combination of analysis steps, such as dereplication of produced 
secondary metabolites, activity tests against Gram-negative and Gram-positive bacteria and 
genome mining/BGC analysis lead to pre-selection of two promising streptomycetes species, 
chosen for further examination. As complement to this, a different approach for the detection 
of novel secondary metabolites has been used during the study presented in Chapter 4.  
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The genome of the marine Streptomyces sp. MP131-18 was sequenced and 36 gene clusters 
involved in the biosynthesis of secondary metabolites were identified using antiSMASH. The 
metabolic analysis revealed the production of the two compound classes: bisindoles and 
pyrones. Isolation and structure elucidation using spectroscopic methods (MS and NMR) lead 
to the identification of two new spiroindimicins E and F. Furthermore, two new α-pyrone 
lagunapyrones D and E were predicted by analysis of respective gene cluster and identified by 
tandem MS fragmentation approach. The biosynthetic pathways for both groups of compounds 
were proposed. As described in Chapter 2, the results show that marine actinomycetes represent 
a promising source of new NPs and that a combined genomic-metabolic approach leads indeed 
to new compounds and enable the identification of their biosynthetic origin. 
Chapter 3 describes the examination of Streptomyces sp. IB2014/011-12 strain isolated from 
samples collected at Lake Baikal with potent activity against Gram-positive bacteria. Activity-
guided isolation leads to the identification of the linear polyketide alpiniamide A and its new 
derivatives B-D. The structures were established by NMR and relative and absolute 
configurations were assigned for alpiniamide A and B. The alpiniamides biosynthesis gene 
cluster was identified by genome mining, feeding of labeled precursors and gene deletion 
experiments. The heterologous expression of the cloned gene cluster confirmed these findings, 
so that the biosynthesis of alpiniamides could be clearly ascribed to a hybrid trans AT- PKS-
NRPS megaenzyme with an unusual domain arrangement. 
The last chapter deals with the development of a new transcriptional repressor-based biosensor 
concept, which allows the detection of a specific NP resulted from activation of a secondary 
metabolism gene cluster in streptomycetes. The biosynthetic gene cluster for the metabolites 
undecylprodigiosin (red) and coelimycin P1 (cpk) present in the genome of Streptomyces 
lividans TK24 have been used for the pivotal study. The biosensor construct was developed by 
placing the bpsA reporter gene for indigoidine synthetase under the control of the 
promoter/operator region, which is controlled by the TetR-like repressor originated from either 
red or cpk gene cluster. The successful application of the coelimycin biosensor was shown, 
since the biosynthesis of indigoidine was induced in response to the production of coelimycin. 
Such reporter/biosensor systems can be used in broader applications for the detection of 
activated cryptic gene cluster, which encode metabolite-sensing repressors proteins. 
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New natural products identified by 
combined genomics-metabolomics 
profiling of marine Streptomyces sp. 
MP131-18
Constanze Paulus1, Yuriy Rebets1, Bogdan Tokovenko1, Suvd Nadmid1, Larisa P. Terekhova2, 
Maksym Myronovskyi1, Sergey B. Zotchev3,4, Christian Rückert5,†, Simone Braig6, 
Stefan Zahler6, Jörn Kalinowski5 & Andriy Luzhetskyy1,7
Marine actinobacteria are drawing more and more attention as a promising source of new natural 
products. Here we report isolation, genome sequencing and metabolic profiling of new strain 
Streptomyces sp. MP131-18 isolated from marine sediment sample collected in the Trondheim Fjord, 
Norway. The 16S rRNA and multilocus phylogenetic analysis showed that MP131-18 belongs to the 
genus Streptomyces. The genome of MP131-18 isolate was sequenced, and 36 gene clusters involved 
in the biosynthesis of 18 different types of secondary metabolites were predicted using antiSMASH 
analysis. The combined genomics-metabolics profiling of the strain led to the identification of several 
new biologically active compounds. As a result, the family of bisindole pyrroles spiroindimicins was 
extended with two new members, spiroindimicins E and F. Furthermore, prediction of the biosynthetic 
pathway for unusual α-pyrone lagunapyrone isolated from MP131-18 resulted in foresight and 
identification of two new compounds of this family – lagunapyrones D and E. The diversity of identified 
and predicted compounds from Streptomyces sp. MP131-18 demonstrates that marine-derived 
actinomycetes are not only a promising source of new natural products, but also represent a valuable 
pool of genes for combinatorial biosynthesis of secondary metabolites.
The discovery of new antibiotics remains one of the most important tasks of modern biotechnology due to the 
rapid emergence of antibiotic resistance among pathogenic bacteria1. The latter leads to an increasing number 
of untreatable or poorly treatable bacterial infections, which can potentially become one of the leading causes of 
mortality2. This makes the search for new antimicrobial compounds of vital importance for modern medicine.
Two thirds of all antibiotics originate from biological sources or are the semi-synthetic derivatives of biologi-
cally produced natural compounds3. Actinomycete bacteria, in particular those of the genus Streptomyces, are one 
of the most promising biological sources of new natural products, and will remain so at least for the near future4. 
Due to the diverse secondary metabolism these bacteria accumulate a large number of compounds, which may 
become drug leads for the development of antibacterials, antivirals, immunosuppressants, antifungals, insecti-
cides, and antitumorals. The intensive exploration of terrestrial actinomycetes in 1950–70 s has led to frequent 
re-discovery of bioactive compounds, thus drawing interest to new ecological niches, which may become sources 
of new actinomycetes5. Given that oceans cover more than 70% of the Earth’s surface and host approximately 87% 
of global biodiversity, they appear largely underexplored in terms of discovery of new microorganisms, including 
actinomycetes. Taking into consideration unprecedented diversity of marine organisms and comparatively little 
work done so far, the reported identification of more than 20.000 new marine natural products is astounding6. 
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Many of these compounds are produced by marine actinomycetes isolated from the deep sea sediments, coral 
reefs, marine invertebrates, and plants7,8. The taxonomic diversity of these actinomycetes ranges from typi-
cal representatives of Streptomyces to more exotic and rare Dietzia, Rhodococcus, Salinispora, Marinophilus, 
Solwaraspora, Salinibacterium, Aeromicrobium, Williamsia and Verrucosispora species, increasing the chances for 
the discovery of new bioactive natural products8. Several compounds produced by marine actinomycetes have a 
strong potential to be developed into pharmaceutical drugs. Diazepinomicin, a dibenzodiazepine alkaloid from a 
marine Micromonospora strain, possessed antibacterial and antitumor activities, and had been in phase II clinical 
trials for the treatment of glioblastoma9,10. Salinosporamide A, a β -lactone-ɣ -lactam from Salinispora tropica, 
entered phase I clinical trials as a drug for treatment of multiple myeloma just three years after its discovery11.
The post-genomic era in actinomycete research is outlined by the discovery of multiple secondary metabolite 
biosynthesis gene clusters in the strains thought to be producing only few compounds12,13. This finding led to a 
rapid development of genomics-based approaches for the discovery of new natural products, resulting in isolation 
of new secondary metabolites from well-studied strains14,15. The application of genomics-based approaches has 
also broadened the diversity of natural products discovered from the marine actinomycetes16,17.
Here, we report the genome sequencing of the marine-derived actinomycete MP131-18. The detailed phy-
logenetic classification identified the strain as Streptomyces. The secondary metabolite biosynthesis gene clusters 
analysis and complete dereplication of secondary metabolites profile of the strain led to identification of several 
known and new natural products, their association with the corresponding gene clusters, and prediction of the 
biosynthetic pathways.
Results
General properties of the Streptomyces sp. MP131-18 genome. Strain MP131-18 was isolated from 
a deep-water marine sediment sample collected in the Trondheim fjord, Norway. The sediment suspension from 
which this isolate was obtained was treated with extremely high frequency radiation (EHF) that was shown to 
selectively promote growth of various rare actinomycete bacteria18. The MP131-18 isolate was recovered after 
plating of the diluted EHF-treated suspension on oatmeal agar. On this medium, the isolate had a cream-colored 
aerial mycelium, while its substrate mycelium and spores were brown with olive tinge. Its cell wall was shown to 
contain LL-diaminopimelic acid, which is characteristic for Streptomyces spp. Still, phenotypic characteristics of 
the isolate MP131-18 were not typical for streptomycetes, prompting phylogenetic analysis of its 16S rRNA gene. 
A 1421 bp PCR fragment obtained from the genomic DNA of MP131-18, representing the almost complete 16S 
rRNA gene, was sequenced and analysed using Ribosomal Database Project Classifier, which strongly suggested 
it belonging to the genus Streptomyces.
Sequencing of the Streptomyces sp. MP131-18 genome was performed using two Illumina MiSEQ libraries 
– short-insert (paired-end, PE) and long-insert (mate pair, MP). The genome was assembled in a total of 10 scaf-
folds. The chromosome of Streptomyces sp. MP131-18 appears to be linear with most of the genome (7,861,428 bp) 
in scaffold 1 (Fig. 1). The other 9 scaffolds cover in total 95 kbp of genomic information with the largest being 
Figure 1. Schematic representation of the Streptomyces sp. MP131-18 genome (scaffold 1 only), created 
with the help of Circos58. Megabases are labeled; smaller ticks correspond to 100 kbp segments. From outside: 
genes on the forward and the reverse strands (blue: shorter than 900 bp, green: between 900 and 1500 bp 
long, orange: longer than 1500 bp); 35 secondary metabolite clusters colored by predicted type; G+ C content, 
10 kbp window (blue color highlights segments with G+ C content < 69%, yellow highlights correspond to G+ 
C content over 76%); G+ C content, 100 kbp window (lighter blue is higher G+ C, darker blue is lower G+ C 
content); G+ C skew (green: positive; blue: negative).
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48 kbp in size, and do not carry any housekeeping or secondary metabolism genes. Based on both PE and MP 
linking evidence (Figs 1S and 2S), the 9 extra scaffolds could represent unplaced parts of the scaffold 1 – that is, 
scaffold 1 is the complete bacterial chromosome, where gaps could be filled by the other 9 scaffolds. No plasmids 
were identified in Streptomyces sp. MP131-18. The G+ C content (72.4%), the number of protein (7,054) and 
tRNA (78) encoding genes are comparable with other streptomycetes12. The genes for chromosomal replication 
initiation factor, dnaA (SBA_03553), and β -subunit of the DNA polymerase III, dnaN (SBA_03552), are located in 
the central part of the scaffold 1. The oriC is located between the dnaN and dnaA genes and contains three DnaA 
boxes (TTGTGCACAGG) conserved in Streptomyces species19. Both ends of scaffold 1 contain telomere-like 
~100 bp inverted repeats with 4 possible hairpin structures.
The analysis of the genome sequence using the secondary metabolites biosynthesis genes search tool antiS-
MASH20 revealed the presence of 36 putative gene clusters (Fig. 1). In comparison, the genomes of S. coelicolor12, 
S. averitilis13, and S. albus J107421 contain 20, 25 and 22 secondary metabolism gene clusters, respectively. The 
location of many of the secondary metabolism gene clusters in the Streptomyces sp. MP131-18 chromosome coin-
cides with regions of low G+ C content (Fig. 1).
Phylogenetic analysis. To taxonomically delineate Streptomyces sp. MP131-18, we performed phylogenetic 
analysis by two complementary approaches using 16S ribosomal RNA sequences (Table 1S) and 5 genes coding 
for housekeeping proteins (RpoB, DnaK1, RecA, SsgB, and SsgA; Table 2S)22,23. A dendrogram based on the 16S 
rDNA gene (Fig. 2A) clearly shows that Streptomyces sp. MP131-18 is closely related to the unclassified actino-
bacterium NPS-12745 (GenBank accession EF551062.1), previously proposed to be a member of the new genus 
Marinispora24. There is only a single ambiguity in the aligned part of both 16S rRNAs: where Streptomyces sp. 
MP131-18 has a cytosine (1516 bp), NPS-12745 has an IUPAC ambiguity code for pyrimidine. The second closest 
hit that showed similarity to 16S rRNA from both Streptomyces sp. MP131-18 and Streptomyces sp. NPS-12745 is 
strain Streptomyces massiliensis, isolated from human gut25.
To perform an alternative protein-based phylogenetic analysis, the amino acid sequences of five highly con-
served proteins (RpoB, DnaK1, RecA, SsgB, and SsgA; Table 2S)22,23 from MP131-18 were used for searches 
(via BlastP) against the NCBI NR database to identify the most similar proteins from other species. Three 
Streptomyces species were occurring the most often in search results for DnaK1, RecA, RpoB and SsgB: marine 
actinomycete Streptomyces sp. SBT34926, as well as the soil isolates S. specialis27, and S. avicenniae, both found in 
the rhizosphere of the mangrove plant28. SsgA search results had protein identities under 70% and thus were not 
considered. The five protein sequences from 4 genomes (MP131-18 and the three aforementioned species) and 
S. fulvissimus as an outgroup were concatenated, multiple-aligned using MAFFT, and used for RaxML dendro-
gram construction (Fig. 2B).
The phylogeny based on the five proteins suggests (and 16S rDNA based phylogeny supports) that Streptomyces 
sp. MP131-18 is most similar to S. specialis and S. avicenniae. Both protein- and 16S-based phylogenies identified 
representatives of the Streptomyces genus as neighbours of MP131-18. Thus, we conclude with a high degree of 
confidence that MP131-18 as well as NPS-12745 and the unclassified Streptomycetaceae bacterium NPS-8920 
belong to the genus Streptomyces.
Functional gene annotation. Functional annotation of Streptomyces sp. MP131-18 proteins with the bac-
tNOG subset of the eggNOG v4 database (using protein BLAST with an expectation value cut-off of 0.001)29 
resulted in identification of possible orthologues with some biological function assigned for 4,533 (64.3%) out of 
7,054 proteins (Table 3S), with some of the genes assigned to more than one category. Of the remainder, 986 CDSs 
(14%) had no hits against bactNOGs, and 1,535 proteins (21.8%) had hits against proteins without functional 
Figure 2. (A) Relation of Streptomyces sp. MP131-18 to the most 16S rRNA similar Streptomyces. S. fulvissimus 
16S rRNA was used as outgroup. B. Relation of Streptomyces sp. MP131-18 to three other Streptomyces, as 
estimated by a 5-protein concatemer phylogenetic analysis. S. fulvissimus concatenated protein was used as 
outgroup.
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category (function unknown). Among the proteins with functional assignment, 2,018 (28.6%) are implicated in 
metabolism, including 170 (2.4%) participating in secondary metabolism.
Analysis of secondary metabolism gene clusters. The antiSMASH3.0 analysis of Streptomyces sp. 
MP131-18 genome revealed 36 gene clusters predicted to be involved in the secondary metabolism of the strain, 
occupying 8.4% of the chromosome. However, the re-evaluation of antiSMASH3.0 results revealed that cluster 1 
is most probably encoding two distinct pathways for terpene and polyketide biosynthesis (designated as cluster 
1a and 1b respectively) (Table 4S).
Within the genome of Streptomyces sp. MP131-18, six gene clusters with type I polyketide synthase (PKS) 
genes were predicted, most of them coding for small mono- or bimodular PKSs. Cluster 35 is probably involved 
in production of a compound containing an α -pyridone ring, based on high similarity to PKS and post-PKS 
enzymes from the piericidin A1 biosynthesis gene cluster30. Other type I PKS gene clusters (9, 10 and 33) have 
no homologues in sequenced bacterial genomes available in the public databases, and their products could be 
just partially predicted from the genes’ organization. Gene cluster 1b is coding for type II PKS most probably 
synthesizing compounds of the angucycline group. The presence of glycosyltransferase and sugar aminotrans-
ferase encoding genes in the 1b cluster suggests glycosylation of the produced polyketide. Gene cluster 7 is cod-
ing for the type III PKS that resembles the α -pyrone type PKS from fungi and plants31. A similar type III PKS 
is also found in the hybrid gene cluster 3, together with a monomodular type I PKS encoding gene. Cluster 19 
is predicted to encode a biosynthetic pathway for a polyunsaturated aryl polyene-like compound. Only three 
non-ribosomal peptide synthase (NRPS) gene clusters were found within the genome of Streptomyces sp. MP131-
18 (2, 15, 17). Cluster 2 is similar to the coelibactin gene cluster from S. coelicolor12. The structure of this com-
pound is not known, but it is thought to act as zincophore. Four gene clusters - 13, 14, 30, and 34 - combine type 
I PKS and NRPS-encoding genes. Clusters 13, 14, and 30 include genes coding for discrete adenylation domain 
proteins that most probably are supplying the amino acid starter units for the PKS components.
Five gene clusters (1a, 8, 16, 18, 29) within the genome of Streptomyces sp. MP131-18 are devoted to terpenes 
biosynthesis, including cluster 18 for the sesquiterpene geosmin. Cluster 23 is coding for a type I PKS and a ter-
pene synthase/cyclase. It also contains a glycosyltransferase suggesting that the putative hybrid product might be 
glycosylated.
Another large group of secondary metabolism gene clusters are coding for ribosomally synthesized and 
post-translationally modified peptides (RiPPs)32. Clusters 6, 21, 25, and 27 are coding for lantipeptide type com-
pounds. Cluster 6, beside the lanM homologue, also harbours a gene for thiazole ring formation. Cluster 20 is 
similar to a recently discovered actinobacterial gene cluster for lasso-peptide biosynthesis33.
Several other secondary metabolites could be potentially produced by Streptomyces sp. MP131-18. Among 
them, two siderophore molecules encoded by clusters 12 and 32 (cluster 32 showed high similarity to desferri-
oxamine B biosynthesis genes), melanine (cluster 26), ectoine (cluster 31), bacteriocin (cluster 28), and A-factor 
like butyrolactone (cluster 4). Cluster 11 is presumably governing biosynthesis of a pyrrolopyrimidine nucleoside 
antibiotic. Two other gene clusters, 22 and 36, are predicted to be responsible for phenazine and indolocarbazole 
type compounds biosynthesis, respectively.
Streptomyces sp. MP131-18 produces a group of bisindole pyrrole antibiotics. Based on the 
genome analysis, Streptomyces sp. MP131-18 appeared to be a strain with prolific potential for production of 
various, potentially new, secondary metabolites. In order to assess this, MP131-18 was grown in two different pro-
duction media, and extracted metabolites were found to be active against Bacillus subtilis but not Pseudomonas 
putida. The extracts were further analysed by high-resolution LC-QTOF mass spectrometry and compounds were 
dereplicated using the Dictionary of Natural Products (DNP) database34.
The dominant metabolites produced by Streptomyces sp. MP131-18 were two groups of closely related bisin-
dole pyrrole antibiotics, lynamicins and spiroindimicins (Fig. 3). Based on the exact masses and absorption spec-
tra, we were able to identify lynamicins A-G (peaks 2-4, 6, 7, 10, 12) and spiroindimicins B and C (peaks 11, 5) 
(Figs 3 and 4). These compounds were previously isolated from the marine actinomycete Streptomyces sp. SCSIO 
03032 and a strain designated as Marinispora NPS-1274524,35,36. Both lynamicins and spiroindimicins were shown 
to have antibacterial activity. Thus, the ability of the Streptomyces sp. MP131-18 extracts to inhibit growth of 
B. subtilis is most probably caused by accumulation of these compounds. Lynamicin E and spiroindimicin B 
were purified (4.8 mg and 2.9 mg from 5L of culture, respectively) and their structures confirmed by NMR. 1D 
1H, 13C NMR spectra and 2D correlations of 1H-1H COSY, HSQC and HMBC NMR spectra are summarized in 
Supplementary Tables 5S and 6S. Moreover, the compound 1 was identified as lycogarubin C37, also known as 
chromopyrrolic acid, the key intermediate in bisindole pyrroles biosynthesis (Figs 3 and 3S)38.
The compound with RT of 11.84 min showed the absorption spectra typical for identified bisindole pyrroles, 
but the detected mass did not correspond to any known lynamicins or spiroindimicins (Fig. 3)24,35,36. During the 
HPLC, the peak was found to separate into two peaks (Fig. 4S), and both of these compounds 8 and 9 were puri-
fied and their structures elucidated by NMR.
The compounds 8 and 9 were obtained as white solids (yield: 0.3 mg and 0.6 mg from 5 L of culture, respec-
tively). The HRESIMS of compound 9 gave a quasimolecular ion peak at m/z 404.1202 [M+ H]+ corresponding to 
a molecular formula of C23H18ClN3O2 (Fig. 3). The UV spectrum of 9 with maxima at 248 and 286 nm was similar 
to other spiroindimicins. Compound 9 displayed the same molecular ion peak at HRESIMS (m/z 404.1202 [M+ 
H+]), UV absorption spectra (λ max 248 and 286 nm) and molecular formula C23H18ClN3O2 as 8, but had slightly 
different retention time. The new compounds were named spiroindimicin E (8) and spiroindimicin F (9). The 
35Da mass difference of both new compounds to spiroindimicin B let us assume that the disparity is caused 
by the lack of one chlorine atom. This was confirmed by the analysis of the isotopic pattern of mass peaks of 
www.nature.com/scientificreports/
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spiroindimicins B, E and F (data not shown). Furthermore the same m/z at HRESIMS and UV spectra for the new 
compounds suggest that they are constitutional isomers (Figs 3 and 4).
2D NMR data of both spiroindimicins E and F showed high similarity to those of spiroindimicin B (Tables 
7S and 8S). Careful analysis of protons and carbons in the aromatic region allowed us to assign the position of 
chlorine atoms. In fact, the 1H NMR spectrum of compound 8 exhibited eight aromatic signals. Proton splitting 
pattern of four of them and their HMBC correlations suggested compound 8 lacks a chlorine atom at C-6” in 
comparison to spiroindimicin B (Table 6S). Furthermore, the remaining two meta coupled doublets revealed the 
chlorine atom is at C-6’ in spiroindimicin E (Table 7S). This finding was further supported by the HMBC corre-
lations. Sequential COSY correlations of protons H5’-H8’ and HMBC correlations of spiroindimicin F suggested 
the indol ring comprising protons H5’-H8’ is not substituted, while the remaining indol ring has chlorine substi-
tution at C6” due to proton splitting patterns as well as HMBC correlations (Table 8S).
Another minor compound with RT of 10.19 min was obtained in scarce amounts and it exhibited a quasimo-
lecular ion peak at m/z 390.1014 [M+ H]+. This compound is predicted to be monochlorinated lynamicin F-like 
bisindole pyrrole based on its HRESIMS and isotopic pattern (Fig. 3). However, further investigation is required 
to establish the exact structure of this metabolite, tentatively designated as lynamicin H.
Isolated compounds (lycogarubin C, lynamicin E, spiroindimicin B and spiroindimicin E) were tested against 
Bacillus subtilis, Escherichia coli and Pseudomonas putida (Table 9S). None of them were found to be active against 
Gram negative test cultures and only spiroindimicin B demonstrated moderate activity against Bacillus subti-
lis. The antibacterial properties of spiroindimicins, similar to lynamicins24, seem to correlate with the degree of 
Figure 3. DAD chromatogram of extracts from Streptomyces sp. MP131-18. The identified compounds 
are indicated by numbers and their features are listed in the table. Compounds identified during this work are 
highlighted in red.
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chlorination. The monochlorinated lynamicins and spiroindimicins are weak inhibitors of bacterial growth, while 
antibacterial activity of both families of compounds is increasing with the increase of number of halogen atoms 
in their structures.
One of the new compounds, spiroindimicin E, as well as previously described lynamicin E and lycogarubin C 
were tested for cytotoxic activity (Fig. 5S). Spiroindimicin E shows a very slight effect on cellular growth of T24 
bladder carcinoma cells, whereas treatment with 10 μ M lynamicin E led to more than 50% reduction of prolifera-
tion capacity. At the same time, as expected, lycogarubin C almost completely inhibited proliferation of the tested 
cancer cell line at this concentration.
Among the secondary metabolite biosynthesis gene clusters, the only candidate identified for bisindole 
pyrroles biosynthesis is cluster 36, thereafter called lyn (Fig. 4, Table 4S). The core genes of the cluster, designated 
SBA_07020, SBA_07021 and SBA_07022, are coding for tryptophan 2-monooxygenase, chromopyrrolic acid syn-
thase, and cytochrome P450, respectively. These genes are known to be involved in assembly of bisindole pyrrole 
core and probably its closing into spiroindimicins structures. Genes SBA_07024 and SBA_07025 are encoding 
two halogenases that presumably attach chlorine atoms at two different positions on the bisindole rings (6’/6” and 
7’/7”) (Fig. 4). The halogenase genes are forming operons with the genes SBA_07022 and SBA_07026 coding for 
flavin reductases participating in halogenation reaction. Lastly, SBA_07018 is encoding a transcriptional regula-
tor of the NarP family, probably controlling the expression of the structural genes, and SBA_07019 is encoding a 
putative transporter protein probably involved in export of metabolites from the cell.
Streptomyces sp. MP131-18 produces unusual α-pyrones. Beside the bisindole pyrroles, 
Streptomyces sp. MP131-18 was found to accumulate other compounds belonging to the α -pyrone group. Three 
lagunapyrones A-C were identified by exact mass and absorption spectra in the extracts from Streptomyces sp. 
MP131-18 culture (Figs 3 and 5). These compounds were originally isolated from the unclassified marine actino-
mycete CNB-984, and comprise a group of closely related α -pyrones functionalized by a highly methyl-branched 
C19 side chain39. Despite the structural similarity of α -pyrones, they can be assembled by PKS enzymes of 
either type I, II or III. The best candidate for lagunapyrones biosynthesis within the genome of Streptomyces sp. 
Figure 4. Structures of bisindole pyrrole compounds identified in the extract from Streptomyces sp. 
MP131-18 and schematic representation of gene cluster 36. Predicted genes functions: SBA_07018 
– transcriptional regulator; SBA_07019 – putative transporter protein; SBA_07020 - tryptophan 
2-monooxygenase; SBA_07021 – chromopyrrolic acid synthase, VioB homologue; SBA_07022 – RebP-like 
cytochrome P450; SBA_07023, SBA_07026 - flavin reductases; SBA_07024, SBA_07025 – halogenases.
Figure 5. Structure of lagunapyrones A-E and schematic representation of gene cluster 3. The domain 
organization of putative lagunapyrone iPKS (SBA_00390) is predicted by antiSMASH 3.020.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:42382 | DOI: 10.1038/srep42382
MP131-18 is cluster 3, which contains genes coding for a single module type I PKS (SBA_00390) and α -pyrone 
type III PKS enzymes (SBA_00389). The possible implication of the type III PKS allowed us to predict the high 
flexibility of the choice of acyl-CoA esters that are utilized by the pathway. Based on this prediction, we were 
able to identify two new lagunapyrones D and E produced by Streptomyces sp. MP131-18. The newly identified 
metabolites have MS2 fragmentation patterns similar to the previously identified compounds A-C (Fig. 6S). The 
characteristic daughter ion peak at m/z 321.3 [M+ H]+ was observed for all lagunapyrones, which is ascribable to 
the side chain cleaved between C6 and C7 after loss of three water molecules. Lagunapyrones D and E differ from 
the described A and C congeners, respectively, by 14Da, most probably indicating a differences in the alkyl chain 
length at C2 position of α -pyrone ring (Fig. 5).
Discussion
The discovery of new antibiotics faced the stagnation phase when scientists realized that the same compounds are 
more and more often isolated from different actinomycete bacteria obtained from soil. Realizing this phenome-
non caused a rapid change in the strategies used for natural product discovery by switching to new sources in the 
search of producing organisms. Undoubtedly, the oceans are the largest source of biodiversity and are relatively 
poorly studied. The growing information on the biosynthetic potential of marine microorganisms further invig-
orated the research in this area6,8.
Here we report the use of a combined genomics-metabolomics approach in order to identify and isolate new 
compounds from a marine-derived actinomycete. Strain MP131-18 was isolated from a deep-water sediment 
sample and its genome was sequenced. The genome size, structure, G+ C content and other features are typical 
for other streptomycetes genomes (Fig. 1). Both 16S rRNA and multilocus marker phylogenetic analyses clearly 
showed that the strain belongs to the genus Streptomyces (Fig. 2). The strain was found to be closely related to 
another marine actinomycete previously classified as Marinispora sp. NPS-1274524. Interestingly, several regions 
in the Streptomyces sp. MP131-18 genome have lower than average G+ C content (Fig. 1). These regions comprise 
putative genomic islands, the recently restructured parts of the chromosome, most likely acquired by horizontal 
gene transfer40. The location of the secondary metabolism gene clusters within these putative genomic islands 
suggests that their origin is most likely other microorganisms, including Proteobacteria and fungi.
For a streptomycete, Streptomyces sp. MP131-18 possesses an average number of gene clusters dedicated to 
secondary metabolism: 36 clusters, occupying 8.4% of the genome. This number is slightly higher than in S. coeli-
color A3(2) (20 gene clusters)12 or S. avermitilis MA-4680 (25 gene clusters)13 with 5% and 6.6% of the genes gov-
erning secondary metabolism biosynthesis, respectively, but still lower than in the case of Kutzneria albida with 
14% of the chromosome devoted to secondary metabolism41. The Streptomyces sp. MP131-18 genome is encoding 
clusters for the synthesis of at least 18 different types of secondary metabolites, proving the high potential of 
marine actinomycetes to produce chemically diverse compounds. These include genes for a lassopeptide that is 
just a second example among actinobacteria33 and aryl polyenes that were found so far only in Proteobacteria42. 
The latter compounds are thought to act as photoprotecting and antioxidant agents.
The gene cluster 36, due to similarity to rebeccamycin biosynthesis genes, was predicted to be involved in the 
biosynthesis of an indolocarbazole type compound. Indeed, two groups of highly halogenated bisindole pyrroles, 
lynamicins and spiroindimicins, were identified in the extracts of Streptomyces sp. MP131-18 (Fig. 3). Beside 
lynamicins A-G and spiroindimicins A-D, previously isolated from the marine actinomycetes Streptomyces sp. 
SCSIO 03032 and Marinispora NPS-1274524,35,36, we have purified two new compounds designated spiroin-
dimicin E and F (Figs 3 and 4). Tentatively, a new lynamicin H was also identified, but was not structurally char-
acterized. Besides that, lycogarubin C can be found in the Streptomyces sp. MP131-18 extract37. This metabolite 
was originally discovered in the extract of the slime mould Lacogala epidendrum, and later as an intermediate in 
staurosporine and rebeccamycin biosynthesis in S. longisporoflavus and Lechevalieria aerocolonigenes A, respec-
tively43,44. The presence of lycogarubin C in the extracts of Streptomyces sp. MP131-18 and its structural resem-
blance to the core of the identified antibiotics suggest that it might act as a common precursor or a shunt product 
in the biosynthesis of lynamicins and spiroindimicins. The fact that halogenation occurs before the assembly of 
the bisindole pyrrole ring system supports the shunt product hypothesis (Figs 3 and 7S)45. This indicates the high 
flexibility in substrate selection by the bisindole pyrrole assembly enzymes. Because of the structural diversity of 
lynamicins and spiroindimicins, the identified gene cluster might comprise a source of individual genes for the 
combinatorial biosynthesis of new bisindole pyrrole and indolocarbazole antibiotics, especially the ones encoding 
halogenation steps and formation of spirane structure.
A group of α -pyrones called lagunapyrones were also identified in the extract of MP131-18 (Fig. 5)39. These 
compounds comprise a long methyl-branched polyketide chain assembled into the final molecule by the linkage 
to the short fatty acid chain through the pyrone ring. The only gene cluster that could be involved in the biosyn-
thesis of such compounds (cluster 3) contains type I and type III PKS genes. The type I PKS resembles the itera-
tive highly reductive PKS enzymes from the fungal plant pathogen Alternaria solani, involved in alternapyrone 
biosynthesis, and is thought to synthesise the C20 polyketide chain (Fig. 6)46. Furthermore, the predicted lagu-
napyrone iPKS does not contain the enoylreductase domain. This activity is thought to be supplied by separate 
enzymes similar to those involved in the biosynthesis of the fungal metabolite lovastatin47. The acyl-transferase 
domains of PKSI enzymes are predicted to be specific for malonate extender units. The highly methyl-branched 
C19 polyketide side chain of lagunapyrones is assumed to be decorated as a post-PKS modification similar of the 
corresponding steps in alternapyrone or nafuredin biosynthesis46,48. However, the lagunapyrone PKSI is lacking 
the C-methyltransferase domain, while a gene coding for standalone C-methyltransferases is located in close 
proximity to the PKSIII gene. The type III PKS is presumably further extending the C20 polyketide chain assem-
bled by PKSI with a single acetate unit. The same enzyme is thought to perform the intermolecular closing of 
α -pyrone ring with the short chain fatty acid-CoA esters49. Taking into account the flexibility of type III PKS 
enzyme in choosing the acyl-CoAs, we predicted the existence of at least two other lagunapyrones with C2 and 
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C5 alkyl chains. Indeed, the corresponding compounds, named as lagunapyrone B and E, were identified in the 
extract of Streptomyces sp. MP131-18 (Figs 3 and 5). This finding proves that the combination of detailed metab-
olomics and genomics is a powerful tool in finding new natural products. The prediction and understanding of 
biosynthetic processes leading to formation of particular metabolites helps to identify these compounds.
Methods
Bacterial strains, cultures conditions and general procedures. Streptomyces sp. MP131-18 was iso-
lated from a marine sediment collected at the depth of 450 m at the Tautra ridge in the Trondheim fjord, Norway 
(63°55,909N, 010°61,846 E). The sediment sample was treated with extremely high frequency radiation and plated 
in dilutions on the oatmeal agar as described in18. Streptomyces strains were grown on mannitol soy flour agar 
(MS agar) and in liquid TSB medium50. NL19 (MS medium without agar)50 and SG51 mediums were used for 
secondary metabolite production.
Genome sequencing. For DNA isolation, Streptomyces sp. MP131-18 strain was inoculated into TSB 
medium and grown at 28 °C with shaking (200 rpm) for 3 days. High quality total cellular DNA was isolated using 
salting out procedure50. The purity and concentration of the genomic DNA was determined using a Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific).
The obtained genomic DNA was sequenced using two MiSEQ libraries (Illumina) – short-insert (paired-end) 
and long-insert (mate pair). Assembly of the shotgun reads was performed with the Newbler v2.8 assembler 
(Roche). Genome annotation was performed using Prokka52. All predicted ORFs were manually re-inspected to 
correct start codon position. For the identification of secondary metabolites clusters antiSMASH 3.0 was used20.
Nucleotide sequence accession number. The Streptomyces sp. MP131-18 Whole Genome Shotgun pro-
ject has been deposited at DDBJ/ENA/GenBank under the accession LZNS00000000. The version described in 
this paper is version LZNS01000000.
Phylogenetic analysis. rRNA delineation was initially performed using the ARB-SILVA database53, which 
suggested a number of neighbour (most similar) species. 16S rRNA sequences of these species were downloaded 
from ARB-SILVA (Table 1S), and multiple-aligned using MAFFT v7.22254 (algorithm: auto, scoring matrix: 
200PAM/k = 2, gap open penalty 1.53, offset value 0.123). The dendrogram was constructed using RaxML 7.2.855 
(nucleotide model: GTR GAMMA, algorithm: rapid bootstrapping and search for best-scoring ML tree, boot-
strap replicates: 1000). The tree was formatted in Geneious 9.0.456.
MAFFT and RAxML were also used for 5-gene alignments, with the same options as above. Accession num-
bers of the used gene sequences are listed in Table 2S.
Strain cultivation and metabolites extraction. The pre-cultures were grown in 10 ml of TSB in 100 mL 
flasks with glass beads for 3 days at 28 °C. Subsequently, the main cultures (50 ml of SG or NL19 medium in 
500 ml flasks) were inoculated with 4 ml of pre-culture and cultivated at 28 °C on a rotary shaker at 180 rpm for 
7 days. Metabolites were extracted with acetone:methanol 1:1 from biomass and with ethyl acetate from cultural 
liquid, evaporated and dissolved in 250 μ l of methanol. The LC-HRMS data were collected on a Dionex Ultimate 
3000 RSLC system using a BEH C18, 100 × 2.1 mm, 1.7 μ m dp column (Waters, Germany). Separation of 1 μ l sam-
ple was achieved by a linear gradient of solvent B (acetonitrile with 0.1% of formic acid) against solvent A (water 
with 0.1% of formic acid) at a flow rate of 600 μ l/min and 45 °C. The gradient started by a 0.5 min isocratic step 
at 5% B then increased to 95% B over 18 min to end up with a 2 min step at 95% B before re-equilibration under 
the initial conditions. UV spectra were acquired by a DAD in the range of 200 to 600 nm. The mass-spec data was 
collected on a maXis 4 G hr-ToF ultrahigh resolution mass spectrometer (Bruker Daltonics, Germany) using the 
Apollo II ESI source. Mass spectra were acquired in centroid mode ranging from 200 to 2500 m/z at a 2 Hz scan 
rate. Extracts from biomass and supernatant were analysed separately.
Data were collected and analysed with the Bruker Compass Data Analysis software, version 4.1 (Bruker, 
Billerica, USA). The screening for known compounds was performed using the Dictionary of Natural Products 
Figure 6. Proposed scheme for lagunapyrones A-D biosynthesis. 
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database version 6.1 (CRC Press, Boca Raton, USA), using the following parameters: accurate molecular mass 
(mass match tolerance 10 ppm), absorption spectra and source of compounds isolation34.
Isolation and purification of compounds. Streptomyces sp. MP131-18 was grown at 28 °C for 3 days in 
6 × 500 ml flasks containing 50 ml of TSB medium and pre-cultures were used to inoculate 100 × 500 ml flasks 
containing 50 ml of SG media. Cultures were incubated at 28 °C for 7 days on rotary shakers at 180 rpm. The bio-
mass and cultural liquid were separated by centrifugation. Metabolites were extracted from supernatant with 3L 
of ethyl acetate and from biomass with 500 ml of a 1:1 mixture of acetone:methanol. Extracts were evaporated and 
resuspended in 20 ml of methanol. Extracts from biomass and supernatant were combined.
Extracts were fractionated in two steps: size-exclusion chromatography and preparative HPLC. The extracts 
were loaded on a 1 m long column packed with LH 20 Sephadex (Sigma-Aldrich) and eluted with methanol as 
solvent. The fractions were collected every 15 min with a flowrate of 1 ml per minute. The obtained fractions were 
evaporated and dissolved in 0.5 ml of MeOH.
Samples were further separated by preparative HPLC (Agilent 1100 Series, Agilent Technologies and 
Dionex UltiMate 3000, Thermoscientific) using NUCLEODUR® C18 HTec column (250 × 10 mm, 5 μ m) 
(Macherey-Nagel) with a linear gradient of solvent B (acetonitrile with 0.1% of formic acid) against solvent A 
(water with 0.1% of formic acid) at a flow rate of 4.5 ml/min and 45 °C. New compounds were separated using a 
gradient starting from 30% and increasing to 70% of B over 30 min. UV spectra were recorded with DAD detector 
at 280 nm. Individual peaks were collected and analysed with a LC-MS amaZon system (Bruker, Daltonics) using 
a BEH C18, 50 × 2.1 mm, 1.7 μ m dp column (Waters, Germany) and a linear gradient 5-95% of B over 9 min.
NMR spectra were acquired on a Bruker Ascend 700 MHz NMR spectrometer equipped with a 5 mm TXI 
cryoprobe. As solvent, deuterated MeOD4 and DMSO-d6 were used and HSQC, HMBC, 1H-1H COSY spectra 
were recorded using standard pulse programs.
Antibacterial assay. Antimicrobial activities of the extracted metabolites were assayed by a disc diffusion 
method, loading 40 μ l of each extract on 6 mm diameter paper discs. Test cultures of Bacillus subtilis ATCC 6633 
and Pseudomonas putida KT 2440 were plated from the liquid cultures on solid LB medium, dried for 20 min-
utes prior applying the discs. Plates were incubated overnight at 37 °C. The zones of inhibition were measured 
manually with accuracy ± 1 mm. The minimum inhibitory concentration (MIC) determination was conducted 
as described57, except that LB medium was used to grow the test cultures. Solution of thiazolyl blue tetrazolium 
bromide (Sigma-Aldrich) was used for growth visualization.
Cell proliferation assays. T24 bladder carcinoma cells were stimulated for 72 h and stained with crystal 
violet solution (0.5% crystal violet (w/v), 20% methanol (v/v) in H2O). Next, unbound dye was removed by rins-
ing with distilled water. Following air-drying, crystal violet was dissolved in ethanol/sodium-citrate solution (50% 
ethanol (v/v), 0.1M sodium-citrate) and the absorbance was measured at 540 nm at day 0 to obtain the initial 
amount of living cells and after 72 h in order to calculate the proliferation rate. Data are expressed as mean ± SEM 
and analyzed using two-way ANOVA followed by Bonferroni’s multiple comparisons test. *p < 0.05, **p < 0.001, 
***p < 0.001.
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Table 1S. 16S ribosomal DNA sequences used for 16S phylogenie. 
Species ARB-SILVA accession / 
rRNA locus_tag 
Identity with the 
SBA_07180, % 
Streptomyces sp. MP131-18 SBA_07180 - 
Streptomyces fulvissimus DSM40593 SFUL_2616 92.53 
Streptomyces sp. 13674L EU741227.1.1494 96.67 
Streptomycetaceae bacterium NPS-8920 EF470589.1.1523 96.43 
Streptomyces avicenniae EU399234.1.1491 96.4 
Streptomyces sp. NEAU-LZS-5 KC304791.1.1538 96.09 
Marinispora sp. NPS-12745 EF551062.1.1533 99.97 
Streptomyces massiliensis AP10 JX101691.1.1502 99 
Streptomyces specialis AM934703.1.1500 97.35 
Streptomyces. sp. SCSIO 03032 JN798514.1 93.88 
 
 
For S. fulvissimus and S. sp. MP131-18, locus_tags are provided; for Streptomyces. sp. SCSIO 
03032 GenBank accession number; other IDs are from ARB-SILVA database. 
 
 
 
 
 
 
 
 
 
 
 
Table 2S. Table of compared gene sequences (locus_tags). 
Protein S. sp. MP131-18 S. fulvissimus S. specialis S. sp. SBT349 S. avicenniae 
RpoB SBA_02824 SFUL_RS21975 BN2279_RS23020 ADY01_RS15195 IF27_RS10465 
DnaK1 SBA_03307 SFUL_RS16290 BN2279_RS14960 ADY01_RS04030 IF27_RS03445 
RecA SBA_01513 SFUL_RS28035 BN2279_RS19870 ADY01_RS00075 IF27_RS21960 
SsgB SBA_03814 SFUL_RS15590 BN2279_RS17305 ADY01_RS23410 IF27_RS03120 
SsgA SBA_04743 SFUL_RS12465 BN2279_RS22425 ADY01_RS28310 IF27_RS06350 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3S. Functional annotation of Streptomyces sp. MP131-18 genes. 
INFORMATION STORAGE AND PROCESSING 1068 
Translation, ribosomal structure and biogenesis 170 
RNA processing and modification 
Transcription 
Replication, recombination and repair 
Chromatin structure and dynamics 
1 
677 
219 
1 
CELLULAR PROCESSES AND SIGNALING 846 
Cell cycle control, cell division, chromosome partitioning 
Defense mechanisms 
Signal transduction mechanisms 
Cell wall/membrane/envelope biogenesis 
Intracellular trafficking, secretion, and vesicular transport 
Posttranslational modification, protein turnover, chaperones 
38 
141 
303 
204 
28 
132 
METABOLISM 2,018 
Energy production and conversion 
Carbohydrate transport and metabolism 
Amino acid transport and metabolism 
Nucleotide transport and metabolism 
Coenzyme transport and metabolism 
Lipid transport and metabolism 
Inorganic ion transport and metabolism 
Secondary metabolites biosynthesis, transport and catabolism 
315 
483 
355 
95 
151 
162 
287 
170 
POORLY CHARACTERIZED 2,227 
General function prediction only 
Function unknown 
692 
1,535 
 
 
 
 
 
 
 
 
 
Table 4S. Secondary metabolism gene clusters classified by the type. 
Cluster type Number of clusters Clusters ID 
PKSI 6 5, 9, 10, 24, 33, 35 
PKSII 1 1b 
PKSIII 1 7 
PKSI-PKSIII 1 3 
NRPS 3 2, 15, 17 
PKS-NRPS 4 13, 14, 30, 34 
Terpene 5 1a, 8, 16, 18, 29 
PKSI-Terpene 1 23 
RiPPs 5 6, 20, 21, 25, 27 
Nuceloside 1 11 
Butyrolactone 1 4 
Siderophore 2 12, 32 
Arylpolyene (PKS) 1 19 
Phenazine 1 22 
Melanin 1 26 
Bacteriocin 1 28 
Ectoine 1 31 
Indole 1 36 
 
 
 
 
 
 
 
Table 5S. NMR data of Lynamicin E. 
position H (J in Hz) C Cosy HMBC 
1 NH - - - 
2 - 122.9 - - 
3     
4     
5 - 122.8 - - 
6 - 161.3 - - 
7 3.69a s 50.6   
8 3.66a s 50.4 - - 
9 - 161.7 - - 
1’ NH - - - 
2’ 6.90 s 126.3 - 3’ 
3’ - 108.0 - - 
4’ - 128.8  - 
5’ 7.02 d (1.7) 118.6 - 9’-6’-7’ 
6’ - 124.4 - - 
7’ 6.92 dd (2.0, 8.6) 120.5 7.18 5’ 
8’ 7.18 dd (0.4, 8.6) 111.7 6.92 4’-6’ 
9’ - 134.2 - - 
1’’ NH - - - 
2’’ 6.87 s 124.4 - 3‘‘-4‘‘-9‘‘ 
3’’ - 107.9 - - 
4’’ - 127.7 - - 
5’’ 7.07 d (7.9) 119.5 6.80 3‘‘-9‘‘ 
6’’ 6.80 t (0.7, 7.6) 118.3 6.97-7.07-7.25 8‘‘-4‘‘ 
7’’ 6.97 ddd (1.0, 7.7) 118.9 6.80-7.25 5’’-9’’ 
8’’ 7.25 d (8.1) 110.6 6.97 6’’-4’’ 
9’’ - 136.1 - - 
Sample was measured in MeOH. Data were recorded on Bruker Ascend 700 MHz. Spectra referenced to internal 
solvent for MeOH at 3.31 ppm (1H) and 49.0 ppm  (13C). a Chemical shifts may be interchangeable. 
 
 
 
 
 
 
Table 6S. NMR data of Spiroindimicin B. 
position H (J in Hz) C Cosy HMBC 
1    NH - - - 
2 6.98 s 111.7 - 5-3 
3 - 127.9 - - 
4 - 142.6 - - 
5 - 117.4 - - 
6 - 162.2 - - 
7 3.59 s 51.1 - 5-6 
1’ - - - - 
2’ 4.09 d (8.8) 
3.67 d (8.8) 
65.2 - 10’-3’-4’-4-2’’-9’ 
3’ - 53.1 - - 
4’ - 135.8 - - 
5’ 6.34 d (2.1) 123.3 7.05 3’-7’-9’ 
6’ - 124.1 - - 
7’ 7.04 (2.1, 8.5) 128.6 6.34-6.64 5’-9’ 
8’ 6.64 d (8.5) 109.4 7.05 5’-4’ 
9’ - 153.8 - - 
10’ 2.95 s 36.3 - 2’-9’ 
1’’ NH - - - 
2’’ - 156.6 - - 
3’’ - 112.8 - - 
4’’ - 122.9 - - 
5’’ 7.58 d (2.0) 119.2 6.99 3’’-7’’-4’’ 
6’’ - 126.1 - 5’’-7’’-6’’-9’’ 
7’’ 6.99 dd (2.0, 8.6) 121.5 7.25-7.58 5’’-4’’-8’’ 
8’’ 7.25 d (8.6) 114.1 6.99 4’’-6’’ 
9’’ - 139.9 - - 
Sample was measured in MeOH. Data were recorded on Bruker Ascend 700 MHz. Spectra referenced to internal 
solvent for MeOH at 3.31 ppm (1H) and 49.0 ppm  (13C).  
 
 
 
 
 
 
Table 7S. NMR data of Spiroindimicin E. 
position H (J in Hz) C HMBC 
1    NH - - 
2 6.95 s 111.4 5-4 
3 - 125.7 - 
4 - 142.9 - 
5 - 117.0 - 
6 - 162.3 - 
7 3.58 s 52.1 6 
1’ - - - 
2’ 4.09 d (8.8) 
3.69 d (8.8) 
65.0 10’-7-4-9’ 
3’ - 52.8 - 
4’ - 136.4 - 
5’ 6.34 d (2.0) 123.7 3’-7’-9’ 
6’ - 123.1 - 
7’ 7.044 (6.06) 128.1 5’-9’ 
8’ 6.64 d (8.5) 109.7 5’-4’ 
9’ - 153.7 - 
10’ 2.95 s 36.2 2’-9’ 
1’’ NH - - 
2’’ - 152.3 - 
3’’ - 118.4 - 
4’’ - 122.0 - 
5’’ 7.28 d (0.7, 7.3) 113.5 7’’-4’’ 
6’’ 7.03 (1.72) 121.0 5’’-7’’-4’’-9’’-8’’ 
7’’ 7.045 (0.81) 120.5 5’’-4’’-8’’ 
8’’ 7.58 (0.7, 7.4) 119.7 5’’-4’’-9’’ 
9’’ - 141.7 - 
Sample was measured in MeOH. Data were recorded on Bruker Ascend 700 MHz. Spectra referenced to internal 
solvent for MeOH at 3.31 ppm (1H) and 49.0 ppm  (13C).  
 
 
 
 
 
 
Table 8S. NMR data of Spiroindimicin F 
position H (J in Hz) C Cosy HMBC 
1    11.35 s - 7.09 5-3-4 
2 7.09 (2.7) 111.0 11.35 5-3-4 
3 - 125.5 - - 
4 - 141.5 - - 
5 - 115.2 - - 
6 - 159.9 - - 
7 3.47 s 50.1 - 6 
1’ - -  - 
2’ 3.64/3.90 d 63.1 - 10’-3’-4’-4-9’-2’’ 
3’ - 51.4 - - 
4’ - 132.2 - - 
5’ 6.33 d (7.3) 121.6 6.44 7’-9’ 
6’ 6.44 t (7.3) 117.1 6.33-7.06 8’-7’-4’ 
7’ 7.06 t (1.2, 8.1) 127.6 6.44-6.71 8’-5’-4’-9’ 
8’ 6.71 d (8.0) 107.2 7.06 6’-4’ 
9’ - 153.3 - - 
10’ 2.9 s 35.7 - 2’-9’ 
1’’ 11.4 s - - 3’’-4’’-9’’-2’’ 
2’’ - 155.7 - - 
3’’ - 110.6 - - 
4’’ - 120.8 - - 
5’’ 7.72 s 117.7 - - 
6’’ - 123.1 6.99 4’’-8’’ 
7’’ 6.99 dd (2.04, 8.6) 119.7 7.25 5’’-8’’-9’’ 
8’’ 7.25 (8.6) 123.5 6.99-11.4 3’’-7’’-8’’-9’’ 
9’’ - 138.0 - - 
Sample was measured in MeOH. Data were recorded on Bruker Ascend 700 MHz. Spectra referenced to internal 
solvent for MeOH at 3.31 ppm (1H) and 49.0 ppm  (13C).  
 
 
 
 
 
 
 
Table 9S. Minimal inhibitory concentrations (μg/ml [μM]) of isolated compounds against 
bacterial test cultures.  
Organism lycogarubin C lynamicin E spiroindimicin B spiroindimicin E 
Bacillus subtilis >100 [>240] >100 [>223] 25 [57] >100 [>247] 
Escherichia coli >100 [>240] >100 [>223] >100 [>228] >100 [>247] 
Pseudomonas putida >100 [>240] >100 [>223] >100 [>228] >100 [>247] 
 
 
 
 
 
 
 Figure 1S. Paired-end links between scaffolds: each link represents a read pair. L, left edge; R, 
right edge; X, neither left nor right edge (i.e. somewhere else in the scaffold). Mean PE insert 
size is 470 with standard deviation ~200; thus scaffold edge was estimated at 670bp. Loops 
depict self-links. Line weight is proportional (within fixed min/max limits) to the number of 
links, which is also shown next to each connecting line. Scaffold 1 (in the center) has no PE links 
from its L/R edges. 
 Figure 2S. Mate-pair links between scaffolds: each link represents a read pair. Mean MP insert 
size is 8100 with standard deviation ~1000; thus scaffold edge was estimated at 9100bp. Scaffold 
1 (in the center) has no MP links from its L/R edges. 
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Figure 3S. MS chromatogram of lycogarubin C  
 
RT: 9.54 min 
m/z = 414.1485 
 Spiroindimicin E   Spiroindimicin F 
 
Figure 4S. Semipreparative HPLC chromatogram for the isolation of spiroindimicin E and F. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5S. Growth-inhibitory effects on T24 bladder carcinoma cells. Cancer cells were 
treated for 72h with increasing concentrations of the indicated substances and proliferation rate 
was analysed by staining with crystal violet.  
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Figure  6S. MS2 for lagunapyrones (continuation). 
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Figure 7S. Proposed biosynthesis pathway for lynamicins and spiroindimicins. 
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New Alpiniamides From
Streptomyces sp. IB2014/011-12
Assembled by an Unusual Hybrid
Non-ribosomal Peptide Synthetase
Trans-AT Polyketide Synthase
Enzyme
Constanze Paulus1,2, Yuriy Rebets2, Josef Zapp2, Christian Rückert3, Jörn Kalinowski3
and Andriy Luzhetskyy1,2*
1 Helmholtz-Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany, 2 Department for Pharmaceutical
Biotechnology, University of Saarland, Saarbrücken, Germany, 3 Center for Biotechnology (CeBiTec), Bielefeld University,
Bielefeld, Germany
The environment of Lake Baikal is a well-known source of microbial diversity. The strain
Streptomyces sp. IB2014/011-12, isolated from samples collected at Lake Baikal, was
found to exhibit potent activity against Gram-positive bacteria. Here, we report isolation
and characterization of linear polyketide alpiniamide A (1) and its new derivatives
B–D (2–5). The structures of alpiniamides A–D were established and their relative
configuration was determined by combination of partial Murata’s method and ROESY
experiment. The absolute configuration of alpiniamide A was established through
Mosher’s method. The gene cluster, responsible for the biosynthesis of alpiniamides
(alp) has been identified by genome mining and gene deletion experiments. The
successful expression of the cloned alp gene cluster in a heterologous host supports
these findings. Analysis of the architecture of the alp gene cluster and the feeding of
labeled precursors elucidated the alpiniamide biosynthetic pathway. The biosynthesis
of alpiniamides is an example of a rather simple polyketide assembly line generating
unusual chemical diversity through the combination of domain/module skipping and
double bond migration events.
Keywords: Streptomyces, secondary metabolites, NRPS-trans-AT-polyketide synthase, stereochemistry,
bioactivity
INTRODUCTION
The consistent development of antibiotic resistance in life-threatening pathogens diminishes the
availability of effective medications for the treatment of infectious diseases. Natural products
originating from plants and microorganisms have inspired medicinal drug research for decades
(Ventola, 2015). They are produced as secondary metabolites and represent a major source of
drug leads and serve as templates for semisynthetic derivatives. A vast number of secondary
metabolites from microorganism, particularly from actinobacteria have been described to date.
Actinobacteria represent one of the most thoroughly examined group of bacteria in terms of
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natural product research, which is reflected in the continuing
discovery of important antibiotics, e.g., teicoplanin, daptomycin,
and fidaxomicin over the years (Procópio et al., 2012). Many
natural products not only serve as antibiotics but also as antiviral,
immunosuppressive and even as anticancer agents (Vaishnav and
Demain, 2011). Hence, the discovery of new bioactive natural
products is still indispensable for sustaining the rapid progress
of medicinal research (Dias et al., 2012).
A large proportion of biologically active secondary metabolites
are polyketide derivatives. These compounds are assembled by
polyketide synthases (PKSs), enzymes that conduct a simple
repetitive condensation of acyl units to form poly-ß-ketide chains
followed by conversion of the chain into structurally diverse
metabolites. Depending on the structure and the enzymatic
pathway, PKSs can be divided into three major types. Type I
PKSs have modular architectures consisting of several modules
each harboring ketosynthase (KS) and acyl carrier protein (ACP)
domains accompanied by an acyltransferase domain (AT), which
is responsible for the selection of the extender unit, as well as a set
of processing enzymes (KR – ketoreductase, DH – dehydratase,
and ER – enolreductase) (Khosla, 2009). Recently, a new type
of modular PKS was discovered that lacked the acyltransferase
domains within the modular proteins (Helfrich and Piel, 2016).
The acyltransferase activity is a standalone protein that is
typically encoded within the respective gene cluster. PKSs of this
type are known as trans-AT and they are believed to be the most
abundant type of secondary metabolite assembly lines.
Bacterial strains of the genus Streptomyces inhabit different
ecological niches. They are found not only in soil but also
in fresh water systems, marine habitats, isolated eco-systems,
and in symbiosis with insects and plants (Hasani et al.,
2014). Lake Baikal is a unique eco-system, rich in endemic
species of living organisms. We have recently isolated a
variety of actinobacteria strains from Lake Baikal (Axenov-
Gribanov et al., 2016). Several of these strains were found to
be active against Gram-positive and Gram-negative bacteria.
The strain Streptomyces sp. IB2014/011-12 showed the most
promising results when tested against Bacillus subtilis. This
finding motivated us to analyze the strain in its entirety to identify
the metabolites responsible for the observed activity.
Here, we report the activity-guided screening of metabolites
produced by Streptomyces sp. IB2014/011-12 that resulted in the
isolation of alpiniamide A (1), which was previously described
as a product of the endophytic Streptomyces sp. YIM66017
(Golinska et al., 2015), and its novel derivatives. The genome of
this strain has been sequenced and analyzed, which has enabled
us to identify the gene cluster responsible for the biosynthesis of
alpiniamides.
MATERIALS AND METHODS
Bacterial Strains, Culture Conditions,
and General Procedures
The isolation and phylogenetic characterization of Streptomyces
sp. IB2014/011-12 were reported in (Axenov-Gribanov et al.,
2016). Streptomyces strains were grown on solid nutrient medium
MS (mannitol soy flour agar) and in liquid TSB medium (Kieser,
2000). For secondary metabolite production, NL19 (MS medium
without agar) and SG (glucose, yeast, Bacto Soytone, and calcium
carbonate) medium have been used. Escherichia coli XL1Blue
(Agilent, United States) was used for routine cloning, and E. coli
MW 6026 was used as a donor in the intergenic conjugation
(Blodgett et al., 2007). E. coli strains were grown in Luria-Bertani
(LB) broth. For MW 6026, diaminopimelic acid was added.
When required, antibiotics were added to the cultures at the
following concentrations: 50 µg ml−1 apramycin, 100 µg ml−1
spectinomycin, 100 µg ml−1 phosphomycin, and 100 µg ml−1
carbenicillin (Sigma, United States; Roth, Germany).
Recombinant DNA Techniques
Chromosomal DNA from Streptomyces strains and plasmid DNA
from E. coli were isolated using standard protocols (Makar
et al., 1975; Kieser, 2000). Restriction enzymes and molecular
biology reagents were used according to the recommendations
of the supplier (Thermo Fisher Scientific, Germany; NEB,
United States).
Genome Sequencing, Assembly, and
Annotation
For DNA isolation, Streptomyces sp. IB2014/011-12 was
inoculated into TSB medium and grown at 28◦C with shaking
(200 rpm) for 3 days. High quality total cellular DNA was isolated
using salting out procedure. The purity and concentration of
the genomic DNA was determined using a Nanodrop 2000
spectrophotometer (Thermo Fisher Scientific).
For sequencing of the Streptomyces sp. IB2014/011-12
genome, an Illumina paired-end sequencing library (TruSeq
sample preparation kit; Illumina, United States) was constructed
according to the manufacturer’s protocol. The Streptomyces sp.
IB2014/011-12 draft genome sequence was established on an
Illumina HiSeq system in rapid run mode (2× 250 nt) with a pair
distance of about 500 bp. Upon sequencing and processing of the
obtained data, a de novo assembly was performed using the GS De
Novo Assembler (version 2.8.) (Roche Diagnostics, Mannheim,
Germany) with default settings. Annotation of the genome was
performed by means of prokka v1.11 and the GenDB 2.0 platform
(Meyer et al., 2003; Seemann, 2014). For the identification of
secondary metabolites clusters antiSMASH 3.0 was used (Weber
et al., 2015). The assembled and annotated draft sequence of
the Streptomyces sp. IB2014/011-12 genome was deposited in the
GenBank database under accession number QEIK00000000.
Generation of the Construct for Gene
Cluster Inactivation
Two DNA fragments, C9-1 and C9-2, flanking the first 2000 bp
of the gene alpA1 have been amplified using the primer pairs
C9-2REcV and C9-2FEcI and C9-1FEcV and C9-1RXba
(Supplementary Table S1). The obtained 2 kb fragments
were cloned into a pST Blue-I AccepTorTM vector (Novagen,
United States). The construct containing fragment C9-1 was
digested with EcoRV (primer) and XbaI (vector MCS) and
ligated with the C9-2 fragment, which was retrieved with the
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same restriction enzymes. The resulting plasmid was digested
with EcoRV and ligated with the spectinomycin-resistance
cassette. The final construct was transformed into pKG 1132
(Myronovskyi et al., 2011). This construct was transferred
into Streptomyces sp. IB2014/011-12 via an intergeneric
conjugation. The exconjugants were grown under non-selective
conditions and screened for white spectinomycin-resistant
colonies when grown on MS supplemented with X-gluc (X-Gluc
DIRECT, United States). The deletion of part of the alpA1
gene was confirmed by PCR using the 11-12DelCheckF and
11-12DelCheckR primer pair (Supplementary Table S1).
Cloning of the alp-Gene Cluster and
Red/ET Mediated Gene Deletion
The two 2.5 kb DNA fragments, Tar1 and Tar2, flanking a 46.7 kb
region of the Streptomyces sp. IB2014/011-12 chromosome
that includes the entire alp-gene cluster were amplified with
the primer pairs 11-12C9TarF1Not and 11-12C9TarR1Nhe
and 11-12C9TarF2NheI and 11-12C9TarR2HindIII, respectively
(Supplementary Table S1), using Phusion DNA polymerase
and cloned into the pJET1.2 vector (Thermo Fisher Scientific,
United States). Fragments were assembled by digesting the
Tar1-containing plasmid with NheI (primer) and HindIII
(vector MCS) and ligating with the NheI/HindIII-retrieved
Tar2 fragment. The resulting construct was sub-cloned into
a NheI/HindIII-digested pCLY10 vector (Bilyk et al., 2016).
The final construct was linearized with NheI and mixed
with Streptomyces sp. IB2014/011-12 chromosomal DNA in
a 1:5 ratio. The mixture was transformed into S. cerevisiae
BY4742 (Winston et al., 1995) with the standard LiAc
protocol (Gietz and Schiestl, 2007). Transformants were
selected on YNB medium supplemented with yeast synthetic
drop-out medium supplements without leucine (Sigma-Aldrich,
United States). Colonies were plated in patches of 100, washed,
and analyzed by PCR for the presence of clones harboring
the desired construct using the primers 11-12C9CheckHind
(Supplementary Table S1) annealed to the cloned region
outside of the homology fragment and pCLYCheckHind
(Supplementary Table S1) annealed to the vector. The positive
clone was further pooled out, the total DNA was purified
using a standard protocol (Green and Sambrook, 2012) and
transformed into E. coli XL1Blue to give 011-12p1-49 clone
carrying the desired region of the Streptomyces sp. IB2014/011-12
chromosome. 011-12p1-49 plasmid DNA was purified and
sequenced by MinION (Oxford Nanopore, United Kingdom).
011-12p1-49 was introduced into S. lividans TK24 and S. albus
Del14 (unpublished data, Dr. M. Myronovskyi, personal
communication) by intergeneric conjugation. The resulting
strains were grown, and the production of alpiniamides was
analyzed as described below. alpD, alpR, and alpE genes were
inactivated by replacement with a hygromycin resistance cassette
from plasmids patt-shyg (Myronovskyi et al., 2011) within the
011-12p1-49 construct. λ-Red recombineering was performed
as described (Gust et al., 2004). Primers used to amplify the
cassette and to verify the deletions are listed in Supplementary
Table S1. The resulting constructs were introduced into the
host S. albus Del 14 via conjugation and clones were selected
with hygromycin. The mutants were cultivated in NL19 and
production was analyzed using LC-MS as described below.
Production, Extraction and LC-MS
Analysis of Alpiniamides
The Streptomyces sp. IB2014/011-12 was grown in 10 ml of TSB
for 2 days at 28◦C on a rotary shaker. The main culture (100 ml
of NL19 in 500 mL flasks with glass beads) was inoculated with
1 ml of the pre-culture and cultivated at 28◦C and 180 rpm for
7 days. The metabolites in the cultural liquid were extracted with
ethyl acetate and from the biomass with a mixture of acetone and
methanol (1:1). The solvents were evaporated, and the residue
was dissolved in 300 µl of methanol.
The LC-MS data were collected on a Dionex Ultimate 3000
RSLC system using a BEH C18, 100 × 2.1 mm, 1.7 µm dp
column (Waters, Germany). Separation of a 1 µl sample was
achieved by a linear gradient of solvent B (acetonitrile with 0.1%
of formic acid) against solvent A (water with 0.1% of formic
acid) at a flow rate of 600 µl/min and 45◦C. The gradient started
with a 0.5 min isocratic step of 5% B then increased to 95%
B over 18 min and ended with a 2 min step of 95% B before
re-equilibration under the initial conditions. UV spectra were
acquired by a DAD in the range of 200 to 600 nm. The mass
spectrometry data were collected on an amazon SL speed mass
spectrometer (Bruker Daltonics, Germany) using an Apollo II
ESI source. Mass spectra were acquired in centroid mode ranging
from 200 to 2000 m/z at a scan rate of 2 Hz. The HRMS data
were collected on a Dionex Ultimate 3000 RSLC system using a
BEH C18, 100× 2.1 mm, 1.7 µm dp column (Waters, Germany).
Separation of a 1 µl sample was achieved by a linear gradient of
solvent B (acetonitrile with 0.1% of formic acid) against solvent A
(water with 0.1% of formic acid) at a flow rate of 480 µl/min and
45◦C. The gradient started with a 0.5 min isocratic step of 5% B
then increased to 95% B over 20 min and ended with a 2 min step
of 95% B before re-equilibration under the initial conditions. UV
spectra were acquired by a DAD in the range of 200 to 600 nm.
High-resolution mass spectrometric data were collected on an
LTQ Orbitrap mass spectrometer (Thermo Fischer Scientific,
United States).
Data were collected and analyzed with the Bruker Compass
Data Analysis software, version 4.2 (Bruker, Billerica, MA,
United States) and the Thermo Xcalibur software, version 3.0.
The screening for known compounds was performed using the
Dictionary of Natural Products Database, version 10.0 (CRC
Press, Boca Raton, FL, United States), using the following
parameters: accurate molecular mass, absorption spectra and
biological source (Running, 1993). Compounds were considered
to be similar when the difference in accurate mass was less than
2 ppm and the absorption spectra were identical.
Feeding Experiments
Thirty milliliter of liquid NL19 medium was inoculated with
300 µl of a 22 h old seed culture of the strain Streptomyces
sp. IB2014/011-12. After 10 h of growth on a rotary shaker
at 28◦C, the culture was supplemented with 200 µl of
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Glycine-2-13C or 200 µl methionine(-methyl-13C) respectively,
solved in water (5.2 mg/ml). This procedure was repeated four
times every 10–12 h. The final concentration of compounds
in the flask was 2.31 mM of Glycine-2-13C and 1.16 mM
of methionine(-methyl-13C). After 7 days of cultivation, the
culture was extracted separately, biomass with acetone/methanol
(1:1) and the supernatant with ethyl acetate. The solvent was
evaporated and the obtained residues solved in MeOH. The
extracts were subjected to LC-MS analysis.
Isolation and Structure Elucidation of
Alpiniamides
For the isolation of the metabolites, the strain was cultivated
as described above in 8 L of NL19. Metabolites were extracted
from cultural liquid with equal volume of ethyl acetate,
solvent was evaporated and resulting 1.56 g of crude extract
was dissolved in 8.5 ml of methanol. The crude extract
was purified through size-exclusion chromatography using
Sephadex R© LH 20 (Sigma-Aldrich) and MeOH as eluent (1 m
long column with 700 ml volume of Sephadex). Fractions
were collected every 15 min with a speed of 1-2 drops
per second (approximately 30 ml per hour). The obtained
fractions with antibacterial activity were further purified by
preparative and subsequent semipreparative high-performance-
liquid-chromatography (HPLC) using the following equipment:
Dionex Ultimate 3000 from ThermoScientific (preparative) and
Agilent 1260 Series and 1100 Series from Agilent Technologies
(semipreparative). For preparative HPLC, a Nucleodur C18
HTEC column (150 × 21 mm, 5 µm) was used with a multistep
gradient from 15–20% B (B: acetonitrile with 0.1% formic acid;
A: water with 0.1% formic acid) over 2 min and 20–60% B over
20 min at a flow rate of 20 ml/min and 45◦C. Semipreparative
HPLC was performed using a Synergi Phusion RP-Column
(250 × 10 mm, 4.6 µm; Phenomenex) with a gradient elution
from 5 to 95% B (B: methanol with 0.1% of formic acid; A: water
with 0.1% formic acid) over 20 min at a flow rate of 4.5 ml/min
and 45◦C. UV spectra were recorded with a DAD detector at
200–600 nm.
NMR spectra were acquired in deuterated methanol (CD3OD)
and deuterated chloroform (CDCl3) at 298 K on a Bruker Avance
III 700 or 500 MHz spectrometer, both equipped with a 5 mm TXI
cryoprobe. NMR shifts were relative to the residual solvent signal
CH3OD at δ 3.30 and CDCl3 δ 7.24 for 1H, or to the solvent itself
at δ 49.00 (CD3OD) and 77.00 (CDCl3) for 13C measurements.
NMR data were analyzed using Topspin, version 3.5 pl7 (Bruker,
United States).
Preparation of the S- and R-MTPA-Ester
of Alpiniamide A (6S and 6R), Alpiniamide
B1 (7S and 7R), and Alpiniamide B2 (8S
and 8R) by the Modified Mosher’s
Method
To a solution of alpiniamide A (1, 0.5 mg, 1.45 µmol) and
dry pyridine (20 µl) in dry deuterated chloroform (100 µl) at
room temperature, α-methoxy-α-(trifluoromethyl)phenylacetyl
chloride (R-MTPA-Cl) (20 µl, 0.10 mmol) was added. The
reaction was mixed at room temperature for 4 h. Another
200 µl of CDCl3 was added, and the sample now containing
the S-MTPA-ester of alpiniamide A (6S) was directly subjected
to NMR measurements (Supplementary Figure S1). The
R-MTPA-ester of alpiniamide A (6R) was prepared in the
same way using S-MTPA-Cl instead of its R-isomer. The
same procedure was carried out with only a fifth of all
ingredients to get 7S and 7R from alpiniamide B1 (2) and 8S
and 8R from alpiniamide B2 (3), respectively (Supplementary
Figure S1).
Bioactivity Assay
The antimicrobial activities of isolated compounds were
measured by a disk diffusion assay. A 30 µl aliquot of each
compound was loaded on a paper disk with a diameter of
6 mm, allowed to dry, and set on an LB agar plate coated
with B. subtilis from liquid overnight culture. The plates were
incubated at 37◦C for 12 h. The zones of inhibition were
measured manually. The minimal inhibitory concentrations were
estimated by standard serial dilutions protocol in 200 µL in 96
well plates. Briefly, serial dilutions (1:1) of alpiniamides were
prepared using DMSO as a solvent prior to aliquoting 10 µL
of each solution into 96 well plate. Kanamycin was used as
a positive control (full inhibition of growth), and DMSO was
used for the negative control (full growth). 190 µL of bacterial
test cultures in appropriate media (1:500 dilution of overnight
culture) were added to each well, and the plates were shaken
at 30◦C for 16-20 h. Then, 5 µL of thiazolyl blue tetrazolium
bromide (10 mg mL−1) solution was added to each well, and the
plates were incubated at 30◦C for an additional hour. MICs were
determined as the concentration of antibiotic in the well where
the additive did not change the color of the solution from yellow
to dark blue.
RESULTS
Genome Analysis
Streptomyces sp. IB2014/011-12 has been isolated from the
net-spinning caddisfly Trichoptera sp. (larvae) (Axenov-
Gribanov et al., 2016). Phylogenetic analysis based on the 16
sRNA showed that the strain IB2014/011-12 belongs to the genus
Streptomyces. The strain grows as a typical actinobacteria forming
colonies with aerial mycelia and gray spores (Supplementary
Figure S2). The strain accumulates a brownish pigment during
growth on a solid medium. When grown in liquid media
(NL19) the strain demonstrated activity against Gram-positive
bacteria. The genome of Streptomyces sp. IB2014/011-12 has
been sequenced and assembled into 71 contigs (Table 1).
The largest contig is 956.9 kbp. The overall size amounts to
8099.23 kbp, which is in the normal range for streptomyces.
The genome consists of a single chromosome and has no
extra chromosomal DNA based on the sequence coverage. The
genome has a G + C content of 71.5%. The chromosome is
predicted to contain 7.282 coding sequences, 5 rRNA clusters,
80 tRNA genes and one tmRNA gene (Palecková et al., 2009).
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TABLE 1 | Features of Streptomyces sp. IB2014/011-12 genome.
Genome size 8099.23 bp
Contigs 71
GC content 71.5%
CDS 7.282
tRNA 80
mRNA 1
rRNA 5
Cluster 29
The analysis of the genome using antiSMASH software revealed
that 29 gene clusters are involved in the biosynthesis of diverse
secondary metabolites including terpenes, lanthipeptides,
non-ribosomal peptides, and polyketides (Supplementary
Table S2).
Based on the gene cluster analysis with antiSMASH the
production of several secondary metabolites by Streptomyces
sp. IB2014/011-12 can be predicted (Supplementary Table S2).
Like most of actinobacteria strains, the genome contains gene
clusters for desferrioxamine, ectoine, and melanin production.
Desferrioxamine B, a high-affinity iron chelator (siderophore),
is important for scavenging ferric iron as a nutrient for the
cells (Barona-Gómez et al., 2004). Ectoine, another common
metabolite, is an osmoprotectant (Zhu et al., 2014). The function
of melanin, a black pigment, that is produced by many
types of bacteria, is still under discussion (Woo et al., 2010).
The compound is most likely involved in protection against
chemical and biological stresses, such as exposure to heavy
metals, oxidizing agents and UV radiation (Allam, 2012), and
it might be the reason why the MS medium is colored by
that strain (Supplementary Figure S2). In addition, the gene
cluster that produces the class III lantipeptide AmfS is present
in the genome of Streptomyces sp. IB2014/011-12. The predicted
amino acid sequence of the precursor peptide from the gene
cluster coincides with the sequence of AmfS isolated from
Streptomyces griseus (Ueda et al., 2002). AmfS-like compounds
are known to be positive regulators of the formation of
aerial-mycelium in streptomyces. Another secondary metabolite
that could be predicted from the Streptomyces sp. IB2014/011-12
genome analysis is roseoflavin. This compound belongs to
the riboflavin antibiotic family, which targets riboswitches
that affect bacterial growth (Mansjö and Johansson, 2011;
Schwarz et al., 2016). Furthermore, the gene cluster no. 3
is probably coding for the class II lasso peptide SRO15-2005
since it shows 100% sequence homology to the corresponding
gene cluster of S. roseosporus NRRL 15998 (Kersten et al.,
2013).
Dereplication of Secondary Metabolites
Produced by Streptomyces sp.
IB2014/011-12
Dereplication is a quick and simple method of analyzing
metabolites based on LC-MS data. It allows known compounds
to be distinguished from potentially new metabolites to avoid
their purification and analysis. With the help of UV/Vis spectra,
high-resolution mass spectrometric data, biological source and
other criteria, one can compare entries in data banks such as
the “Dictionary of Natural Products (DNP)” in order to identify
metabolites in the extract of interest (Whittle et al., 2003).
At first, to estimate the potential novelty of the compounds
produced by Streptomyces sp. IB2014/011-12, we analyzed the
LC-MS data of the extracts of the strain grown in NL 19
media. The obtained exact masses from MS data were further
compared to the DNP. This led to the identification of some
known compounds and prediction of putative new metabolites
produced by this strain (Figure 1). The major class of compounds
produced by this strain is polycyclic tetramate macrolactams
(PTM) (Supplementary Figures S3, S4) (Xu et al., 2015).
We identified alteramide A (9) (Shigemori et al., 1992) and
several isomers that were not distinguishable since they all have
m/z 511.28207 [M+H]+ (510.27427 [M], calculated 510.2730)
ions and UV curves typical for PTMs but different retention
times. Under the used conditions, the isomers elute at RTs
of 17.7, 18.6 and 19.0 min. Alteramide B (10) and several
isomers with m/z 495.28549 [M+H]+ (494.27769 [M], calculated
494.2781) were present in the extract as well. They eluted
at RT 18.3, 18.9, 19.3, and 19.5 min. In addition to these,
the strain also produces clifednamide A (11) (m/z 509.26395
[M+H]+, 508.25615 [M] calculated 508.2573, RT at 18.4) and
clifednamide B (12) (m/z = 493.27017 [M+H]+, 492.26237
[M] calculated 492.2624, RT at 18.7) (Cao et al., 2010) and
possible isomers of these compounds that eluted at different
retention times (RT at 18.8 and 18.9 min). Furthermore,
the compound eluting at RT 18.2 min with m/z 513.29565
[M+H]+ (512.28785 [M], calculated 512.2886) corresponds to
dihydromaltophylin (13) (heat-stable antifungal factor, HSAF)
(Li et al., 2008).
Alteramide A and B, isolated from marine bacterium
Alteromonas species, are macrocyclic lactams that contain a
dienone and a dienoyl tetramic acid moiety (Shigemori et al.,
1992; Ding et al., 2016). They exhibit activity against leukemia
cells but are not active against bacteria. Dihydromaltophilin
is similar to alteramide in that it also has three five-
membered rings. The compound was isolated from S. maltophilia
R3089 and exhibits activity against a broad spectrum of
fungi but is not active against Gram-positive or Gram-
negative bacteria (Jakobi et al., 1996). The clifednamides,
another group of PTMs, were first isolated from Streptomyces
sp. JV178. The biological activity of these compounds has
not yet been published. In the genome of Streptomyces sp.
IB2014/011-12, a hybrid type I PKS-NRPS cluster no. 13
has been identified, and it is similar to the known gene
clusters for PTMs biosynthesis (Supplementary Figure S5).
The biosynthetic gene cluster for alteramide, clifednamide and
dihydromaltophilin differ slightly in their structures. Cluster
no. 13, with the core gene coding for iterative hybrid NRPS-
type I PKS, provide all necessary enzymatic activities for PTM
production (CDCs: 14650–14675, Supplementary Figure S5).
The gene cluster encodes for a putative hydroxylase (14675),
an iterative type 1 PKS-NRPS (14670), two oxidoreductases
(14665–14660), alcohol dehydrogenase (14655), and cytochrome
P450 hydroxylase (14650) in the same arrangement as in the
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FIGURE 1 | LC-MS chromatogram (minute 4 to 20 from an overall 20 min run) of extract of Streptomyces sp. IB2014/011-12 cultivated in NL19 medium. The peaks
for different alpiniamides are marked with letters. Peaks for polycyclic tetramate macrolactams are highlighted with the bracket.
biosynthetic gene cluster for HSAF and frontalamides (Lou et al.,
2011).
Isolation and Structure Elucidation of
Alpiniamide A–D (1–5)
Streptomyces sp. IB2014/011-12 produced additional metabolites
(Figure 1) that we could not dereplicate against known
products. For this reason, we assumed that the activity was
caused by potentially new metabolite(s). We grew the strain
in 8 L of NL19 and extracted the produced metabolites.
Subsequently, a bioactivity-guided purification was carried out
by tracking down the bioactive compounds using the disk
diffusion assay at each step of purification. The crude extract
was first fractionated using size-exclusion chromatography, and
the obtained fractions were tested against B. subtilis. The active
fractions were combined and further purified with preparative
HPLC and then with semipreparative HPLC. The fractions
collected after each separation step were tested for antibacterial
activity. This resulted in the isolation of five compounds.
The structure elucidation showed that they are alpiniamides
(Figure 2).
Alpiniamide A (1) was obtained as a slightly red solid
(4 mg), with a molecular formula of C17H29NO6 as determined
by high-resolution electrospray ionization mass spectrometry
(HRESIMS) at m/z 344.20596 [M+H]+, indicating 4 degrees
of unsaturation. Its NMR spectra, acquired in CD3OD
(Supplementary Table S3) revealed 17 carbons, five methyls
(one adjacent to a double bond), two methylenes, six methines
(two secondary alcohols and one as part of a double bond),
and four quarternary carbons (three carbonyls and one as part
of a trisubstituted double bond). The chemical shifts of the
methylene group at δH 4.13 and 4.25 and δC 49.0 indicated
the presence of an amide nitrogen atom nearby. These data
together with the results of 2D 1H-1H-COSY, HSQCED, HMBC,
and ROESY led to the structure of alpiniamide, which was
previously isolated from the Streptomyces sp. YIM660107 (Zhou
et al., 2013), with NMR data recorded in CDCl3. In order to
compare the literature data with our data, we reran the 1D
NMR spectra of 1 in CDCl3 (Supplementary Table S3 and
Supplementary Figures S6, S7). The obtained data were close
to those from the reported structure. But the remarks to the
relative stereochemistry of alpiniamide were confusing. C-2/C-3
was found to be threo, but the structure of alpiniamide showed
the erythro-form. C-2′/C-3′/C-4′ was announced as threo as
well, which is ambiguous and most likely a wrong phrasing
for a system with three chiral centers. However, the structure
showed C-2′/C-3′ and C-3′/C-4′ both in erythro-configuration.
Therefore, we were motivated to investigate the stereochemistry
of 1 in more detail.
Due to the large vicinal coupling constant of 9.5 Hz for
JH2H3, the configuration for C-2/C-3 in part A (C-1 to C-9) was
found to be threo. We are aware, that a single coupling constant
cannot usually distinguish which of two diastereomers might be
present since there are three possible staggered conformations
for each diastereomer, two of which will typically have very
similar predicted coupling constants for a pair of vicinal protons.
But assignments become possible when one can make some
reliable predictions on which conformation predominates. Such
a situation is given for part A of 1, where the hydroxyl at C-3
can form an intramolecular hydrogen bond with carbonyl C-1
when measured in the non-polar solvent CDCl3. Then, the 3JHH
coupling constant of two vicinal protons are considerably large
when they are in the threo configuration. Small values for 3JHH
indicate the erythro form (Stiles et al., 1964; House et al., 1973).
A similar situation predominates in part B between the hydroxyl
at C-3′ and the carbonyls C-1′ and C-5′. Careful analysis of
3JHH coupling constants led to 7.0 Hz for JH2 ′H3 ′ and 4.5 Hz
for JH3 ′H4 ′ . The small coupling constant for H-3
′
/H-4
′
give rise
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FIGURE 2 | Revised structure of alpiniamide A (1) and structures of new alpiniamides B-D (2–5) from Streptomyces sp. IB2014/11-12.
to an erythro configuration, whereas the moderate high J value
for H-2
′
/H-3
′
is a hint for the threo-form (Supplementary Table
S3) (Xu et al., 2017). Nevertheless, a final proof of the relative
stereochemistry of 1 requires a complete set of 3JHH and 2,3JHC
coupling constants as shown in Murata’s method (Matsumori
et al., 1999; Bifulco et al., 2007). Due to the limited amount of
1 and its insufficient stability during storing, we were not able to
perform it.
In order to determine the absolute configuration as well, we
applied Mosher’s method (Dale and Mosher, 1973; Hoye et al.,
2007). Portions of 1 were separately treated with (R)-MTPA-Cl
and (S)-MTPA-Cl to yield the Mosher ester 6S and 6R,
respectively (Supplementary Figure S1). The differences in the
proton chemical shifts of 6S and 6R (1δ(S−R)) should give
positive or negative values from which the configuration can be
established. For part A of the molecule we obtained negative
values for H-2 and H-8 and positive values for H-5, H-6, H-7, and
H-9 (Supplementary Table S4 and Supplementary Figure S8).
On the basis of these results, the absolute configuration can
be determined as R at C-3. From the relative configuration,
the neighboring positions can also be assigned, resulting in
R-configuration at C-2. The results for part B are less clear.
We obtained negative values for H-2,’ and positive values for
H-4,’ H-7,’ and H-8’. For an appropriate interpretation H-2’
and H-7’ should have one sign and H-4’ and H-8’ the opposite
sign. However, H-7’ does not coincide with this rule and makes
therefore a distinct statement about the absolute configuration for
H-3′ impossible. Such issues with the assignment of the absolute
configuration with MTPA are known for linear secondary
alcohols (Seco J.M. et al., 2004). The reason for inconsistent
sign distribution and small 1δ(S−R) values often lies in the
presence of different conformers of the MTPA ester. Theoretical
calculations revealed that a rotation about the Cα – CO and Cα
– Ph bond generates three conformers (Latypov et al., 1996).
All three conformers are present in similar populations and
each conformer has a different shielding/deshielding effect, and
therefore it influences the final spectrum in different ways.
This information together with the inconsistent results from
Mosher’s method for the identical parts of the close related
compounds 2 and 3 (see below) hinders the assignment of
the absolute configuration for C-3′. Alternative reagents, e.g.,
methoxyphenylacetic acid (MPA) or α-(9-anthryl)-α-methoxy-
acetic acid (9-AMA) should give more precise values (Seco J.M.
et al., 2004). Due to the little amount of 1 we had to refrain from
further efforts to determine the absolute configuration for this
part of the molecule.
Therefore, the structure of 1 was established as shown
in Figure 3. We named it alpiniamide A, due to the
close relationship to alpiniamide from a Streptomyces species
mentioned above. It is not excluded that alpiniamide and
alpiniamide A have identical structures. But due to the confusion
concerning the relative configuration of alpiniamide in the
literature and the lack of coupling constants especially for
H-2′-H-4′, we were not able to determine it.
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FIGURE 3 | Mass spectra of alpiniamide A (m/z 326.32 [M-H2O+H]+) extracted from Streptomyces sp. IB2014/011-12 culture cultivated in the presence of
unlabelled (A) and 13C labeled (B) glycine and unlabelled (C) and 13C labeled (D) methionine. The % of isotope containing ions is indicated.
Alpiniamide B1 and B2 (2 and 3), were both isolated as red
solids (0.5 mg), with a molecular formula of C17H29NO6
as determined by their HRESIMS data (m/z 344.20596
[M+H]+). The 1H NMR data (Supplementary Table S3
and Supplementary Figures S9, S10) of both epimers were very
close to each other and to those found for 1. But in contrast
to it, the double bond in part A of 2 and 3 was shifted from
C-4 to C-3 and the secondary alcohol from C-3 to C-5. The
only difference between alpiniamide B1 and B2 was found in
the stereochemistry of the secondary alcohol at C-5. When
applying Mosher’s method to both isomers, the stereocenter at
C-5 was assigned as S in alpiniamide B1 and R in alpiniamide
B2 (Figure 2, Supplementary Table S4, and Supplementary
Figure S8). Due to the high conformity in the chemical shifts
of H-2 and its neighboring atoms the configuration at C-2 is
the same in both molecules and most likely R as it is given for
alpiniamide A. The E-geometry of the double bond C-3/C-4
was confirmed by ROESY measurements with key correlation
between double bond proton H-3 and the H-5 of the secondary
alcohol. Part A is identical in all three alpiniamides. Even
the coupling constants for H-2′, H-3,′ and H-4′ of the three
compounds were identical indicating the same stereochemistry
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for this substructure in all three molecules. As for alpiniamide A,
the determination of the absolute stereochemistry via Mosher’s
method failed for 2 and 3 due to the anomaly of the detected
1δ(S−R) values (Supplementary Figure S8).
Alpiniamide C (4) was obtained as a white solid (0.8 mg)
with a molecular formula of C17H27NO5 as determined from
its HRESIMS at m/z 326.19589 [M+H]+. The mass difference
of 18 units compared to 1–3 indicated the loss of a water
molecule. The 1H and 13C resonances (Supplementary Table S3
and Supplementary Figure S11) lacked one methine and a
secondary alcohol function. Instead, resonances for an additional
trisubstituted double bond (δH 6.87; δC 134.8 and 147.0) appeared
in the spectra. The chemical shifts of part A were close to those
of 1. Therefore, the additional double bond must be located in
part B. Its position between C-3′ and C-4′ was established by
HHCOSY correlations starting from methyl H-7′ (δH 1.29 d,
7.0 Hz) via H-2′ (δH 3.40 m) to H-3′ (δH 6.87 d, 9.5 Hz).
Alpiniamide D (5) is the derivative with the lowest molecular
mass. It is a colorless solid (0.4 mg) with a molecular formula of
C14H23NO5 as determined from its HRESIMS at m/z 286.16458
[M+H]+. Due to its NMR data, part B of 5 is identical to that of
1. However, signals for methines C-2 and C-3 and methyl C-8 in
part A were missing in the spectra of 5 (Supplementary Table S3
and Supplementary Figure S12) and gave therefore a hint of their
deletion in part A. Vicinal HMBC correlations from carbonyl C-
1 (172.2) to the double bond proton at δH 6.39 and the adjacent
methyl protons at δH 1.84 supported this observation and led to
structure 5 for alpiniamide D.
Alpiniamide A was previously isolated from the Streptomyces
sp. YIM 66017. The crude extract of that strain was tested against
the Bacillus anthracis and fungi Fusarium solani (Zhou et al.,
2013). In both cases inhibition zones were observed. Hence,
we have tested the known alpiniamide A and its derivatives
C and D on a panel of bacterial and yeast test cultures. The
minimal inhibitory concentration (MIC) was determined against
the Gram positive bacteria Staphylococcus carnosus DSMZ 20501,
Kocuria rhizophila DSMZ 348, Enterococcus mundtii DSMZ
4840, Micrococcus luteus DSMZ 1790, Mycobacterium smegmatis
DSMZ 43286, and B. subtilis DSMZ 10, against the Gram negative
bacteria Erwinia persicina DSMZ 19328 and Pseudomonas putida
KT2440 and against yeast Candida glabrata DSMZ 11226. In
all cases we did not observe growth inhibitory activity in the
concentration range up to 100 µg/ml. Also, pure compounds
were found to be not active against B. subtilis in disk diffusion
test. Since the mixture of all alpiniamides in the last stage of the
purification was clearly active against B. subtilis we assume that
the inhibitory concentration of alpiniamides lies above 100µg/ml
or the observed antibacterial activity is caused by synergistic
effect with some minor compound(s).
Feeding Experiments
From the structures of the isolated compounds we can predict
that they are synthesized by the combined action of NRPS
and PKS enzymes. The left and the right sides of the amide
bond are typical products for a type I PK, whereas the
peptide bond in the middle most likely arises from the amino
acid glycine introduced by an NRPS enzyme. The methyl
groups of the alpiniamides could originate from the direct
use of methylmalonate during polyketide assembly or from
a secondary methylation event with S-adenosyl methionine
(SAM) as a donor. We grew two cultures of Streptomyces
sp. IB2014/011-12 fed with 13C-labeled glycine and with 13C-
labeled methionine (methyl-13C), respectively. The glycine was
fed for the first time at 10 h post-inoculation. Methionine
was fed for the first time at 36 h after inoculation. For both
compounds, the feeding was repeated four more times every
10 h resulting in final concentration 2.31 mM of Glycine-2-
13C and 1.16 mM of methionine(-methyl-13C). As a control,
the culture supplemented with the corresponding unlabeled
compound was used. The metabolites were extracted and
analyzed by LC-MS. As result, the +1 isotopic peaks of all
alpiniamides in the 13C-labeled glycine culture increased in
intensity (42%) indicating the successful incorporation of the
compound (Figures 3A,B). In contrast, the +1 isotopic peaks
of alpiniamides in the culture supplemented with unlabeled
glycine were observed at their normal intensity (19%). In the
case of methionine, the results demonstrated the successful
incorporation as well. The +1 isotopic peak of alpiniamides
in the 13C-labeled methionine culture reached an intensity of
38.7% (Figures 3C,D). The +1 isotopic peaks of alpiniamide
in the unlabeled culture appeared at their normal intensity of
20%. These results suggest that glycine is incorporated intact
into alpiniamides and is the source of the amino group. On
the other hand, we confirmed that at least some methyl groups
originate from the SAM-dependent C-methyltransferase activity
rather than methylmalonate.
Alpiniamide Gene Cluster Inactivation
and Heterologous Expression
The labeled substrate feeding tests suggest that the alpiniamides
probably arise from the action of a hybrid PKS/NRPS assembly
line that facilitates the incorporation of glycine. The only gene
cluster in the genome of Streptomyces sp. IB2014/011-12 that
corresponds to the hypothesized biosynthetic scheme is no.
9 (Figure 6A and Table 2). This cluster encodes a hybrid
NRPS-trans-AT-PKS that consists of four ketosynthase and one
NRPS modules and a single NRPS module with an adenylation
domain predicted to be specific for glycine as substrate.
Two PK modules contain SAM-dependent C-methyltansferase
domains. Overall, the architecture of the PKS-NRPS enzymes
of cluster no. 9 suggests that it might be involved in the
biosynthesis of alpiniamides. To verify this assumption, we
replaced 2 kb of gene 12750 encoding the first PKS megaenzyme
and its promoter with the spectinomycin-resistance cassette.
The deletion was achieved through targeted gene disruption
via double homologous recombination. The utilization of the
pKG1132 suicide vector simplified the selection of colonies with
double crossover by blue-white phenotypes due to the presence
of the gusA gene in the vector backbone (Myronovskyi et al.,
2011). The mutant strain and the wild type were cultivated
in NL19 production medium, and the produced metabolites
were analyzed by LC-MS. Compared to the wild-type strain,
the mutant IB2014/011-121alpA1 completely lacks the ability to
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TABLE 2 | Description of alpiniamide biosynthesis gene cluster and deduced function of alp-genes.
ID Name Predicted function Closest characterized homologs (% of identical
amino acids)
GenBank accession
number
12715 alpI fatty acyl-CoA reductase putative short chain dehydrogenase, hitachimycin, 46%
(Streptomyces scabrisporus)
LC008143
12720 alpH TetR family transcriptional regulator ∗TetR/AcrR family; Streptomyces sp. IB2014 011-1
(100%)
-
12725 alpW transporter, ATP binding protein UvrA-like protein, quinomycin, 76% (Streptomyces
griseovariabilis)
JN852959
12730 alpG glyoxalase protein putative lyase, pentalenolactone, 82% (Streptomyces
avermitilis)
BA000030
12735 alpF transcriptional activator/DNA repair
enzyme
putative AraC-family transcriptional regulator,
pentalenolactone, 86% (Streptomyces avermitilis)
BA000030
12740 alpT malonyl-CoA ACP transacylase acyltransferase/oxidoreductase, chivosazole, 50%
(Sorangium cellulosum)
DQ065771
12745 alpE 3-oxoacyl-ACP synthase 3 3-oxoacyl-ACP synthase, cosmomycin D, 48%
(Streptomyces olindensis)
JJOHO1000002
12750 alpA3 PKS: KS, AT, ACP; KS, DH, KR, ACP polyketide synthase, kijamimicin 48% (Actinomadura
kijaniata)
EU301739
12755 alpA2 PKS: KS, ACP, cMT, TE polyketide synthase, bacillaene, 38% (Bacillus
amyloliquefaciens)
AJ634060
12760 alpA1 PKS/NRPS: C, A, PCP; KS, ACP, cMT;
KS, DH, tDH, KR, ACP
OnnI, Onnamide, 44% (Candidatus Entotheonella sp.) AY688304
12765 alpD acyl-CoA dehydrogenase ∗acyl-CoA dehydrogenase, dutomycin, 88%
(Streptomyces minoensis)
KP710956
12770 alpR ribosomal RNA large subunit
methyltransferase G
methyltransferase containing protein; Streptomyces sp.
IB2014 011-1 (100%)
-
∗shown are closest homologs.
produce alpiniamides (Figure 4). This proves that gene cluster
no. 9, designated alp-cluster (Table 2), is indeed responsible for
the biosynthesis of alpiniamides.
In addition, we have cloned the 46.7 kb region of the
chromosome of Streptomyces sp. IB2014/011-12 harboring
the entire alp gene cluster and surrounding regions using
transformation associated recombination in yeast. The cloning of
the right region of Streptomyces sp. IB2014/011-12 chromosome
and overall architecture of the cluster was verified through
sequencing with MinION (Oxford Nanopore, United Kingdom).
The construct was introduced into S. lividans TK24 and S. albus
Del14. The recombinant strains bearing the cloned alp-gene
cluster were found to produce alpiniamides (Figure 5). However,
we were able to identify only alpiniamides A, B, and C in
the extracts of generated strains. The lack of alpiniamide D
could be caused either by a change in the behavior of the
enzymatic assembly line or by the relatively low production of
this minor derivative, hindering its identification. Moreover, a
set of mutant constructs with deletion of alpD, alpR, and alpE
genes were created. The resulting plasmids were introduced into
S. albus Del14 and analyzed for production of alpiniamides.
The deletion of alpD encoding an acyl-CoA dehydrogenase and
alpR encoding a ribosomal RNA methyltransferase (Table 2)
had no significant effect on the production of compounds
FIGURE 4 | Production of alpiniamides A-B (m/z 326 [M-H2O+H]+) and alpiniamide C (m/z 308 [M-H2O+H]+) by Streptomyces sp. IB2014/011-12 and its mutant
strain IB2014/011-121alpA1 lacking alpA1 gene. LC-MS chromatogram RT 2–6 min out of an overall 9 min gradient run is shown. Black line – extract of wild type
Streptomyces sp. IB2014/011-12 and red line – extract of mutant strain lacking part of alpA1 gene and its promoter. Strains were cultivated for 7 days in NL19
medium. The peaks for alpiniamides are highlighted. Alpiniamide D elutes under these conditions together with main alpiniamides A and B.
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FIGURE 5 | LC-MS chromatogram RT 2–6 min out of an overall 9 min gradient run of extracts of S. albus Del14/011-12p1-49 and S. lividans TK24/011-12p1-49
strains carrying the alp-gene cluster construct. The strains were cultivated in NL19 media and compounds were extracted from the biomass. Peaks that correspond
to alpiniamides are highlighted. Alpiniamide A-B (m/z 326 [M-H2O+H]+) and alpiniamide C (m/z 308 [M-H2O+H]+).
(Supplementary Figure S13). On the contrary, S. albus Del14
carrying the construct with deleted alpE gene was not able
to produce alpiniamides (Supplementary Figure S13). Lastly,
in order to determine the boundaries of alp gene cluster we
performed the blastn search for the actinobacterial genome
lacking the alp gene cluster but preserving the regions flanking
the cluster in the genomes of Streptomyces sp. IB2014/011-12. As
such, the Kitasatospora albolonga YIM 101047 and Streptomyces
sp. IB2014/011-12 whole genome alignment have revealed that
the alp gene cluster include gene between alpA1 and alpG,
when alpR,D and alpW-I are most probably not involved in
alpiniamides biosynthesis (Supplementary Figure S14).
Deduction of Alpiniamide Biosynthesis
The predicted architecture of a hybrid NRPS-trans-AT-PKS
mega-enzyme encoded by the alp gene cluster made it
possible to propose the biosynthetic steps for the assembly
of alpiniamides (Figure 6B). Polyketide synthases lacking the
acyltransferase (trans-AT-PKS) were thought to be rare systems
in actinomycetes. Only recently it has been discovered that they
are present in several actinobacterial strains (Helfrich and Piel,
2016). However, in general, this type of PKS enzymes is thought
to be the major class of polyketide biosynthesis machineries.
In these systems the usual in-line acyltransferase domains are
missing, and instead, free-standing enzymes take their place
(Jenner et al., 2013). Apparently, the orientation and location of
the core genes in the alp-gene cluster do not reflect the order of
the biosynthetic steps in alpiniamide assembly. The organization
of the alp gene cluster lacks the co-linearity due to its unusual
domain orders and domains acting across modules, which is a
well-known feature of trans-AT-PKSs (Helfrich and Piel, 2016).
The synthesis is initiated by the loading module 0, which is
part of the bimodular protein encoded by gene alpA1 (12750)
(Table 2). Unlike the others, this module possesses its own
AT domain that is predicted to be specific for methylmalonate.
Since the starter unit in alpiniamide biosynthesis is thought
to be a propionate, we believe that loading module 0 loads
the methylmalonate and then decarboxylates it to produce
propionate. Such a decarboxylative loading process is known
for several cis-AT-PKS systems, including the ones involved in
the biosynthesis of tylosin, niddamycin, pikromycin, spinosyn,
and monensin (Fouces et al., 1999; Xue and Sherman, 2001).
However, unlike the cis-AT systems, which typically harbor a
KSQ decarboxylative domain with the active site Cys mutated
to a Gln, the Cys in the canonical CHH motif of AlpA1 KS0 is
substituted with a Ser (KSS). Similar substitutions were found
in the loading KS of trans-AT oocydin synthase (Matilla et al.,
2012) and several cis-AT PKSs from the nystatin, rimocidin, and
pimaricin biosynthesis (Aparicio et al., 2000; Brautaset et al.,
2003; Seco E.M. et al., 2004). These KSS domains are proposed
to participate in decarboxylation or synthesis of the starter
substrates. At least in the case of the nystatin loading module,
it was shown that the Ser residue of KSS0 is not crucial for
proper initiation of the biosynthesis (Brautaset et al., 2003).
However, in all of the cases described above, the polyketide chain
is initiated by acetate rather than propionate. At the same time,
another scenario cannot be excluded. The alpE gene located
close to alpA1 is predicted to encode the KSIII enzyme. This
enzyme is similar to the daunorubicin loading KS as well as
to the ACP-shuttle-type KSs from several other anthracycline
polyketides that are initiated with a propionate starter unit,
such as cosmomycin D and cinerubin B (Garrido et al., 2006;
Kersten et al., 2013). The high similarity between AlpE and these
KSs point on alternative scenario at which the decarboxylative
function of the loading module in alpiniamides assembly might
be provided by the standalone decarboxylative KSIII, similar to
daunorubicin/aklavinone biosynthesis (Tsukamoto et al., 1992).
The essentiality of AlpE for the production of alpiniamides in
heterologous hosts supports this idea.
Subsequently, two elongation steps conducted by module 1
and 2 occur and incorporate two units of malonate. The substrate
is passed on to the PKS by the trans-acting acyltransferase
encoded by gene 12740. This protein is a bidomain AT-ACP
enzyme that is predicted to be specific for malonate. The
function of the ACP domain cannot be deduced from the
available data, but it harbors a Ser residue for attachment of
phosphopantetheine. Module 1 possesses KR and DH domains
for ketoreduction and dehydration reactions, respectively. As
expected, a double bond is present in alpiniamide A, C, and
D between C-4 and C-5. However, in the case of alpiniamides
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FIGURE 6 | Scheme of the organization of alp-gene cluster (A). The line above shows the deduced boundaries of the cluster. The scale bar corresponds to 2 kb.
Proposed pathway for the biosynthesis of alpiniamide (B). Domains: KS - ketosynthase, AT, acyltransferase; DH, dehydratase; KR, ketoreductase; ACP, acyl carrier
protein; cM, C-methyltransferase; AD, acyl-transferase docking domain; TE, thioesterase; C, condensation; A, adenylation; DHt, truncated dehydratase. ∗ Indicates
the DH presumably responsible for double bond migration and corresponding position at growing alpiniamide chain.
B1 and B2, the DH domain is apparently skipped, resulting in
a hydroxyl group at C-5. The ketoreductase domain is missing
in module 2; although, alpiniamides have the hydroxyl group
at the corresponding position. A possible explanation for this
would be that the activity of the KR domain from module 1
is shared between modules 1 and 2. Interestingly B1 and B2
differ in the stereochemistry at C-5 position. Ketoreductases
are highly stereospecific and are divided into groups depending
on which stereochemistry they provide (Keatinge-Clay, 2016).
The in silico analysis of module 1 KR place it in B1
stereospecificity type performing D-α-reduction that correspond
to the configuration observed in alpiniamide B2 (Kitsche and
Kalesse, 2013). Therefore, it is unclear how the different
stereochemistry at position C-5 as well as the threo configuration
at C-2/C-3 is generated. Module 2 has a C-methyltransferase
domain. The acyltransferases in trans-AT-PKS are known to
solely utilize malonyl-CoA as opposed to branched substrates as
elongation units, and the side chain methyl groups are typically
incorporated by C-methyltransferases. This seems to also be true
in the case of the alpiniamides. From the labeled methionine
feeding experiment, we clearly see that the methyl groups of
the alpiniamides are introduced by the S-adenosyl-methionine
(SAM) dependent methyltransferases present in module 2 and
4. Since these compounds each contain four methyl groups,
we assume that both methyltransferases need to act twice
during the biosynthesis. Thus, modules 2 and 4 provide the
C-methyltransferase activity also to module 1 and 5. Another key
feature of module 2 is the presence of a thioesterase domain.
This TE is predicted to be a class II TE of the α/β hydrolase
family. These enzymes hydrolyze the residues attached to the
phosphopantetheine group of ACPs. The exact function of the
TE domain of AlpA2 is not clear, especially considering its
location. A similar architecture was observed in the case of
the burkholderic acid trans-AT PKS, which harbors internal
TE domains with unknown functions (Franke et al., 2012).
TE II domains are often not essential for biosynthesis, but
can be involved in removing aberrant substrates from stalled
PKS megasynthases and control the loading of the starter unit
(Kotowska and Pawlik, 2014). The TE domain of AlpA2 has
the Cys in place of Ser residue of catalytic triad Ser/Asp/His
(Supplementary Figure S15). However, such substitutions are
not rare and can be found in TE14 family of thioesterases (Cantu
et al., 2010).
Another interesting feature of module 2 is the possible
migration of the double bond. The double bond in alpiniamides
B1 and B2 is shifted from the canonical position between C-2 and
C-3 to the position between C-3 and C-4. A so-called double bond
migration is described for several trans-AT produced polyketides
such as bacillaene, corallopyronin A, and rhizoxin (Butcher et al.,
2007; Partida-Martinez and Hertweck, 2007; Lohr et al., 2013),
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and this process is thought to be mediated by a dehydratase
domain either by direct β-γ dehydration or α-β dehydration and
subsequent isomerization (Gay et al., 2014). However, it is not
clear if alpiniamides B1 and B2 arise from alpiniamide A through
the catalytic action of one of the DH domains (most likely by the
DHt of module 5 that is predicted to be non-functional) or from
an acid-induced double bond migration.
At the next step, a non-ribosomal peptide synthetase module
within AlpA3 extend the polyketide intermediate with a glycine.
Interestingly, glycine is often found to act as a bridge between
two polyketide chains in hybrid NRPS-trans-AT-PKS assembled
natural products, such as bacillaene, batumin, calyculin,
corallopyronin, misakinolide and oxazolomycin (Helfrich and
Piel, 2016).
Modules 4 and 5 further extend the molecule with two
malonate units. Typically, ketosynthases ensuing a NRPS module
are highly substrate specific and do rarely accept aberrant
substrates with bulkier amino acid residues (Kohlhaas et al.,
2013). As in module 2, module 4 lacks the ketoreductive function
even though the hydroxy group at C-3′ is present. This activity
is most likely provided by module 5, which contains KR and
DH domains. However, based on the structures of alpiniamide
A, B and D, we assume that the DH domain is occasionally
skipped. Only alpiniamide C seems to be dehydrated at this
step, which resulted in the double bond between C-3′ and C-4′.
Module 5 is missing the ACP and TE domains, which are instead
located in module 2. The mechanism by which alpiniamides are
released from the biosynthetic enzyme is not clear. Most likely,
the TE activity is provided by the respective domain of module
2. However, the location of the TE domain is unusual as well as
the composition of catalytic triad (Cys/Asp/His). The fact that it
is placed right before the NRPS module 3 makes us think that it
also might be involved in the cleavage of aberrant substrates than
in the release of the final product.
In the case of alpiniamide D, module 2 is probably skipped
entirely during the biosynthesis since it lacks the C-1 and C-2
part of the molecule. Such a case is very rare but was previously
described for epothilone K (Moss et al., 2004) and for the
trans-AT-PKS-derived compound albicidin (Huang et al., 2001).
Even though alpiniamides are quite small molecules they
provide a fascinating example of high chemical diversity
introduced by the PKS assembly line. The alpiniamides
NRPS-trans-AT-PKS utilizes a combination of domain and
module skipping, in-line methylation and double bond migration
events to produce a variety of chemical structures from a simple
initial building block.
CONCLUSION
We have isolated five new alpiniamide derivatives and identified
the gene cluster responsible for their biosynthesis in the new
Streptomyces sp. IB2014/011-12. This shows that there are still
great opportunities to discover promising natural products,
especially from unique and largely unexplored ecological niches
such as Lake Baikal.
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2 Supplementary Figures and Tables 
2.1 Supplementary tables 
Table S1. Primer used in this work. 
Name sequence 
11-12_12720ChF  TCGACAGACAGCTGCCCTG 
11-12_12720ChR  GCACACAGTAGAACGTGTTG 
11-12_12715ChF  ACCCGAAGTTCGTGGTCCTG 
11-12_12715ChR  CGGACCGTTGCGTGTTCACA   
11-12_12695ChF  CACGCTGGTGTTCGACTACC 
11-12_12695ChR  AGAGCTCTTCGATGGGGTAG 
11-12_12720DF  TGGGGCGCCCCCGGTTCCTCGGTTAGCCTGAGTGACATATGAAACTACGCCCCCAACTGAGAG 
11-12_12720DR  GGAAGGGCCGGGAACCCTGATCTCCGCCGTCAGCGCTTGACTCGACCCGGTACCGGAGTA 
11-12_12715DF  CACGGGCGACGCAGACGCGAGACTCTGGAGGGGCCGTGCAACTACGCCCCCAACTGAGAG 
11-12_12715DR  GACGCGTCGCGCCACCGCGAGCCAGCGCCTCACCGCCGCACTCGACCCGGTACCGGAGTA 
11-12_12695DF  TGAGAGGGAACGAGAAGTGAAGACAGAGGCCCTGTTCATCGACTACGCCCCCAACTGAGAG 
11-12_12695DR  CCCTGTCCCGGGAACACGTAGCAGCGCATCAGAGCCGCCCGCTCGACCCGGTACCGGAGTA 
C9-2REcV atGATATCATCCAGGAGATGATCTCGCG 
C9-2FEcI atGAATTCAATCTGGACCGCAACGGCCT 
C9-1FEcV atGATATCG CCTGAAGGACCAACTCGT 
C9-1RXba atTCTAGAACTTCGATGGGAT CGCCGA 
11-12DelCheckF AAGTGCTGGTCGAGGACGTA 
11-12DelCheckR TACGCCTGGCTGATGG AGAT 
11-12C9TarF1Not ATGCGGCCGCAACGGCGTGAAGCCGAAGAT 
11-12C9TarR1Nhe ATGCTAGCGAATGCTGCTCATGGGGTGT 
11-12C9TarF2NheI ATGCTAGCCTGCACACGATCATCAGCGA 
11-12C9TarR2HindIII ATAAGCTTGATTGGACGGAATGTCCGTG 
11-12C9CheckHind GACGAC ACGTACTACCAGGA 
pCLYCheckHind CTCTTCGGTGAACTTCGGG 
Sequence highlighted in yellow anneal with the priming sites of hygromycin resistance cassette from 
patt-shyg-oriT. 
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Table S2. Secondary metabolism gene clusters identified within the genome of Streptomyces sp. 
IB2014/011-12 with the use of the antiSMASH software. 
BGC Type Most similar known cluster. 
1 Lantipeptide AmfS antibiotic (Ueda et al., 2002) 
2 Terpene - 
3 Lassopeptide Lassopetide similar to SRO15-2005 (Kersten et al., 2011) 
4 Lantipeptide - 
5 Siderophore Desferrioxamine B (Barona-Gómez et al., 2004) 
6 Bacteriocin - 
7 Butyrolactone - 
8 Terpene - 
9 NRPS-Trans-at-type 1-PKS - 
10 Melanin-NRPS Peptide similar to Coelichelin (Challis and Ravel, 2000) 
11 Type 3 PKS - 
12 NRPS - 
13 type 1 PKS-NRPS Similar to polycyclic tetramate macrolactams (Luo et al., 2013) 
14 Terpene Squalene antibiotic similar to Hopene (Pan et al., 2015) 
16 Type 1 PKS - 
17 Other Riboflavin antibiotic similar to Roseoflavin (Schwarz et al., 
2016) 
18 Terpene - 
19 thiopeptide - 
20 Melanin Phenoxazinone antibiotic Grixazone (Suzuki et al., 2007) 
21 Ectoine Ectoine (Zhu et al., 2014) 
22 NRPS - 
23 Type 3 PKS Alkylresorcinol (Cook et al., 2010) 
24 Melanin Dihydroxynaphthalene Melanin (Woo et al., 2010) 
25 NRPS - 
26 Siderophore - 
27 Type 2 PKS - 
28 Terpene - 
29 NRPS - 
   
Table S3. NMR spectroscopic data (MeOD4) for alpiniamides 1-5. 
Position 
(1) (1)1 (2) (3)                   (4) (5) 
δC a δH b δC a δH b δC a δH b δC a δH b δC a δH b δC a δH b 
1 178.3, C  176.75, C  178.0, C  177.2, C  178.2, C  172.2, C  
2 45.1, CH 2.54, dq (9.5, 7.0) 44.28, CH 2.52, dq (9.5, 7.0) 40.4, CH 
3.36, dq (9.5, 
7.0) 
40.5, CH 
3.36, dq (9.5, 
7.0) 
  45.5, CH 
2.56, dq (9.5, 
7.1) 
130.7, C  
3 81.0, CH 3.98, d (9.5) 80.40, CH 4.03, d (9.5) 126.6, CH 5.43, br d (9.3) 127.2, CH 
5.43, br d 
(9.3) 
  81.0, CH 3.98, d (9.5) 139.4, CH 
6.39, tq (7.2, 
1.5) 
4 135.1, C  133.13, C  140.6, C  139.8, C  135.0, C    22.3, C 
2.20, quint (7.5, 
1.0) 
5 131.8, CH 5.41, t (7.2) 131.94, CH 5.40, t (7.2) 79.3, CH 3.85, t (6.7) 79.8, CH 3.85, t (6.8) 132.0, CH 5.42, t (7.3) 
  13.2, 
CH3 
1.05, t (7.5) 
6 21.5, CH2 2.06, quint (7.5) 20.85, CH2 2.02, quint (7.5) 28.5, CH2 1.54, m  28.1, CH2 1.55, m    21.5, CH2 2.06, quint (7.5) 
  12.2, 
CH3 
1.85, br s 
7 14.1, CH3 0.97, t (7.5) 13.88, CH3 0.94, t (7.5) 10.1, CH3 0.85, t (7.5) 10.3, CH3 0.85, t (7.5)   14.2, CH3 0.97, t (7.5)   
8 14.8, CH3 0.93, d (7.0) 14.38, CH3 0.95, d (7.0) 18.5, CH3 1.22, d (7.0) 18.6, CH3 1.20, d (7.0)   14.7, CH3 0.94, d (7.0)   
9 10.3, CH3 1.60, s 10.41, CH3 1.57, s 11.6, CH3 1.66, d (1.5) 11.1, CH3 1.66, d (1.5)   10.5, CH3 1.61, s   
1’ 178.4, C  179.03, C  178.7, C  178.3, C  180.8, C  178.1, C  
2’ 44.6, CH 2.50, quint (7.0) 42.71, CH 2.54, quint (7.0) 44.60, CH 2.48, quint (7.0) 44.7, CH 
2.47, quint 
(7.0) 
  44.3, CH 
3.41, dq (9.5, 
7.1) 
  44.4, CH 2.55, quint (7.1) 
3’ 74.2, CH 
4.01, ddd (7.0, 
5.3, 1.5) 
73.54; CH 4.02, m 74.4, CH 
3.96, ddd (7.0, 
5.3, 1.5) 
74.4, CH 
3.95, ddd (7.0, 
5.3, 1.5) 
146.7, CH 
6.87, dq (9.5, 
1.5) 
  74.1, CH 
4.03, dd (7.1, 
5.3) 
4’ 47.7, CH 2.92, qd (7.0, 5.3) 47.23, CH 2.79, d (7.0, 4.5) 47.9, CH 
2.87, qd (7.0, 
5.5) 
48.1, CH 
2.88, qd (7.0, 
5.5) 
135.0, CH    47.7, CH 
2.93, qd (7.1, 
5.3) 
5’ 209.9, C  209.27, C  209.5, C  209.1, C  197.4, C  209.9, C  
6’ 49.0, CH2 
4.13, d (18.5) 
4.25, d (18.5) 
48.81, CH2 
4.19, dd (19.0, 5.0) 
4.29, dd (19.0, 5.5) 
48.8 CH2 
4.12, d (18.5) 
4.16, d (18.5) 
48.8, CH2 
4.13, d (18.5) 
4.17, d (18.5) 
  46.0, CH2 
4.44, d (18.5) 
4.48, d (18.5) 
  49.0, 
CH2 
4.18, d (18.5) 
4.22, d (18.5) 
7’ 15.0, CH3 1.16, d (7.0) 14.49, CH3 1.17, d (7.0) 14.9, CH3 1.15, d (7.0) 15.0, CH3 1.15, d (7.0)   18.4, CH3 1.30, d  (7.0) 
  14.8, 
CH3 
1.15, d (7.0) 
8’ 10.5, CH3 1.13, d (7.0) 9.79, CH3 1.14, d (7.0) 10.8, CH3 1.12, d (7.0) 10.8, CH3 1.12, d (7.0)   11.2, CH3 1.82, d (1.5) 10.6, CH3 1.14, d (7.0) 
     NH    7.09, t (5.3)         
1 = NMR data aquired in CDCl3; 
a = followed by multiplicity; b = followed by coupling constant J in Hz; all 13C chemical shifts were taken from 2D spectra 
HSQC/HMBC except for (1) in CDCl3.  
 5 
Table S4. 1H chemical shifts (in ppm, recorded in CDCl3) and ∆δ(S-R) values for Mosher derivatives 6R and 6S of alpiniamide A (1), 7R and 7S of 
alpiniamide B1 (2) and 8R and 8S of alpiniamide B2 (3). 
Position 
(1) (2) (3) 
6S δH 6R δH ∆δ(S-R) 7S δH 7R δH ∆δ(S-R) 8S δH 8R δH ∆δ(S-R) 
1 - - - - - - - - - 
2 2.69 2.72 -0.03 3.32 3.36 -0.04 3.40 3.36 +0.04 
3 5.53 5.48 +0.05 5.60 5.67 -0.07 5.64 5.57 +0.07 
4 - - - - - - - - - 
5 5.75 5.69 +0.06 5.17 5.20 -0.03 5.31 5.26 +0.04 
6 2.04 2.00 +0.04 1.68 1.64 +0.04 1.70 1.74 -0.04 
7 0.95 0.93 +0.02 0.90 0.82 +0.08 0.83 0.89 -0.06 
8 1.01 1.02 -0.01 1.25 1.30 -0.05 1.26 1.25 +0.01 
9 1.58 1.41 +0.17 1.54 1.69 -0.15 1.70 1.53 +0.17 
1’ - - - - - - - - - 
2’ 2.96 3.00 -0.04 3.42 3.46 -0.04 3.46 3.45 +0.01 
3’ 4.21 4.20 +0.01 4.29 4.28 +0.01 4.39 4.38 +0.01 
4’ 3.46 3.42 +0.04 3.02 3.00 +0.02 3.07 3.05 +0.02 
5’ - - - - - - - - - 
6’ 
4.11 
3.78 
4.26 
4.01 
-0.15 
-0.23 
n.d. 
n.d. 
n.d. 
n.d. 
- 
- 
n.d. 
n.d. 
n.d. 
n.d. 
- 
- 
7’ 1.27 1.22 +0.05 1.37 1.36 +0.01 1.38 1.37 +0.01 
8’ 1.37 1.35 +0.02 1.29 1.27 +0.02 1.30 1.30 0 
 
n.d.: not detected due to overlap with MTPA signals. 
  
   
2.2 Supplementary Figures 
 
 
Supplementary figure S1. Reaction of alpiniamides with R-MTPA-Cl and S-MTPA-Cl in order to 
determine the absolute configuration. 
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Supplementary figure S2. Streptomycetes sp. IB2014/011-12 grown on MS medium for 7 days. 
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Supplementary figure S3. Structures of polycyclic tetramate macrolactams (9-13) identified in the 
extract of Streptomyces sp. IB2014/011-12. 
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Supplementary figure S4. (A) MS and UV spectra of polycyclic tetramate macrolactams identified 
in the extract of Streptomycetes sp. IB2014/011-12. (B) alteramide A (9); (C) alteramide B (10); (D) 
clifednamide A (11); (E) clifednamide B (12); (F) dihydromaltophylin (13) (HSAF). 
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Supplementary figure S5. Genetic organization of gene cluster for PTMs production from the 
genome of Streptomyces sp. IB2014/011-12 and gene cluster of dihydromaltophylin, alteramide and 
clifednamide. 
  
   
 
 
Supplementary figure S6. 1H NMR-spectra of alpiniamide A in MeOD4 500 MHz. 
  Supplementary Material 
 12 
 
 
Supplementary figure S7. 13C NMR-spectra of alpiniamide A in CDCl3 500 MHz. 
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Supplementary figure S8. ∆δ(S-R) values (x10-2 ppm) of the MTPA esters of 1-3. 
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Supplementary figure S9. 1H NMR-spectra of alpiniamide B1 in MeOD4 500 MHz. 
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Supplementary figure S10. 1H NMR-spectra of alpiniamide B2 in MeOD4 500 MHz. 
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Supplementary figure S11. 1H NMR-spectra of alpiniamide C in MeOD4 500 MHz. 
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Supplementary figure S12. 1H NMR-spectra of alpiniamide D in MeOD4 500 MHz. 
 

   
 
 
Supplementary figure S13. LC-MS chromatogram of extracts of S. albus Del14 carrying 011-12p1-
49 plasmid and it’s variants with the deletion of individual alp genes: S. albus Del14/011-12p1-49∆E 
– alpE; S. albus Del14/011-12p1-49∆D – alpD; S. albus Del14/011-12p1-49∆R – alpR. Peak that 
corresponds to alpiniamides are highlighted: m/z 326 [M-H2O+H]
+ for alpiniamides A and B, m/z 308 
[M-H2O+H]
+ for alpiniamide C. In the case of S. albus Del14/011-12p1-49∆E small peak eluting 
around same RT as alpiniamide A has m/z of 285 [M+H]+. 
   
 
 
Supplementary figure S14. Alignment of whole genome of Kitasatospora albolonga YIM 101047 (GenBank accession number CP020563) 
and contig 08 of Streptomyces sp. IB2014/011-12 genome containing alp gene cluster and regions surrounding it.  The alignment was 
performed with Geneious v. 8.1.7 software (Biomatters Ltd., New Zealand) using progressive Mauve algorithm.  
   
                       10        20        30        40        50        60        70        80 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
gi 17548863 5391 RPLFLVHEITGLDGYFTQLGAWIDAD-IPVYGLPAVGWG----EPQLRTIEGLAKRLKAAMRAVQPHG---PYRLAGWSF 5462 
query          1 RPVFWIHGALAGVESYRTIAERI--D-RPFYGIQARGLLt--eDEPIEGITAMAEHYTEVIRSVQPEG---PYDVGGFCL 72 
gi 17989334    1 -------------------MGLLAGAaLVLPSLPAEAKt-----QQAAMPPNATSPHQADVYLLRGFA---DIFSTGIDE 53 
gi 730829   1058 QIIFAFPPVLGYG-------LMYQN-----LSSRLPSYKl--cAFDFIEEEDRLDRYADLIQKLQPEG---PLTLFGYSA 1120 
gi 19554061 1348 PAVFMFHPAGGS-------SVVYQPL-MRRLPEDVPVYg---vERLEGDLADRAAAYVDDIKKYSDGF---PVVLGGWSF 1413 
gi 15610936 1469 VPVFVFHPAGGS-------TVVYEPL-LGRLPADTPMYg---fERVEGSIEERAQQYVPKLIEMQGDG---PYVLVGWSL 1534 
gi 2120647  2170 SPLFMFHPSFGSVHCYKTLAMALRDR-HPVKGVVCRALLg--aGREVPEWDDMVAEYAEQLLQEHPEG---VFNLAGWSL 2243 
gi 15598523 2077 PPLFLVHPLGGHVLCYLPLVRALPPD-QPVYALQAAGTGq--gSTPLAVLEDIAASYLAAIRRVQPEG---PYYLGGWSF 2150 
gi 17546530 1727 RTLVCVHASDGHAAAYRPLAAVLAGT-VQCVALQSPGLEa--gQAPLRSVEAQAACYLAALRAGREAGaqaPWHVLGWSM 1803 
gi 17549641 1173 PAVFAIPGVGGLAAAFAPLGTELRRHgIELVAFDSPGWHadrtLPIDARLLAYVQHVVDAIRRRTPHG---PYQLIGHSF 1249 
                         90       100       110       120       130       140       150       160 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
gi 17548863 5463 GGVLAYEIAIQLIGED-EEVEFLGLLDTR-------QPalvsGGKPKWAAENRPH----HAQLLELCLAYWQ-QRSPGgP 5529 
query         73 GGIVAYEVTRRLQAQG-QDVASLTMVDSPdetglakSN----ANGFQSARSAALQvvnsLLWPAGEKDPAALrARLVH-R 146 
gi 17989334   54 IGAELQAAGVNAHVQG-HAAWRLVLNRIV-------AD----------------------------QQKNGH-LPVVL-- 94 
gi 730829   1121 GCSLAFEAAKKLEEQG-RIVQRIIMVDSY-------KK---------QGVSD--------------LDGRTV-ESDV--- 1165 
gi 19554061 1414 GGAVAFEVAHQLVGSD-VEVATVALLDTV-------QPsn-pAPDTAEETRARWT----RYADFAKKTY-GL-DFEVP-F 1477 
gi 15610936 1535 GGVLAYACAIGLRRLG-KDVRFVGLIDAV-------RAge-eIPQTKEEIRKRWD----RYAAFAEKTFNVT-IPAIP-Y 1599 
gi 2120647  2244 GGNLAMDVAARLEQRG-RQVAFVGWIDAP-------AP---------VRVEAFWN----EIGPTPEAVPNLS-VGEMR-V 2300 
gi 15598523 2151 GGFVAYEMARQLRALDpQAVAQLIVLDSI-------TVdr-nHAG--SASDEALL----LFFYWELVWFERS-DKEVEpL 2215 
gi 17546530 1804 GAYVAVEMARQLAQAG-ECVAQLLLVDPA-------PQ----EAMRAAARSEYDL----LLSLAPEAVRREL-AEQVGsA 1866 
gi 17549641 1250 GARVAFDVALALEEAG--GTVALTMLDAL-------PG------N--DLVDMSRW----RVGQTPRELAGWL-LGAMQ-- 1305 
                        170       180       190       200       210       220       230       240 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
gi 17548863 5530 ESAKLAGLAGVEDFSALLERCRAQallAPDL-ADVTEPDLW--HVLDRIVAHGDAQANYTVfpmplKLHLFVAAHEQRDD 5606 
query        147 DEIADDLDEDAFVL-RLAELAAER---GLAMrPDRTARFVRrnMAIQLAYRLGEHTIRPLP-----RPEAVVctyfrnrr 217 
gi 17989334   95 -IGHSLGANAAIYIAEELERRGIA---VDYM-ATFAATGPD--PLPGNVRRVVNFYFKQHG-----WGLPLVPGPR---- 158 
gi 730829   1166 EALMNVNRDN---EALNSEAVKHG---LKQK-THAFYSYYV--NLISTGQVKADIDLLTSG--------ADFDMPE---- 1224 
gi 19554061 1478 EILDTIGEDG--MLSMMTDFLANTdasEHGL-SAGVLEHQR--ASFVDNRILAKLNFADWAnv--eAPVILFRAERMHDG 1550 
gi 15610936 1600 EQLEELDDEG--QVRFVLDAVSQS---GVQI-PAGIIEHQR--TSYLDNRAIDTAQIQPYD-----GHVTLYMADRYHDD 1666 
gi 2120647  2301 ELLGVMFPERAEHIERAWSSICSAttdDEQR-WTRMSDWAE--AEIGAEFATLRSEIAQSN-----ELEVSWELKQILDE 2372 
gi 15598523 2216 PEGASLEQKLDHIVERAIEAGVLPagtPRAT-VQRLYELFR--ASWQALIGYRPEVSDQDMtllraDGPLPLALKPMHDA 2292 
gi 17546530 1867 DAFASLPPARRLAHWRAGLRLAAPs--PADD-DAALERMVA--VLLANVTAMVDYRLPILD-----LPTVALYQASEHPA 1936 
gi 17549641 1306 --NGDVPAEPGEDAVASLARLQIYg--DLDV-HDALALVDD--QMLASRRYRPARRLRATR------VQMVYAEHGLIGA 1372 
                        250       260       270       280       290       300 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*.. 
gi 17548863 5607 EPP---------------PHKRWLGWNAILPDTQlqrivV--PGTHQSMVLE-HAQALGEALSAALHAAAGQPQP 5663 
query        218 glflgevepyfqvtgetfsldhvnyrqdwgrempglrlveidaanHmtilndaep-------------------- 272 
gi 17989334  159 --------------------FHGHLENRDFSNAK--------DVGHFNIEKQrPLQAEVVRDVLAVVNAD----- 200 
gi 730829   1225 ------------------WLASWEEATTGVYRVKr------GFGTHAEMLQG-ETLDRNAEILLEFLNTQTVTVS 1274 
gi 19554061 1551 AIElepnyakidQDGGWSGIVNDLEIVQ-------------LNGDHLAVVDE-PEIGTVGAHLSRRIDEISRKN- 1610 
gi 15610936 1667 AIMfepryavrqPDGGWGEYVSDLEVVP-------------IGGEHIQAIDE-PIIAKVGEHMSRALGQIEADRT 1727 
gi 2120647  2373 RLKamdyprltaKVSLWWAARSTNAIQRs-----------aVERSMAEAIGA-ERVEPVRVLDTRHDKIIDHPEF 2435 
gi 15598523 2293 AGThy-----gdPKNGWQHWTSGRLDVId------------VPGDHLVLMKE-PYVETVAAEIAALLEPSTSSER 2349 
gi 17546530 1937 GWGd--------VIAPWRDVFPRGIQAEt------------LAGTHWSVVGAeVLGPVLAQRLREGGAAAPATPA 1991 
gi 17549641 1373 HAHd-------aIVDSLRAWADTVAVAR-------------LDADHFSMLKA-APALAGHVMAHGRA-------- 1418 
 
Supplementary figure S15. Multiple sequence alignment of TE domain of AlpA2 using the 
Conserved Domain BLAST with the closest representatives of COG3319 super-family. The proposed 
active site residues (catalytic triad) are marked with red frames. The catalytic triad is deduced based 
on structural data for thioeserase domain of surfactin synthetase subunit 3 SrfA-C (730829, 
highlighted in yellow) (Bruner et al., 2002). 
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ABSTRACT: Genome mining of actinomycete bacteria aims at the discovery of novel
bioactive secondary metabolites that can be developed into drugs. A new repressor-
based biosensor to detect activated secondary metabolite biosynthesis gene clusters in
Streptomyces was developed. Biosynthetic gene clusters for undecylprodigiosin and
coelimycin in the genome of Streptomyces lividans TK24, which encoded TetR-like
repressors and appeared to be almost “silent” based on the RNA-seq data, were chosen
for the proof-of-principle studies. The bpsA reporter gene for indigoidine synthetase
was placed under control of the promotor/operator regions presumed to be controlled
by the cluster-associated TetR-like repressors. While the biosensor for undecylprodi-
giosin turned out to be nonfunctional, the coelimycin biosensor was shown to perform
as expected, turning on biosynthesis of indigoidine in response to the concomitant
production of coelimycin. The developed reporter system concept can be applied to
those cryptic gene clusters that encode metabolite-sensing repressors to speed up
discovery of novel bioactive compounds in Streptomyces.
KEYWORDS: Streptomyces, secondary metabolite biosynthesis, orphan gene clusters, TetR repressor, biosensor
Natural products from Streptomyces and other actinomycetebacteria remain a rich source for the discovery of new
bioactive compounds that may have a potential to be developed
into human medicines. Recent advances in genomics of these
important bacteria revealed their unprecedented capacity to
synthesize structurally diverse secondary metabolites, while
only a few of those are actually produced in standard laboratory
conditions.1 Consequently, a concept of genome mining was
developed, that utilizes information on secondary metabolite
biosynthesis gene clusters in order to either activate their
expression in native producers, or express them heterologously
in engineered bacterial hosts.2 Despite some success stories,3
genome mining still appears to be unpredictable in terms of
outcomes and may yield unexpected results.4 The most
laborious part of genome mining remains analytics aimed at
detection and identiﬁcation of a compound expected to be
produced as a result of activation or heterologous expression of
a targeted gene cluster. Development of a robust biosensor that
could be used to directly assess actual production of a cluster-
speciﬁc compound would be of great advantage, also with
respect to high-throughput screening after random muta-
genesis.
Certain types of proteins provide unique opportunities for
development of such biosensors. For example, resistance to
tetracycline in Gram-negative bacteria is due to the export of
this antibiotic by the TetA eﬄux pump. Expression of tetA is
under tight transcriptional control of the repressor TetR, which
is encoded by a divergently transcribed gene. Upon binding to
tetracycline, TetR dissociates from its operator upstream of
tetA, thus allowing its transcription, and consequently, eﬄux of
tetracycline by TetA.5 The ﬁrst biosensor capable of detecting
oxytetracycline production by Streptomyces rimosus was
constructed in Escherichia coli based on the original TetR
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repressor.6 TetR-like repressor-coding genes have been
identiﬁed within or in the vicinity of secondary metabolite
clusters in many Streptomyces, which implied their potential
roles in sensing cluster-speciﬁc molecules. Some of such
repressors were indeed conﬁrmed to bind both the end
products of cluster-speciﬁc biosynthetic pathways, and/or its
precursors. One of the ﬁrst examples that concerned TetR-like
repressors responding to secondary metabolites other than
tetracyclines was that of LanK, the repressor controlling
landomycin biosynthetic pathway in Streptomyces cyanogenus.7
This protein was shown to bind various landomycins with
altered aglycon structure, as well as extremely low concen-
tration of the ﬁnal product, landomycin A. Consequently, the
authors have suggested that LanK can be used to develop a
biosensor for detection of landomycin-related compounds. The
Repressor function of SymR, a TetR-like protein encoded by
the simocyclinone biosynthesis gene cluster of S. antibioticus,
was shown to be abrogated upon its binding to either
simocyclinone D8 or its precursor C4.8 Recently, chlorothricin
and its biosynthetic intermediates were shown to modulate
binding of a TetR-like repressor ChlF1 to its target genes in the
chlorothricin gene cluster of Streptomyces antibioticus.9
These ﬁndings prompted us to investigate if TetR-like
repressors in Streptomyces can be used for development of
robust biosensors, which would couple easily detectable
expression of the reporter with the production of speciﬁc
secondary metabolites. Such biosensor would represent a clear
advantage over the earlier described reporter system that
detects expression of the secondary metabolite biosynthesis
genes, as described by Guo et al. for gaudimycin biosynthesis.10
Indeed, our design would allow direct monitoring of the
cluster-speciﬁc product, not just expression of its biosynthetic
genes. Here, we present a proof-of-principle for such a
biosensor, and argue that similar design can greatly assist in
the genome-based bioprospecting for novel bioactive com-
pounds in Streptomyces and other actinomycete bacteria.
■ RESULTS AND DISCUSSION
Identiﬁcation of Poorly Expressed Secondary Metab-
olite Biosynthesis Gene Clusters in Streptomyces lividans
TK24. Analysis of the S. lividans TK24 genome11 using online
version of the software antiSMASH 3.012 revealed 27 gene
clusters for the biosynthesis of secondary metabolites, but this
number was amended to 29 after manual curation using BLAST
searches (Table 1). Out of those, 17 gene clusters for known
compounds were identiﬁed, governing biosynthesis of actino-
rhodin, undecylprodegiosin, coelibactin, albaﬂavenone, coeli-
mycin, hopanoids, desferroxamine, lanthionine-containing
peptide SapB, 2-methylisoborneol, calcium-dependent anti-
biotic, melanin, spore pigment, ectoine, coelichelin, 1,3,6,8-
tetrahydroxynaphthalene, isorenieratene and geosmin. It is
worth noting that S. lividans TK24 has two identical gene
clusters for the biosynthesis of albaﬂavenone, apparently
located within the terminal inverted repeats of the linear
chromosome. Next, we decided to explore the transcriptional
landscape of the secondary metabolite biosynthesis gene
Table 1. Secondary Metabolite Biosynthesis Gene Clusters in the Genome of S. lividans TK24 Identiﬁed Using AntiSMASH 3.0,
Followed by Manual Curationa
no cluster type TetR-like repressor product scaﬀold-building gene expression, max TPM
1 Terpene − Terpene SLIV_00150 (1.7)
2a Terpene + 2-methylisoborneol SLIV_00800 (324.1)
3 NRPS + Coelibactin SLIV_00885 (179.9)
4a PKSIII − Polyketide SLIV_00945 (0.28)
5 Indole − Indole (putative) SLIV_01965 (16.0)
6a Other − Unknown, likely false-positive N/A
7 Terpene − Hopanoids SLIV_04695 (109.3)
8 Lantipeptide − Lanthionone-containing peptide SapB SLIV_05105 (35.4)
9 NRPS − Nonribosomally synthesized dipeptide SLIV_06265 (20.7)
10 PKS I-butyrolactone + Coelimycin SLIV_06770 (0.4)
11 Siderophore − Siderophore (putative) SLIV_07005 (4.1)
12a Terpene + Geosmin SLIV_07775 (417.9)
13 Bacteriocin − Bacteriocin (putative) SLIV_07915 (955.7)
14 PKS I + Undecylprodigiosin SLIV_09145 (2.0)
15 Siderophore − Siderophore (putative) SLIV_09615 (7.5)
16 PKS II − Spore pigment SLIV_11780 (5.9)
17 Terpene − Albaﬂavenone SLIV_12255 (63.5)
18 PKSII + Actinorhodin SLIV_12950 (192.9)
19 NRPS − Calcium-dependent antibiotic SLIV_21540 (3.4)
20 Siderophore − Desferroxamine B SLIV_23760 (1035.8)
21 Melanin − Melanin SLIV_24170 (19.8)
22 Ectoine − Ectoine SLIV_28385 (1011.2)
23a PKS III + 1,3,6,8-tetrahydroxynaphthalene SLIV_31765 (27.7)
24 Bacteriocin − Bacteriocin (putative) SLIV_34165 (71.5)
25 NRPS + Coelichelin SLIV_35480 (217.1)
26 Lantipeptide − Class I lantipeptide (putative) SLIV_36570 (38.7)
27 Terpene − Isorenieratene SLIV_36960 (32.3)
28a PKS I − Polyunsaturated fatty acid (putative) SLIV_37285 (10.6)
29 Terpene − Terpene SLIV_37475 (1.8)
aClusters misannotated or missed by the software via artiﬁcial fusion of several clusters.
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clusters using RNA-seq technology.13 Total RNA was isolated
from S. lividans TK24 cultures growing in liquid minimal media
with or without addition of casamino acids at early and late
logarithmic phases, as well as at stationary phase. The mRNA
fractions were enriched by depletion of stable RNA and then
converted to strand-speciﬁc transcriptome libraries. After
sequencing by Illumina technology, gene expression analysis
was performed for every scaﬀold-building gene of a secondary
metabolite gene cluster by calculating the transcripts per
million reads (TPM) in order to ﬁnd transcriptionally silent
and therefore putatively repressed secondary metabolite gene
clusters (a detailed description of the RNA-seq experiments will
be published elsewhere). We speciﬁcally examined the data for
the gene clusters encoding TetR-like repressors, namely those
for 2-methylisoborneol (cluster 2), coelimycin (cluster 10),
geosmin (cluster 12), undecylprodigiosine (cluster 14), spore
pigment (cluster 16), actinorhodin (cluster 18), 1,3,6,8-
tetrahydroxynaphthalene (cluster 23), and coelichelin (cluster
25). Full overview of the gene expression proﬁles for the
S. lividans TK24 secondary metabolite biosynthesis gene
clusters is presented in Supporting Information, Table S1.
We have focused our examination on the genes from the
targeted clusters, which encode enzymes responsible for the
assembly of secondary metabolite scaﬀolds, reasoning that such
scaﬀolds would represent a minimal structure that TetR
repressors could bind. Out of examined gene clusters, only
those for coelimycin and undecylprodigiosine fulﬁlled the
criteria of being expressed at very low levels and encoding
TetR-like repressors.
Attempts on Construction of the Undecylprodegiosin
Biosensor. First, we have focused on the undecylprodigiosin
biosynthetic gene cluster (red, Figure 1A), which has been
characterized in quite some details.14 These earlier studies,
however, did not address the function of the divergently
transcribed genes SLIV_09075 and SLIV_09080 located ca. 9
kb downstream of redE. SLIV_09075 encodes a TetR-like
repressor, and the SLIV_09080 gene product is similar to
MMPL domain-containing transporters. Since the red cluster
does not encode any transporters, it seemed logical to suggest
that the SLIV_09075+SLIV_09080 pair is responsible for
undecylprodigiosin eﬄux in response to the production of this
compound, with the TetR-like repressor being the receiver of
the signal. Considering this, we PCR-ampliﬁed the putative
promoter/operator region upstream of SLIV_09080, and
placed it upstream of the bpsA reporter in an integrative
plasmid. BpsA is a monomodular nonribosomal peptide
synthetase responsible for the biosynthesis of the blue pigment
indigoidine, which is easily detectable both visually and
spectroscopically.15 When the resulting putative undecylprodi-
giosin reporter plasmid pYQS042 (Table S1) was introduced
into S. lividans TK24, no indigoidine production was observed
in the recombinant strain, suggesting that the SLIV_09075-
encoded repressor blocks expression of bpsA.
Protein RedD encoded by the SLIV_09220 gene in the red
cluster of S. lividans was shown to be a positive activator of the
undecylprodigiosin gene cluster in S. coelicolor.16 Therefore,
overexpression of RedD was expected to trigger biosynthesis of
undecylprodigiosin in S. lividans as well, to which the
constructed biosensor would react. Consequently, genes
encoding RedD (SLIV_09220) and another putative regulator
of the LuxR family, RedZ (SLIV_09200)14 in the red cluster
were overexpressed in the recombinant S. lividans TK24
harboring reporter plasmid pYQS042. Overexpression of both
redD and redZ led to apparent activation of undecylprodigiosin
production (activation was more eﬃcient upon overexpression
of redD), while no production of indigoidine could be observed
in the engineered strains. These results implied that the TetR-
like repressor encoded by SLIV_09075 does not bind
undecylprodigiosin, and its gene may not belong to the red
cluster.
In the next attempt to construct undecylprodigiosin-speciﬁc
biosensor, we decided to combine the features of TetR-like
repressor and LuxR-type activator in one hybrid protein. The
N-terminal part of LuxR activator proteins are known to
contain autoinducer-binding domains that have aﬃnity to N-
acyl homoserine lactones (AHLs).17 Taking into account the
fact that no AHL synthase is encoded by the red cluster, and
recent reports on the LuxR “solos” that respond to diverse
small molecules instead of AHLs,18 we considered it possible
that an N-terminal domain in the RedZ response regulator may
sense undecylprodigiosin or its precursors. Therefore, we
decided to generate hybrid proteins that would combine the
Figure 1. (A) Organization of the undecylprodegiosin biosynthesis gene cluster and its right ﬂank in S. lividans TK24. Regulatory genes redD and
redZ are shown in dark green, while TetR-like repressor- and its putative cognate transporter-encoding genes are shown in blue and light blue,
respectively. (B) Scheme of hybrid repressor construction. HTH, helix-turn-helix DNA binding domain; REC, putative ligand binding receiver
domain.
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DNA binding domain of the TetR-like repressor encoded by
SLIV_09075 and a putative metabolite-sensing domain of
RedZ. The rationale behind this attempt to construct hybrid
repressors stems from the earlier reported success in creating a
hybrid transcription factor that combines the regulatory and
activation domains of cAMP-responsive element binding
protein with the DNA binding domain of the TetR repressor.19
Functional metabolite-sensing hybrid repressors have also been
reporter by Keasling group, which combined domains of
metabolic enzymes to the DNA-binding domain of TetR.20
Consequently, we constructed two versions of a hybrid
repressor that, providing our assumption noted above was
correct, could respond to the production of undecylprodigiosin.
These versions were made by linking a putative N-terminal
receiver domain of RedZ with the helix-turn-helix (HTH) DNA
binding domain of the SLIV_09075-encoded TetR-like
repressor. The domain boundaries of both proteins were
predicted using online ProDom software tool, corresponding
parts of the genes were ampliﬁed by PCR from the genomic
DNA of S. lividans TK64 and fused using Gibson ligation (see
Methods section for details).
The two versions of hybrid repressor were made with
diﬀerent interdomain linkers originating either from RedZ (for
HR1 version) or TetR-like (for HR2 version) regulators
(Figure 1B, Table S1: constructs pYQS065 and pYQS066,
respectively). The wild type copy of the SLIV_09075 gene was
replaced by either of the SLIV_09075-redZ hybrid genes in
S. lividans TK24 using double crossover recombination. The
reporter construct pYQS042 was then integrated into the
chromosomes of the strains carrying hybrid genes. Both
resulting recombinant strains showed production of indigoidine
without overexpression of redD, suggesting that the hybrid
proteins lost the repressor function characteristic of
SLIV_09075. Most likely, the HTH DNA-binding domain of
SLIV_09075 in hybrid proteins could no longer bind to the
operator upstream of the reporter gene, probably due to the
perturbations in their tertiary structures. Yet another possible
explanation could be that the hybrid proteins acquired an
activator function and, in the absence of the intact
SLIV_09075, can activate expression of the bpsA reporter
gene. In order to simplify visual detection of indigoidine
production, which could be masked by actinorhodin and
undcylprodigiosin, a recombinant strain S. lividans RedStrep1
was constructed, which lacks red and act clusters, but retains
SLIV_09075. To delete both clusters in S. lividans TK24, an
eﬃcient deletion system based on the positive selection of
double crossover events with bpsA reporter gene was used14
(see Methods for details). Two RedStrep1-based recombinant
strains were constructed, which harbored both the integrated
reporter pYQS042, and a low-copy number autonomously
replicating plasmid expressing HR1 or HR2 proteins under
control of the ermE*p promoter (Table S2). No indigoidine
production was observed by these recombinant strains, which
excluded the possibility that hybrid proteins had direct activator
function and could outcompete the SLIV_09075-encoded
repressor. In summary, hybrid proteins constructed here
proved to be nonfunctional, prompting further studies toward
robust design of the hybrid TetR-like repressors.
Construction of the Coelimycin-Speciﬁc Biosensor.
Our failure to construct undecylprodigiosin-speciﬁc biosensor
was mainly due to the fact that TetR-like repressor encoding
gene located at the border of the red cluster apparently had no
function in the biosynthesis of this antibiotic. To establish a
proof of concept, we next focused on the coelimycin gene
cluster (cpk) for biosensor development, since this compound
has never before been identiﬁed in S. lividans, while methods
for its detection were available from the earlier reports on the
closely related strain S. coelicolor M145.21 Coelimycin is a
polyketide alkaloid, the biosynthetic gene cluster for which in
S. coelicolor is silent, but can be activated upon deletion of the
scbR2 repressor gene.22 In S. coelicolor, scbR2 is located proximal
(but transcribed in opposite direction) to the gene scoT
encoding a type II thioesterase that proved to be important for
coelimycin biosynthesis in the latter organism.23 In S. lividans
TK24, the arrangement of genes is similar (Figure 2), and it
was safe to assume that the SLIV_06715-encoded repressor
would control the expression of the divergently transcribed
thioesterase II-encoding gene SLIV_06710. We PCR-ampliﬁed
putative promoter/operator region upstream of SLIV_06710,
and placed the bpsA reporter gene under its control in an
integrative vector pSET152.24 This reporter construct
pYQS040 was integrated into the chromosome of S. lividans
RedStrep1. The reporter strain RedStrep1 [pYQS040] showed
no indigoidine production in a range of conditions, indicating
that the SLIV_06715-encoding repressor acts in trans, and
blocks the transcription of the reporter gene.
Testing of the Coelimycin Biosensor Using Artiﬁcial
Activation of the cpk Gene Cluster. In order to obtain
proof-of-principle for our biosensor system, we decided to force
coelimycin production in the reporter strain RedStrep1
[pYQS040] using overexpression of a pathway-speciﬁc
regulator. The latter strategy was shown to be useful in
genome mining aimed at the discovery of novel compounds.25
However, this approach may lead to unexpected results, and
detection of the products of potentially activated clusters may
prove diﬃcult, especially in case of complex and unusual
Figure 2. Organization of the coelimycin biosynthetic gene cluster and its parts used for the biosensor construction. Genes encoding putative
positive activators are shown in orange, and a TetR-like repressor-encoding gene is shown in red. To construct a reporter, indigoidin synthetase gene
bpsA was cloned downstream of the putative promoter/operator region controlling expression of type II thioesterase ScoT.
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clusters.4 The cpk gene cluster in S. lividans encodes two
putative positive regulators of the SARP family, SLIV_06705
(CpkN) and SLIV_06745 (CpkO) (Figure 2). The cpkO gene
product was previously shown in S. coelicolor to positively
regulate the cpk gene cluster expression,26 while the function of
cpkN gene was unclear. These putative regulatory genes were
expressed under control of the PermE promoter from the
SCP2*-based replicative plasmids pYQS060 (cpkN) and
pYQS061 (cpkO) in strain RedStrep1 [pYQS040]. Indigoidine
production was observed in both RedStrep1 [pYQS040/
pYQS060] and RedStrep1 [pYQS040/pYQS061] recombinant
strains, which indicated activation of the cpk cluster. The
recombinant strain overexpressing SLIV_06705 also showed
more pronounced indigoidine production, suggesting that this
SARP regulator is a stronger activator for the cpk cluster. In
order to conﬁrm that positive regulator-induced reporter
expression was due to the relief of the SLIV_06715-encoded
repressor upon coelimycin binding, gene SLIV_06770 encod-
ing a scaﬀold-building PKS in the cpk cluster was inactivated by
insertion of a suicide vector pYQS070. The resulting
recombinant colonies of RedStrep1 [pYQS040/pYQS060/
pYQS070] were no longer producing indigoidine, thus
conﬁrming that the developed biosensor system indeed
responds to the production of coelimycin (Figure 3).
To obtain a ﬁnal proof of coelimycin production, we
compared metabolic proﬁles of the recombinant strains
S. lividans RedStrep1 [pYQS040] carrying just the biosensor,
and RedStrep1 [pYQS040/pYQS060] that in addition ex-
pressed the SARP activator RedD. The recombinant strains
were cultivated in several commonly used liquid media (TSB,
SG, NL19, phage medium and R5A) and extracted metabolites
were analyzed by LC-MS. When grown in R5A or SG media
strain RedStrep1 [pYQS040/pYQS060] was found to produce
both coelimycin P1 and blue pigment indigoidine. Coelimycin
P1 was by its absorption spectrum (characteristic peak at 360
nm), its exact mass (detected m/z 349.1213 [M + H]+,
calculated 349.1215 [M + H]+), and by its MS/MS
fragmentation pattern (Figure S2). Interestingly, trace amounts
of coelimycin P1 were also detected in the extract of S. lividans
RedStrep1 [pYQS040] strain when incubated in the R5A
media, but not in SG. In these conditions, the biosensor did not
react to the production of minute amounts of coelimycin P1,
probably due to its eﬃcient and rapid eﬄux from the cells. The
accumulation of coelimycin P1 was not detected when strains
were grown either in TSB, phage media or NL19 media. Under
these conditions production of indigoidine by S. lividans
RedStrep1 [pYQS040] was also not observed.
■ CONCLUSIONS
The genome mining approach has shown a considerable
potential in discovery of novel microbial secondary metabo-
lites.25 Still, the metabolomes of proliﬁc secondary metabolite
producers are often very complex, precluding identiﬁcation of
cluster-speciﬁed compounds. Biosensors coupled to the actual
production of target compounds would be very helpful in
streamlining the discovery process, eliminating nonproducers
from the screening. In a recent report Guo et al. constructed a
reporter system linking the expression of genes for gaudimycin
biosynthesis to a reporter system in Streptomyces.10 However,
authors have reported high percentage of false-positives which,
while expressing a reporter, did not actually produced a target
metabolite. Also, in some cases expression of biosynthetic genes
does not correlate with the compound production, probably
due to some obstacles aﬀecting translation or post-translational
modiﬁcation of biosynthetic enzymes.27 In our study, TetR-like
repressors and bpsA reporter gene were used to construct
biosensors that would directly detect production of secondary
metabolites. Apparently, success in construction of a functional
biosensor depends on whether identiﬁed TetR-like repressor
gene actually belongs to the biosynthetic cluster, and can bind
the cluster-speciﬁed compound. In the case of coelimycin, we
have obtained a proof-of-principle, demonstrating the utility of
such a biosensor, although we cannot exclude the possibility
that biosensor may also react to some intermediates in the
biosynthetic pathway. Publicly available genome sequences,
especially those for actinomycete bacteria, provide access to
hundreds of biosynthetic gene clusters encoding TetR-like
repressors, for which biosynthetic products remain unknown.
Moreover, there is a plethora of other regulator families, in
which the binding of a metabolite leads to the release of the
repressor from its operator (e.g., LacI family regulators),28
which are associated with the secondary metabolite biosynthesis
gene clusters. Using the metabolite-sensing repressor-based
biosensor principle, it will become possible to assess functional
expression of these clusters either after random mutagenesis,
under various cultivation conditions, or through genetic
manipulation. On the basis of the promising results reported
by Chou and Keasling on metabolite-sensing hybrid repress-
ors,20 it seems plausible that a more versatile and modular
biosensor system can be developed. Indeed, fusion of a
metabolite sensor represented by a domain of a biosynthetic
enzyme predicted to bind the ﬁnal product (or a critical
intermediate) to a standardized part representing HTH domain
that binds speciﬁc operator controlling a reporter can be done
quickly and eﬃciently. Replacement of the receiver domain in a
standardized hybrid repressor with a domain of a biosynthetic
Figure 3. UV chromatogram (at 360 nm) of metabolites produced by S. lividans RedStrep1 [pYQS040] and RedStrep1 [pYQS040/pYQS060] when
grown in SG medium. The peak presumably corresponding to coelimycin P1 is indicated by arrow. More detailed analysis, including MS/MS-based
identiﬁcation of coelimycin P1, was done as reﬂected in Figure S2 (Supporting Information).
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enzyme predicted to bind the ﬁnal product (or a critical
intermediate) would only require minimal engineering in order
to tune the biosensor to a particular gene cluster.
■ METHODS
Bacterial Strains, Plasmids, and Growth Conditions.
Description of plasmids and bacterial strains used or generated
during this study is provided in Tables S1 and S2 (Supporting
Information), respectively. S. lividans TK24 was used as the
wild-type strain. RedStrep 1 (Δact Δred) was constructed as
shown in Figure S1 (Supporting Information) with the
deletions of nt 2961047−2982325 (act cluster) and nt
2081767−2113444 (red cluster) in S. lividans TK24 genome.11
The deletions were validated by genome sequencing. RedStrep
1 was used in this study to avoid the potential color disturbance
due to production of pigmented antibiotics speciﬁed by the act
and red clusters in S. lividans TK24.
Escherichia coli strains were grown in Luria−Bertani (LB)
broth or on LB agar. XL1-blue was used for general cloning.
ET12567 (pUZ8002) was used for intergeneric transfer of
plasmids to Streptomyces with the standard procedure of
conjugation.28 Streptomyces spore preparation was obtained by
growing on soy ﬂour mannitol medium (SFM) at 30 °C for 4−
7 days. Antibiotics were supplemented to growth medium at
the following concentrations when applicable: ampicillin 100
μg/mL; apramycin 50 or 100 μg/mL; chloramphenicol 20 μg/
mL; hygromycin 100 μg/mL; kanamycin 25 μg/mL; nalidixic
acid 30 μg/mL, and thiostrepton 30 μg/mL.
RNA Isolation, Library Preparation and cDNA Se-
quencing. S. lividans TK24 cells were grown in MM media
supplemented with and without casamino acids. Samples were
taken at early and late logarithmic phases, as well as at
stationary phase. Harvesting and RNA isolation were
performed as previously described.29 RNA quality and quantity
was checked by an Agilent 2100 Bioanalyzer (Agilent
Technologies, Böblingen, Germany) and Trinean Xpose system
(Gentbrugge, Belgium) prior and after rRNA depletion by
using the Ribo-Zero rRNA Removal Kit (Bacteria) (Illumina,
San Diego, CA, USA). The TruSeq Stranded mRNA Library
Prep Kit (Illumina, San Diego, CA, USA) was used to prepare
the cDNA libraries, which were then sequenced in paired-end
mode on an Illumina HiSeq 1500 system (San Diego, CA,
USA) with 2 × 27 nt read length.
Read Mapping, Data Visualization and Analysis of
Gene Expression. Reads were trimmed to a minimum of 20
bases in length using Trimmomatic V0.33.30 Mapping of the
trimmed reads to the S. lividans TK24 genome sequence10 was
performed with Bowtie 2 using standard settings.31 Read-
Xplorer 2.2.032 was used for visualization of short read
alignments and calculation of transcripts per million reads
(TPM) of every scaﬀold-building gene of a secondary
metabolite gene cluster.33
DNA Manipulation. General DNA cloning, DNA digestion
with restriction enzymes and plasmid transformation into
Escherichia coli were performed as described in Sambrook et
al.34 PCR fragments were ampliﬁed using MasterAmp Extra-
Long DNA Polymerase Mix and buﬀers (Epicenter, USA). The
primers used in this study were described in Table S1. Primers
for PCR were designed using Clone Manager Professional
Version 9 (Sci-Ed Software, USA). To construct new vectors,
PCR and vector fragments were assembled either by T4 DNA
ligase or Gibson ligation.35 Recombinant constructs were
veriﬁed by DNA sequencing by GATC Biotech. Streptomyces
genomic DNA was isolated using Wizard Genomic DNA
Puriﬁcation Kit (Promega, USA).
Construction of S. lividans RedStrep1 Strain. Two
DNA fragments ﬂanking the act cluster were PCR ampliﬁed
from the genomic DNA of S. lividans TK24. A 2.7-kb DNA
fragment ﬂanking the 3′ end of SLIV_12925 (Figure S1A) was
ampliﬁed with the primers 12925Dir and 12925Rev (Table S4).
This DNA fragment was digested using MfeI and ClaI and
cloned into pAMR415 resulting in pAct1. A 3-kb DNA fragment
ﬂanking the 3′ end of SLIV_13030 (Figure S1) was ampliﬁed
with the primers 13030Dir and 130130Rev (Table S4). This
DNA fragment was digested with Af lII and HindIII and cloned
in pAcl1, resulting in pAct2. The plasmid was introduced into
S. lividans TK24 by conjugation, and after several rounds of
propagation bpsA-negative apramycin-resistant and kanamycin-
sensitive colonies (indicating a double crossover event) were
selected. The replacement of the act cluster by apramycin-
resistance cassette was conﬁrmed by Southern-blot hybrid-
ization (data not shown). One clone (S. lividans Δact) was used
for further deletion of the red cluster. Likewise, two DNA
fragments ﬂanking the red cluster were PCR ampliﬁed from the
genomic DNA of S. lividans TK24. A 2.9-kb DNA fragment
ﬂanking the 5′ end of SLIV_09220 (Figure S1A) was ampliﬁed
with the primers 9220Dir and 9220Rev (Table S4), digested
with MfeI and BamHI and cloned into pSPR11, resulting in
pRed1. The cloning vector pSPR11 was prepared by replacing
the apramycin-resistance gene aac(3)IV in pAMR4 with
synthetic spectinomycin-resistance gene aadA from the plasmid
paat-saadA-oriT, containing oriT and P-GG and G-CC
recombination sites for phiC31 recombinase.36 A 3-kb DNA
fragment ﬂanking the 3′ end of SLIV_13030 (Figure S1A) was
ampliﬁed with the primers 9115Dir and 9115Rev (Table S4),
digested with Af lII and HindIII and cloned in pRed1 resulting
in pRed2. The plasmid was introduced into S. lividans Δact by
conjugation with selection for spectinomycin resistance. After
several rounds of sporulation, four bpsA-negative spectinomy-
cin-resistant and kanamycin-sensitive colonies were selected,
and the correct double crossover event in the red cluster was
conﬁrmed by Southern-blot hybridization (data not shown).
One S. lividans Δact Δred clone was used for further studies.
Both antibiotic resistance markers, the apramycin resistance
marker with FRT sites for recombination,37 and the
spectinomycin resistance marker with B-CC and P-GG sites
for recombination, were removed from the S. lividans Δact Δred
strain by successive transformation of the plasmid
pUWLHFLP, containing Flp recombinase38 and pKHint31,
containing phiC31 recombinase.39 The removal of both
markers was conﬁrmed by antibiotic sensitivity tests after ﬁve
rounds of nonselective sporulation. Elimination of the plasmids
carrying recombinase genes was achieved after two rounds of
nonselective propagation. The representative clone from the
resulting strain, S. lividans Δact-FRT Δred-BCC, later termed
RedStrep1, was veriﬁed by Southern blot hybridization (Figure
S1B) using probes for both clusters.
Construction of Genes Encoding Hybrid Proteins. The
products of genes SLIV_09075 and SLIV_09200 (redZ) were
analyzed using ProDom online tool (http://prodom.prabi.fr/
prodom/current/html/home.php) in order to predict protein
domain boundaries. Accordingly, hybrid proteins of the
following compositions were designed: (i) HR1 would contain
C-terminal HTH domain of the SLIV_09075 gene product
with a C-terminal linker (aa 1−104) fused to the putative
receiver domain of RedZ (aa 1−115); (HR2 would contain C-
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terminal HTH domain of the SLIV_09075 gene product (aa
1−78) fused to the putative receiver domain of RedZ followed
by its C-terminal linker (aa 1−145). Parts of the corresponding
genes encoding respective domains were ampliﬁed by PCR
from the genomic DNA of S. lividans TK24 (primers given in
Table S3, Supporting Information) and joined using Gibson
ligation.36 The resulting fragments were cloned into the
pKC1218HygR vector under control of ermE*p promoter,
and veriﬁed by DNA sequencing.
Analysis of Secondary Metabolites Produced by the
Recombinant Strains. Strains were grown for 3 days at 28 °C
in 10 mL of TSB medium. Subsequently, 4 mL of the
preculture was used to inoculate 50 mL of production media in
500 mL ﬂasks: NL19, SG, R5A or phage medium. The main
cultures were cultivated at 28 °C on a rotary shaker at 180 rpm
for 5 days. Metabolites were extracted with acetone:methanol
1:1 from biomass and with ethyl acetate from cultural liquid,
solvents were evaporated and extracts were dissolved in 300 μL
of methanol.
Samples were separated on a Dionex Ultimate 3000 RSLC
system (Thermoscientiﬁc) using a BEH C18, 100 × 2.1 mm,
1.7 μm dp column (Waters) with linear gradient of solvent B
(acetonitrile with 0.1% of formic acid) against solvent A (water
with 0.1% of formic acid) at a ﬂow rate of 600 μL/min and 45
°C. The gradient started by a 0.5 min isocratic step at 5% B
then increased to 95% B over 9 min to end up with a 2 min
isocratic step at 95% B before re-equilibration under the initial
conditions. UV spectra were acquired by a DAD in the range of
200 to 600 nm. The mass-spec data was collected on an
amaZON speed resolution mass spectrometer (Bruker
Daltonics, Germany) using ESI source. Mass spectra were
acquired in centroid mode ranging from 100 to 2000 m/z at a 2
Hz scan rate. Data was collected and analyzed with the Bruker
Compass Data Analysis software, version 4.2 (Bruker, Billerica,
USA).
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Figure S1. (A) Physical maps of chromosomal DNA containing the wild-type S. lividans TK24 act cluster for actinorhodin and red 
cluster for undecylprodigiosin, and the deleted alleles of the S. lividans, ∆act ∆red and S. lividans, ∆act-FRT ∆red-BCC strains. Thick 
arrows denote the direction and size of genes. Red arrows represent the act and red genes. Gene labelling is based on the genomic 
sequence of S. lividans TK24 (GenBank Acc. No. CP009124)
1
. The black bars below the maps represent the probes used for Southern 
hybridization analysis. Relevant restriction sites are indicated.  
(B) Southern hybridization analysis of chromosomal DNA from the indicated strains verifying the correct integration and removing of 
the antibiotic cassette. 1 µg of gDNA from the corresponding strain was digested with the restriction enzymes indicated, separated by 
electrophoresis in 0.8% (w/v) agarose gel and transferred on Hybond N (Amersham) as described in Ausubel et al.
2
 Hybridization 
followed the standard DIG protocol (Roche, Mannheim, Germany) using the DIG-labelled probes 1 and 2 for verification of correct 
red and act deletion, respectively. Lambda DNA-BstEII digest was used as the size standard.  
 
2 
 
 
3 
 
Figure S2. Absorptions, accurate mass and MS/MS profile of metabolite detected in the extract of S. lividans RedStrep1 [pYQS040/pYQS060] 
strain. Detected compound has m/z of 349.1213 [M+H]
+
 (calculated for coelimycin P1 (C17H20N2)4S) 349.1215 [M+H]
+
) and three UV 
maximums at 225, 275 and 360 nm with peak at 360 nm being characteristic for coelimycin P1
3
. The MS/MS fragmentation pattern is the same as 
described for coelimycin P1
4
. 
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Table S1. Plasmids used in this study. 
Plasmid name Description Construction details Source 
pSET152 
Integrative E.coli-Streptomyces vector, ɸC31 
attachment site, Am
R
  
5 
pUWL-oriT E.coli- Streptomyces shuttle vector, Amp
R
, Tsr
R
 
 
6 
pBpsA 
Integrative E.coli-Streptomyces vector, ɸBT1 
attachment site, Am
R
  
7 
pKC1218 hyg_mut E.coli- Streptomyces shuttle vector, Hyg
R
 
Am
R
 marker replaced with HygR, one EcoRI site 
eliminated 
This study 
pTSA101 Intermediate/construction vector 
pKC1218hyg_mut backbone with bpsA gene 
under control of P21 promoter and CymR operator 
This study 
pYQS031 Intermediate/construction vector  
Ligation of PCR PermE-dnaQ2 with pKC1218 
hyg_mut (HindIII/EcoRI) 
This study 
pYQS040 SLIV_06710 PO - BpsA in pSET152 backbone 
Ligation: pSET152 (BamHI/EcoRI) + PCR 
SLIV_06710 PO (BamHI/SpeI) + pTSA101 
(SpeI/EcoRI, bpsA) 
This study 
pYQS041 SLIV_06815 PO - BpsA in pSET152 backbone 
Ligation: pSET152 (BamHI/EcoRI) + PCR 
SLIV_06815 PO (BamHI/SpeI) + pTSA101 
(SpeI/EcoRI, bpsA) 
This study 
pYQS042 SLIV_09080 PO - BpsA in pSET152 backbone 
Ligation: pSET152 (BamHI/EcoRI) + PCR 
SLIV_09080 PO (BamHI/SpeI) + pTSA101 
(SpeI/EcoRI, bpsA) 
This study 
pYQS046 
Backbone was used for double crossover to 
knockout target gene 
Ligation: PCR dnaQ1 flanking A (AgeI/BamHI) + 
PCR dnaQ1 flanking B (BamHI/HindIII) + 
pTSA101 (HindIII/AgeI) 
This study 
pYQS056 SLIV_31825 PO - bpsA in pSET152 backbone 
Ligation: pSET152 (BamHI/EcoRI) + PCR 
SLIV_31825 PO (BamHI/SpeI) + pTSA101 
(SpeI/EcoRI, bpsA) 
This study 
pYQS060 
Cluster specific positive regulator: PermE-
SLIV_06705 in pKC1218, Hyg
R
 
Ligation of pYQS031 with PCR SLIV_06705 
(EcoRI/XbaI) 
This study 
5 
 
pYQS061 
Cluster specific positive regulator: PermE-
SLIV_06745 in pKC1218, Hyg
R
 
Ligation of pYQS031 with PCR SLIV_06745 
(EcoRI/XbaI) 
This study 
pYQS062 
Cluster specific positive regulator: PermE-
SLIV_09200 in pKC1218, Hyg
R
 
Ligation of pYQS031 (EcoRI/XbaI) with PCR 
SLIV_09200 (MfeI/XbaI)  
This study 
pYQS063 
Cluster specific positive regulator: PermE-
SLIV_09220 redD in pKC1218, Hyg
R
 
Ligation of pYQS031 with PCR SLIV_09220 
RedD (EcoRI/XbaI) 
This study 
pYQS064 
Cluster specific positive regulator: PermE-
SLIV_31695 in pKC1218, Hyg
R
 
Ligation of pYQS031 with PCR SLIV_31695 
(EcoRI/XbaI) 
This study 
pYQS065 
Used to construct hybrid repressor HR1: REC 
SLIV_09200 - linker SLIV_09200 - HTH 
SLIV_09075 
Gibson assembly: Reverse PCR pYQS046 + PCR 
SLIV_09075 flanking A1 + PCR HR1-frag4 + 
PCR HR1-frag1 + PCR SLIV_09075 flanking B1 
This study 
pYQS066 
Used to construct hybrid repressor HR2: HTH 
SLIV_09075 - linker SLIV_09075 - REC 
SLIV_09200 
Gibson assembly: Reverse PCR pYQS046 + PCR 
SLIV_09075 flanking A2 HR2-frag2 + PCR HR2-
frag3 + PCR SLIV_09075 flanking B2 
This study 
pYQS070 
single crossover plasmid for insertion knockout of 
SLIV_06770, Amp
R
 and Tsr
R
 
Ligation PCR SLIV_06770 middle with pUWL 
(NdeI/BamHI) 
This study 
pYQS079 PermE-HR1, pKC1218 backbone, Hyg
R
 
Ligation of PCR Hybrid Repressor 1 (XbaI/MfeI) 
with pYQS060 (XbaI/EcoRI) 
This study 
pYQS080 PermE-HR2, pKC1218 backbone, Hyg
R
 
Ligation PCR Hybrid Repressor 2 (XbaI/MfeI) 
with pYQS060 (XbaI/EcoRI) 
This study 
PO: promoter-operator. HR: hybrid repressor. PR: putative positive regulator 
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Table S2. Escherichia coli and Streptomyces lividans strains used in this study. 
Strain name Description Plasmid(s) used for conjugation Source/reference 
Escherichia coli XL1-blue 
General cloning host: recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F´ proAB lacI
q
 
Z∆M15 Tn10 (Tet
R
)] 
 Stratagene 
Escherichia coli ET125671 
(pUZ8002) 
Mediates conjugative DNA transfer from RP4 
oriT with helper plasmid pUZ8002 (Kan
R
, Cm
R
). 
Methylation deficient (dam
−
, dcm
−
, hsdM
−
) 
 8 
S. lividans TK24 S. lividans wild-type strain 
 
2 
RedStrep1 TK24 ∆act ∆red 
Deleted clusters for actinorhodine 
and undecylprodigiosin 
This study 
TK24 + Reporter 1 TK24 attBC31 :: SLIV_06710PO-bpsA pYQS040, attBC31 integrative This study 
TK24 + Reporter 2 TK24 attBC31 :: SLIV_06815PO-bpsA pYQS041, attBC31 integrative This study 
TK24 + Reporter 3 TK24 attBC31 :: SLIV_09080PO-bpsA pYQS042, attBC31 integrative This study 
RedStrep 1 + Reporter 1 RedStrep 1 attBC31 :: SLIV_06710PO-bpsA pYQS040, attBC31 integrative This study 
RedStrep 1 + Reporter 2 RedStrep 1 attBC31 :: SLIV_06815PO-bpsA pYQS041, attBC31 integrative This study 
RedStrep 1 + Reporter 3 RedStrep 1 attBC31 :: SLIV_09080PO-bpsA pYQS042, attBC31 integrative This study 
RedStrep 1 + Reporter 4 RedStrep 1 attBC31 :: SLIV_31825PO-bpsA  pYQS056, attBC31 integrative This study 
RedStrep 1 + Reporter 1+ PR1  
RedStrep 1 SLIV_06710PO-BpsA + ermEp-
SLIV_06705 
pYQS060, replicative This study 
RedStrep 1 + Reporter 1+ PR2 
RedStrep 1 SLIV_06710PO-BpsA + ermEp-
SLIV_06745 
pYQS061, replicative This study 
RedStrep 1 + Reporter 4+ PR5 
 RedStrep 1 SLIV_31825PO-BpsA + ermEp-
SLIV_31695 
pYQS064, replicative This study 
TK24 + Reporter 3 + PR3  
RedStrep 1 SLIV_09080PO-BpsA + ermEp-
SLIV_09200 
pYQS062, replicative This study 
7 
 
TK24 + Reporter 3 + PR4  
RedStrep 1 SLIV_09080PO-BpsA + ermEp-
SLIV_09220 RedD 
pYQS063, replicative This study 
TK24 ∆SLIV_09075 :: HR1 TK24 ∆SLIV_09075 :: Hybrid repressor_1 
pYQS065, for deletion knockout by 
double crossover 
This study 
TK24 ∆SLIV_09075 :: HR2 TK24 ∆SLIV_09075 :: Hybrid repressor_2 
pYQS066, for deletion knockout by 
double crossover 
This study 
TK24 ∆SLIV_09075 :: HR1 + 
Reporter 3 
TK24 ∆SLIV_09075 :: Hybrid repressor_1 + 
SLIV_09080PO-BpsA 
pYQS042, attBC31 integrative This study 
TK24 ∆SLIV_09075 :: HR2 + 
Reporter 3 
TK24 ∆SLIV_09075 :: Hybrid repressor_1 + 
SLIV_09080PO-BpsA 
pYQS042, attBC31 integrative This study 
RedStrep 1 + Reporter 1 + PR1 
∆SLIV_06770 
SLIV_06770 was knocked out in “RedStrep 1 + 
Reporter 1 + PR1” 
pYQS070, for insertion knockout 
by single crossover  
This study 
RedStrep 1 + Reporter 3+ HR1 RedStrep 1 SLIV_09080PO-BpsA + ermEp-HR1 pYQS079, replicative This study 
RedStrep 1 + Reporter 3 + HR2 RedStrep 1 SLIV_09080PO-BpsA + ermEp-HR2 pYQS080, replicative This study 
PO: promoter-operator. HR: hybrid repressor. PR: putative Positive Regulator 
HR1: REC SLIV_09200 - linker SLIV_09200 - HTH SLIV_09075 
HR2: HTH SLIV_09075 - linker SLIV_09075 - REC SLIV_09200 
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Table S3. Primers for plasmid construction used in this study. 
Primer name 
5’-3’ sequence  
(Italic: endonuclease restriction enzyme site) 
PCR product (size bps, template) 
Enzyme/paired 
primer 
YQ30_SE TAATGGATCCGTCGTGCTCCGTGGTCGC 
PCR SLIV_06710 PO (258, TK24)  
BamHI 
YQ30_AS ACACCACTAGTCGCCTTTTCCCCTTACCGTTC SpeI 
YQ31_SE TATAGGATCCGCCTGCCTCCTTGTTCAT 
PCR SLIV_06815 PO (137, TK24) 
BamHI 
YQ31_AS CAGTACTAGTGGGTCCCCCCCAGGAATC SpeI 
YQ32_SE AGATGGATCCTTTCTCCGCTTCACCTCG 
PCR SLIV_09080 PO (164, TK24) 
BamHI 
YQ32_AS AATTACTAGTCGGGCAGCCTTCGGCAGGA SpeI 
YQ42_SE CAATGGATCCGACGCCTCCTTCCAGTG 
PCR SLIV_31825 PO (120, TK24) 
BamHI 
YQ42_AS ACACCACTAGTGAACCCCCACCTCCTTAAG SpeI 
YQ47_SE ATCATCTAGACATCCGCGGCACGGCAAAC 
PCR SLIV_06705 (927, TK24) 
XbaI 
YQ47_AS GTACTGAATTCCGAGATCGGGCGCGTCAC EcoRI 
YQ48_SE CGCATCTAGAAGTCGTGGCCAGGAGAATAC 
PCR SLIV_06745 (1743, TK24)  
XbaI 
YQ48_AS ATACTGAATTCGACGGCGGAGACGGTGGG EcoRI 
YQ49_SE ATCATCTAGAGCCCGCACGCCACGTACGGT 
PCR SLIV_09200 (739, TK24)  
XbaI 
YQ49_AS ATACTCAATTGGCCGGACCGGGGCATTCAGC MfeI 
YQ50_SE ATCATCTAGACCGATCGTTCGGTGGATGAC PCR SLIV_09220 redD (1097, 
TK24) 
XbaI 
YQ50_AS ATACTGAATTCCCGGGTCGTCAGGCGCTGAG EcoRI 
YQ51_SE GGCATCTAGAATGCGGGCACTGTATCCAGG 
PCR SLIV_31695 (863, TK24)  
XbaI 
YQ51_AS ATACTGAATTCCTCACGGCCTCCGCATGAGC EcoRI 
YQ54_SE GATAAGCTTGGGCTGCAGGTC Reverse PCR pYQS046 (7884, 
pYQS046) 
 
YQ54_AS ACCGAGTCCCACCGGTCGAAAC 
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YQ55_SE TTCGACCGGTGGGACTCGGTGCTGGAGCGCAGGTTGTC PCR SLIV_09075 flanking A1 
(1530, TK24)   
 
YQ55_AS GGGTCGTCATTTTCTCCGCTTCACCTCGG  
YQ56_SE AGCGGAGAAAATGACGACCCGTGTCCTG 
PCR HR1-frag4 (455, TK24)   
 
YQ56_AS CAATCTTGGGTTCGGGGCGGAGGTTCTTC  
YQ57_SE CCGCCCCGAACCCAAGATTGAAGCCGGC 
PCR HR1-frag1 (218, TK24)   
 
YQ57_AS GGGTGCGTCAGACGACGAGTTCGAGCAGG  
YQ58_SE ACTCGTCGTCTGACGCACCCCGTCCAGG PCR SLIV_09075 flanking B1 
(1530, TK24)  
 
YQ58_AS ACCTGCAGCCCAAGCTTATCCGGCGGTCCTCTCGTCGG  
YQ59_AS CACGGGTCGTGCGAGCTGCCTGTTCGAG 
PCR SLIV_09075 flanking A2 
HR2-frag2 (1845, TK24) 
YQ55_SE 
YQ60_SE GGCAGCTCGCACGACCCGTGTCCTGGTG 
PCR HR2-frag3 (359, TK24)  
YQ60_AS GGGTGCGTCAGATGGTTCTGATGACGTGCAC 
 
YQ61_SE CAGAACCATCTGACGCACCCCGTCCAGG 
PCR SLIV_09075 flanking B2 
(1530, TK24) 
YQ58_AS 
YQ68_SE ATCACATATGAACTTCCCGCCAGCCTGAAC PCR SLIV_06770 middle (2142, 
TK24) 
NdeI 
YQ68_AS ATAAGGATCCAAGAAGTCGGCGTCGAACTC BamHI 
YQ75_SE ACGGTGTCTCGTACACCTTC Amplify SLIV_06770 to identify 
insertion knockout (9894) 
 
YQ75_AS TTCCGTAGGTGGCCATGAGG 
YQ80_SE GCCATCTAGAGGTGAAGCGGAGAAAATGACGA PCR Hybrid Repressor 1 (678, 
pYQS065) 
XbaI 
YQ80_AS CTACTCAATTGGGTGCGTCAGACGACGAGTT MfeI 
YQ81_SE GCCATCTAGAAGGTGAAGCGGAGAAAATGC PCR Hybrid Repressor 2 (696, 
pYQS066) 
XbaI 
YQ81_AS CCGCTCAATTGCGTCAGATGGTTCTGATGAC MfeI 
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Table S4. Primers used in construction of S. lividans RedStrep1. 
 
Oligonucleotide                    Sequence (5′ − 3′)                    
12925Dir    CCCCCAATTGCGCTGAGCAAGCAGATCCGGGCCC  
129215Rev CCCCATCGATGGAAGGCCGTCAGCGGCCCGTGGC   
13030Dir CCCCAAGCTTCGAAGACCGCCAGGGACGTCAGCC 
13013Rev CCCCCTTAAGTGACGCGCACCCTCGCCTTCGCGC 
9220Dir CCCCCAATTGCCGGTACGCTTCAGATATGAGTGC   
9220Rev  CCCCGGATCCACCGTCAATGTGTTGAGGCCG 
9115Dir  CCCCCTTAAGCGTGTACTGACCCCGCCCGTCACG  
9115Rev  CCCCAAGCTTCGATCTCCTCGGCGACCCGGTCG  
 
References 
(1)   Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.O., Seidman, J.S., Smith, J.A., and Struhl, K. (1995) Current Protocols in 
Molecular Biology. Wiley, New York. 
(2)   Ruckert, C., Albersmeier, A., Busche, T., Jaenicke, S., Winkler, A., Friethjonsson, O. H., Hreggviethsson, G. O., Lambert, C., 
Badcock, D., Bernaerts, K., Anne, J., Economou, A., and Kalinowski, J. (2015) Complete genome sequence of Streptomyces 
lividans TK24, J Biotechnol 199, 21-22. 
(3)   Whittle, M., Willett, P., Klaffke, W. and van Noort, P. (2003) Evaluation of similarity measures for searching the Dictionary 
of Natural Products database. J.  Chem. Inform. Comp. Sci. 43, 449-457. 
11 
 
(4)   Gomez-Escribano, J.P., Song, L., Fox, D.J., Yeo, V., Bibb, M.J., and Challis, G.L. (2012) Structure and biosynthesis of the 
unusual polyketide alkaloid coelimycin P1, a metabolic product of the cpk gene cluster of Streptomyces coelicolor M145. 
Chem. Sci. 3, 2716–2720. 
(5)   Bierman, M., Logan, R., O'Brien, K., Seno, E. T., Rao, R. N., and Schoner, B. E. (1992) Plasmid cloning vectors for the 
conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene 116, 43-49. 
(6)   Luzhetskyy, A., Zhu, L., Gibson, M., Fedoryshyn, M., Durr, C., Hofmann, C., Hoffmeister, D., Ostash, B., Mattingly, C., 
Adams, V., Fedorenko, V., Rohr, J., and Bechthold, A. (2005) Generation of novel landomycins M and O through targeted 
gene disruption, Chembiochem 6, 675-678. 
(7)   Knirschova, R., Novakova, R., Mingyar, E., Bekeova, C., Homerova, D., and Kormanec, J. (2015) Utilization of a reporter 
system based on the blue pigment indigoidine biosynthetic gene bpsA for detection of promoter activity and deletion of genes 
in Streptomyces. J. Microbiol. Methods 113, 1-3. 
(8)   Flett F., Mersinias, V., and Smith, C.P. (1997) High efficiency intergeneric conjugal transfer of plasmid DNA from 
Escherichia coli to methyl DNA-restricting streptomycetes. FEMS Microbiol. Lett. 155, 223-229. 
 
 
Discussion 
 
 
130 
 
5. Discussion 
New pharmaceuticals for the treatment of infectious diseases and especially those caused by 
multi-resistant pathogens are of urgent need. Even carbapenems, long considered as 
invulnerable, are of risk to loose effectiveness due to the spread of new types of β-lactamases 
which makes some of the Gram-negative bacteria untreatable.1 Microorganisms such as 
actinomycetes are a rich source of secondary metabolites whereof many possess antibacterial, 
antiviral, anticancer or immunosuppressive properties. The decades of exploitation of these 
bacteria species lead to the discovery of many pharmaceutical and medicinally important drugs. 
NPs remain one of the major sources of biologically active compounds with potential to combat 
antimicrobials resistance. However, to find a long-term solution for the issue of fast developing 
resistance, novel NP scaffolds introducing an unusual mode of action would be needed. The 
discovery of such compound classes became unfortunately difficult. The overexploitation of 
soil actinomycetes leads meanwhile to a frequent re-isolation of already known NPs. Therefore, 
the exploration of unusual sources of new bacteria is necessary in order to increase the chances 
to find novel secondary metabolites with unique chemical scaffolds and thus enhanced 
biological activities.  
In the attempt to discover novel compounds, we have examined several actinobacteria strains 
obtained from different sources. The first screening covered 15 strains from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen) and 9 strains isolated from sediment 
samples collected at Trondheim Fjord.2,3 Genomes of these actinobacteria were sequenced and 
based on phylogenetic analysis 10 of them belong to the genus Streptomyces and 14 are 
representatives of other minor genera of actinomycetes (Dactylsporangium, Nocardiopsis, 
Lechevaleria, Actinopolyspora, Actinomadura, Micromonospora, Kribella, Actinoalluteichus, 
Verrucosisspora and Glycomyces). Dereplication of extracts from these strains has revealed 
that several of them produce known metabolites e.g. nonactins, neocarzilin, matlystatin, 
flavofungin, lynamicins, napyradiomycin, rapamycin, azalomycin, rosamicin as well as 
putatively new NPs. One strain, Streptomyces sp. MP131-18 was considered to be the most 
promising based on the metabolic profiling and genome mining. The potent anticancer activity 
of bisindole compounds lynamicins found in the extracts of Streptomyces sp. MP131-18 
prompted us to investigate the strain in more detail. In a second activity-guided screening 
program, 36 strains obtained from macroinvertebrates collected from Lake Baikal4 were tested 
against Gram-positive (Bacillus subtilis) and Gram-negative (Pseudomonas putida and 
Escherichia Coli) bacteria. Due to the strong inhibition of B. subtilis by Streptomyces sp. 
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IB2014/011-12, we decided that this strain would be a good candidate for discovery of new 
NPs. The thorough examination of the two strains MP131-18 and IB 2014/011-12 lead to the 
discovery of new derivatives of spiroindimicins, lagunapyrones and alpiniamides. 
Spiroindimicins, belonging to the well-examined compound class indoles, were previously 
identified in Streptomyces sp. SCSIO 03032 isolated from the Bay of Bengal in Indian Ocean.5 
Similarly, alpiniamide A, an amino acid bearing linear polyketide has been discovered before 
in the endophytic Streptomycetes sp. YIM66017.6 Although, both streptomycetes strains 
MP131-18 and IB 2014/011-12 were indeed new, the isolated metabolites were previously 
identified from the extracts of very distinct strains sampled from distant locations. Apparently, 
even the shift from soil actinomycetes to their aquatic counterparts does not prevent the frequent 
re-discovery of known NP scaffolds. One of the most possible reasons for the re-discovery of 
the same secondary metabolites from different actinobacteria species might be an active 
exchange of genomic material among them. As such, we found alpiniamide gene cluster in 8 
other Strepomyces sp. isolated from different regions e.g. Streptomyces sp.  CFMR 7 (Penang, 
Malaysia)7, S. cavourensis TJ430 (Yunnan province, China)8, Streptomyces sp. DUT11 (marine 
sediment, Xinghai Bay, China).9 At the same time, four strains Streptomyces sp. Tü6075, 
Streptomyces globisporus TFH56, Kitasatospora albolonga YIM101047 and Streptomyces sp. 
ZFG47 are missing the alp cluster at the same highly conserved genomic locus (Suppl. Fig. 
S14, chapter 3). This finding is another support of the hypothesis that secondary metabolism 
genes are widespread among actinobacteria due to lateral gene transfer. Hence, in order to 
disclose the hidden potential of not yet discovered metabolites a deeper look into the 
microbiome is required. Not only exploitation of unusual niches but the application of new 
biotechnological procedures is inevitable. The use of metagenomics, an approach mediated by 
the direct recovery of genomic DNA from the environment, is thus a solution to access the 
diversity of secondary metabolites derived from yet uncultivated strains. Prominent examples 
of the success of metagenomic approaches are the aforementioned teixobactin and malacidins 
which exhibit both considerable biological activities. 
In order to avoid the frequent rediscovery, dereplication became an important step during NP 
discovery. The well advanced analytical techniques and the growing databases for data 
alignment ensures in many cases the preceding discard of known compounds. However, not 
always an unambiguous identification of known metabolites can be achieved. In the extract of 
IB2014/11-12, several PTMs have been identified by alignment of exact mass and UV 
absorption with DNP entries. Unfortunately, closely related derivatives were not distinguish-
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able solely by these parameters. For instance, the compound with m/z 511.28207 [M+H]+ 
coincides with alteramide A but as well with the its isomers maltophylin and xanthobaccin A. 
MS/MS fragmentation patterns can be taken into account as additional parameter for metabolite 
identification. However, depending on the chemical structure, MS/MS fragmentations are not 
always easy to interpret and are not a clear sign for a specific compound. Databases, like Global 
Natural Products Social Molecular Networking (GNPS)10, that contain fragmentation patters 
for many NPs, can be of a great help in such situations. Although it might occur that the 
searched compound is not included. In contrast, we were able to identify unambiguously the 
bisindoles lynamicins/spiroindimicins and lagunapyrones in the extract of MP131-18 solely 
through comparison of exact mass and UV absorption with hits from DNP. Surely, the 
characteristic isotopic pattern of the mono-, di-, tri- and tetra-chlorinated lynamicins facilitated 
their identification. Likewise, the different isotopic pattern of the new spiroindimicins 
derivatives indicating monochlorination compared to the dichlorinated spiroindimicins B and 
C, gave a hint about their structural novelty. In case of lagunapyrones, the specific MS/MS 
fragmentation pattern with the multiple water loss helped eventually to clearly assign the 
compound to a DNP entry. Additionally, two new lagunapyrones were identified by the mass 
difference of 14 Da originating from different length of their alkyl side chain, predicted on the 
basis of proposed biosynthetic pathway. Dereplication plays an important role during NPs 
discovery and further advances of hyphenated analytical techniques and improvement of natural 
products databases will greatly speed up and simplify research in this direction. 
The genomic era, expanding rapidly in the last 20 years, gave rise to sequencing of many 
bacterial genomes. The analysis of sequenced genomes using bioinformatics tools like 
antiSMASH or PRISM, reveals the secondary metabolism potential through prediction of the 
respective biosynthetic gene clusters. Within the genome of MP131-18 34 BGCs were 
identified whereas for IB2014/0111-12 analysis revealed 29 gene clusters. A majority of these 
clusters encode known secondary metabolites present in many different actinomycetes. For 
instance, BGCs responsible for production of coelibactin, ectoine, piericidin, roseoflavin, 
melanin or desferrioxamin are often present in many actinobacterial species due to their role in 
maintaining cell survival and adaptation to the environmental conditions. The desferrioxamin, 
a high-affinity iron chelator ensures for example the strain growth under iron limiting 
conditions. The deletion of desferrioxamin gene cluster in S. albus was lethal to the strain.11 
Beside these adaptive clusters, remaining BGCs open up the possibility to discover novel 
compounds since many of them have not been assigned to a putative metabolite yet. However,
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often the identification of a respective compound is challenging. Most of the BGCs remain 
silent under the standard laboratory conditions or the metabolite can’t be identified in the extract 
due to low production, compound stability or extraction issues. For example, the coelimycin P1 
is produced by S. coelicolor only for a very short period of time between 24 and 60 hours of 
cultivations and is quickly degraded afterwards. The structural studies of this compound were 
strongly complicated by the fact of its ectopic production.12 Thus, tools for activation of silent 
gene clusters are of great demand. Many strategies and approaches are indeed available for 
induction of silent gene cluster expression. However, the detection of corresponding metabolite 
often remains quite challenging. Since many strategies are based on influencing the global 
regulatory networks it is difficult to assign the activated gene cluster to a particular compound 
found in the extract of the manipulated strain. One such way is the use of a reporter guided 
approach.13,14 In this case, the promoter of a structural gene from the BGC of interest is fused 
to the reporter gene allowing to monitor changes in its transcription and thus expression of the 
entire gene cluster. However, this technique still detects the changes in expression level of a 
gene rather than directly responds to the presence of a compound, providing a space for a high 
rate of false-positive results. As described in chapter four, biosensors represent a promising tool 
for the fast direct detection of produced secondary metabolites in actinomycetes. By simply 
putting a reporter gene under the control of a TetR-type repressor, originating from the BGC of 
interest, makes it possible to monitor the accumulation of a compound that is an outcome of the 
corresponding BGC activation. We have used this strategy to detect the induced production of 
coelimycin P1 in S. lividans TK24, which normally does not accumulate this metabolite. The 
successful application of the aforementioned technique makes us believe that it can be 
successfully used in combination with many other approaches (Tn-mutagenesis, random 
mutagenesis, promoter insertion, cluster remodeling, etc.). Besides that, it obviously can be 
expanded to applications, such as adjustment of fermentation conditions, overproducer 
selection and search for new producing strains.  
Despite the well-established extraction and separation techniques, the isolation of secondary 
metabolites is still a challenging task. Although the amount of a compound needed for 
acquisition of NMR spectra and structure elucidation has significantly decreased, the yield is 
often still not sufficient for downstream applications and testing. Quite high amounts of 
metabolites are needed if stereochemistry has to be determined or if degradation experiments 
are needed to elucidate more complex structures. The activity tests against microorganisms or 
cell lines require additional amounts of the isolated NP. Whereas the known lynamicins/spiro-
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indimicins were easy to isolate in high quantity, their new derivatives were only sparsely 
present in the extract of the strain. Nevertheless, we managed to obtain 0.6 mg and 0.3 mg of 
two new spiroindimicins E and F, respectively. Thereof, spiroindimicins E were subjected to 
activity test against T24 bladder carcinoma cells, in addition to the antibacterial test. 
Spiroindimicin E showed only slight effect on cellular growth compared to lynamicin E (50% 
inhibition of proliferation capacity) and lycogarubin C, which almost completely inhibited cell 
proliferation at the concentration of 10 µM. Furthermore, four new alpiniamides have been 
successfully isolated. Even though the amount was limited, alpiniamides B1 and B2, as well as 
the main product alpiniamide A, were used for determination of stereochemistry. Although, 
alpiniamide A had been isolated before, the stereochemistry seemed to be determined 
incorrectly. Therefore, we attempted to elucidate the correct configuration via NMR 
experiments. As result, we have assigned the left part of alpiniamide A as threo configuration, 
whereas the right side of the molecule was more complicated due to inconsistent results of the 
Mosher experiment. Such issues can be solved by the use of different derivatization agents, 
which would increase the chemical shift differences between the examined compounds, and 
thus yield more reliable result. Examples for such compounds would be for instance α-
methoxyphenylacetic acid (MPA) or 9-anthrylmethoxyacetic acid (9-AMA). These and other 
compounds were extensively studied for a variety of polyfunctional derivatization agents by 
Riguera et al..15 The right part of alpiniamides B1 and B2 was equally problematic while the left 
part could be unambiguously assigned as S and R, respectively. In addition to this, genome-
mining tools are meanwhile able to predict the stereochemical outcome of the ketoreductase 
mediated reaction. In the case of alpiniamide PKS the KR domain of module 1 is predicted to 
be a B1 type by antiSMASH, meaning the resulting hydroxy group is supposed to be in D 
configuration. This bioinformatics prediction coincides with the structures of alpiniamides A 
and B2, since the respective stereocenter is in D-configuration in both compounds, but is wrong 
for alpiniamide B1. It is not clear how two different stereochemistry can be present in the 
position resulting from the activity of the same KR domain. The situation is even more 
complicated by the fact that this KR domain is shared between module 1 and 2. Specialized 
tools for the prediction of stereocenter configuration within polyketides such as the pHHM web 
application can be even of a greater help.16 The stereocenter resulting from KR domain in 
module 1/2 is predicted to be D by this tool as well. Prediction of stereochemistry using a 
bioinformatics approach is useful and might be already applicable to certain metabolites, 
although it still needs to be further developed and tuned to get reliable results. Hence, so far the 
method of choice for stereochemistry determination is still the chemical way. 
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With both genome sequences and chemical structures on hand, we were able to predict the 
biosynthetic pathways of spiroindimicins, lagunapyrones and alpiniamides. The structural 
information gave a first hint about the type of the enzymatic machinery responsible for the 
assembly of corresponding metabolite. In the case of spiroindimicin the identification of the 
BGC was simple due to the very characteristic core enzymes needed for construction of the 
indole skeleton. Halogenase genes for chlorination, tryptophan monooxygenase for formation 
of indolpyruvatimin, chromopyrrolic acid synthase for pyrrole formation and cytochrome P450 
for indole formation are typically involved in assembly of these NPs. The antiSMASH mediated 
Streptomyces sp. Mp 131-18 genome analysis revealed a gene cluster similar to the one 
responsible for biosynthesis of the indole compound rebeccamycin.17 A detailed analysis of all 
genes, present in this cluster and their products allowed us to predict the steps in 
lynamicin/spiroindimicin biosynthesis.  
The identification of the alpiniamide BGC was more challenging. Within the genome of 
Streptomyces sp. IB2014/11-12, two BGCs are present, which could be potentially involved in 
the biosynthesis of these NPs. We hypothesized that alpiniamide, a linear polyketide, bearing 
an amino group in the middle, can be synthesized either by type I PKS and additional enzyme(s) 
for insertion of the amino group or by the combined action of NRPS and PKS. Thus, cluster no. 
16 (type I PKS, harboring aminotransferase gene) and cluster no. 9 (hybrid NRPS trans-AT-
PKS) were worth considering. However, we could not rule out one of the clusters solely based 
on analysis of the present genes. Cluster no. 9 seemed to be more likely candidate due to the 
presence of NRPS module with predicted glycine specificity of A domain, and in line 
methyltransferase domains within the PKS part for generating the methyl branches. However, 
the order of domains of this unusual PKS-NRPS megaenzyme did not correspond to the 
structure of alpiniamide. Therefore, an experimental proof has been required for the 
unambiguous identification of the alp gene cluster. We have used two different approaches, 
feeding with labeled precursors and classical gene disruption experiments, to prove that gene 
cluster no. 9 is indeed responsible for the biosynthesis of alpiniamides. The successful feeding 
experiments with labeled glycine and methionine gave a first hint that cluster no. 9 might be 
involved in biosynthesis of NPs of interest. Furthermore, as a second proof we aimed to delete 
putative gene cluster in the native produced strain. This was achieved by disruption of gene 
12750 through replacing a 2 kb region with the spectinomycin resistance cassette. The mutant 
completely lacked production of alpiniamides. This experiment confirmed that cluster no. 9 is 
responsible for alpiniamide biosynthesis. However, genetic manipulation in the wild type strain
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is not straightforward due to many reasons e.g. low conjugation efficiency. Thus, a heterologous 
expression of the gene cluster in a model strain greatly facilitates further genetic experiments 
in order to establish the particular steps and gene functions in the biosynthesis of respective 
NPs.  
As mentioned before, the production of secondary metabolites is often low in native strain and 
in some cases not stable. Therefore, increase and stabilization of the production yield by 
manipulating the gene cluster, preferably in a heterologous host, is of high importance. In 
addition, the genetic manipulations in order to decipher biosynthetic pathways are easier to 
perform in a well-established and genetically tractable model strain with defined or even clean 
metabolic background, rather than in a native producer. Despite the visual simplicity of the 
heterologous expression approach it is not always successful. In many cases, the expression of 
the gene cluster of interest cannot be achieved. For instance, we have cloned the spiroindimicin 
gene cluster from MP 131-18 by TAR-cloning procedure and successfully introduced into S. 
lividans TK24 and S. albus J1074. However, the cluster was not expressed under multiple tested 
conditions. The attempt to induce production of lynamicins/spiroindimicins in the heterologous 
hosts by insertion of a strong promoter in front of the halogenase and regulatory genes also 
failed. Zhang et al. also attempted to express the spiroindimicin cluster from Streptomyces sp. 
SCSIO 03032 in S. coelicolor YF11 resulting in production of small amounts of chromopyrolic 
acid but not the final chlorinated and cyclized products.18 Deletion of cytochrome P450 gene 
(spmP) in the Streptomyces sp. SCSIO 03032, which did not affect production of 
spiroindimicins, confirmed that this gene is not relevant for synthesis. The authors suggest that 
this function might be provided by any of the 15 other cytochromes P450 located elsewhere in 
the genome of the native strain. In contrast, the heterologous expression of the alpiniamide gene 
cluster was successful. This allowed us to perform deletions of biosynthetic genes using Red/ET 
recombineering technique. As result, we were able to examine the functions of several genes in 
the biosynthesis of alpiniamides. We constructed mutants lacking alpD (acyl-CoA 
dehydrogenase), alpR (ribosomal RNA methyltransferase) and alpE (3-oxoacyl-ACP synthase 
3) respectively and analyzed their ability to produce alpiniamides. Deletion of alpD and alpR 
did not affect the alpiniamide production suggesting that these genes do not participate in 
alpiniamide biosynthesis. Whereas, deletion of alpE lead to complete abolishment of 
alpiniamides production.  
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In conclusion, two new members of the spiroindimicin family and two new lagunapyrones have 
been identified in the extract of the marine derived Streptomyces sp. MP131-18, as well as four 
new alpiniamides were discovered from the Streptomyces sp. IB2014/11-12. These findings 
show clearly that screening of streptomycetes species from new ecological niches represent a 
great source for valuable natural products. The combined metabolic and genomics approach is 
a powerful tool for their identification and elucidation of the biosynthetic origin. Additionally, 
the application of biotechnological tools such as biosensors will speed up the natural product 
research even further.  
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